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Zusammenfassung
Hintergrund und Ziele: Nuklearmedizin wird heutzutage häufig in der Diagnostik und der
Therapie angewendet. Hierzu werden radioaktive Tracer mit biologischen Komplexen zu
sogenannten Radiopharmaka verbunden, die den Patienten verabreicht werden. Dies führt
zur Emission von radioaktiver Strahlung im Körper des Patienten. Die therapeutische
Wirkung wird erzielt, indem ein Teil der Energie zum Beispiel in Tumorgewebe deponiert
wird. Der Anteil der Strahlung, der den Körper verlässt, kann außerhalb des Patienten de-
tektiert werden und dient zur Erstellung eines funktionellen Bildes des untersuchten Systems.
Dosisabsorption im übrigen Teil des Patienten ist ein unvermeidbarer und unerwünschter
Nebeneffekt, da hierdurch potentiell das Risiko für Tumor- und Erbkrankheiten steigt und
die Bildqualität verschlechtert wird. Diese Dosis muss aus rechtlichen Gründen sowie zur
Bewertung von Risiko und Nutzen für den Patienten abgeschätzt werden. Darüber hinaus
werden personalisierte Dosisabschätzungen für die Therapie und epidemiologische Studien
benötigt. Nach der gängigen Lehrmeinung benötigt man zur personalisierten Dosimetrie
patientenspezifische pharmakokinetische Modelle, die die Verteilung und Ausscheidung des
verabreichten Radiopharmakons beschreiben, sowie personalisierte anatomische Modelle, die
die Simulation des Strahlentransportes im menschlichen Körper für die interne Dosimetrie
ermöglichen. Aufgrund des hohen Zeitaufwandes kommen diese Modelle allerdings in
der klinischen Routine nicht zum Einsatz. Infolgedessen werden in der Regel Referenz-
dosen angewendet, welche sich stark von personalisierten Dosen unterscheiden können.
Die vorliegende Arbeit hat das Ziel zu untersuchen, wie die Zuverlässigkeit von internen
Dosisabschätzungen des individuellen Patienten mit praktikablen Methoden erhöht werden
kann.
Material und Methoden: Personalisierte pharmakokinetische Kompartmentmodelle wur-
den für fünf gesunde Probanden erstellt und deren interindividuelle Variabilität in der
Pharmakokinetik analysiert. Der Einfluss der Aktivität im Blut auf Organdosen wurde
untersucht, indem die Organdosen auf zwei verschiedene Arten berechnet wurden: mit und
ohne Blut als individuelle Strahlungsquelle. Ein Referenz-Polygonnetzphantom wurde auf
ausgesuchte Körpermaße eines schlanken und eines übergewichtigen Menschen skaliert. Die
skalierten Körpermaße umfassten den Abstand zwischen Beckenkamm und Schlüsselbein,
Körpergröße und Tiefe und Breite des Brustkorbes. Anschließend wurde untersucht, ob
die durch interindividuelle Abweichungen hervorgerufenen Dosisdifferenzen durch die ent-
wickelte Skalierung abgebildet werden können. Zum Abschluss wurde eine varianz-basierte
Sensitivitätsanalyse erstmalig auf die interne Dosimetrie angewendet. Dadurch wurde es
möglich, die Varianzen in den Organdosen zu quantifizieren, die durch interindividuelle
Unterschiede in Pharmakokinetik und Anatomie hervorgerufenen werden. Die implemen-
tierte Sensitivitätsanalyse ermöglicht zudem die Bewertung der Inputfaktoren nach ihrem
Einfluss auf diese Varianzen.
Ergebnisse: Es wurde gezeigt, dass die Aktivität im Blut einen erheblichen Einfluss hat
auf die absorbierte Dosis von gut durchbluteten Regionen, die keine Strahlungsquellen
sind. Die Anpassung des Referenz-Polygonnetzphantomes ermöglichte es, die interindi-
viduellen anatomischen Unterschiede teilweise abzubilden und folglich den Fehler in den
Organdosen aufgrund von unterschiedlicher Anatomie zu reduzieren. Die Ergebnisse der
Sensitivitätsanalyse zeigen, dass die genaue Bestimmung der zeitlich integrierten Ak-
tivitätskoeffizienten zusammen mit der Bestimmung der individuellen Masse der Strahlen-
quellregionen und der Benutzung von geeigneten Blutverteilungen im Patientenkörper
großes Potential haben, die Varianz in den internen Dosen zu reduzieren. Für Organe,
die sich in direkter Umgebung zu Strahlenquellregionen befinden, spielen auch spezifische,
durch sogenanntes Cross-fire beeinflusste absorbierte Fraktionen eine Rolle.
Schlussfolgerungen: Messprotokolle für pharmakokinetische und dosimetrische Studien soll-
ten die Auswertung der Aktivität in Blutproben beinhalten. Blut sollte im Anschluss als
eigenständige Strahlenquellregion in die Berechnung der internen Dosen eingehen. Es ist
möglich und auch im Klinikbetrieb realisierbar, die Dosisabschätzung durch Anpassung
von ausgewählten Körpermaßen des Referenz-Polygonnetzphantoms zu verbessern. Alterna-
tiv könnten die ausgewählten Körpermaße benutzt werden, um das am besten passende
Phantom zu bestimmen. In dieser Arbeit wurde die leistungsfähige varianz-basierte Sen-
sitivitätsanalyse an die Anforderungen für die interne Dosimetrie in der Nuklearmedizin
angepasst. Sie ermöglicht die Identifizierung der Inputfaktoren, die den größten Einfluss auf
die Varianz der Dosiskoeffizienten haben. Eine genaue Bestimmung dieser Inputfaktoren hat
das große Potential, die Unsicherheiten in den Organdosiskoeffizienten in der Nuklearmedizin
auf höchst effiziente Weise zu reduzieren. Die implementierten und ausgewerteten Methoden
sowie die entwickelten Programme können dafür eingesetzt werden, die Zuverlässigkeit der
individuellen Organdosenbestimmung für Patienten der Nuklearmedizin zu verbessern.
Abstract
Purpose: Nuclear medicine applications are extensively used for diagnostic and therapeu-
tic purposes nowadays. In these modalities radioactive tracers labeled with biological
compounds, so-called radiopharmaceuticals, are internally administered to the patients.
Subsequently, radiation is emitted by the radiopharmaceuticals in the patient’s body.
Therapeutic function is achieved by depositing a fraction of energy in e.g. tumor tissue.
The fraction of radiation that leaves the patient’s body can be detected externally and is
employed to obtain a functional image of a studied system. The dose absorption in the rest
of the patient’s body is an unavoidable and undesirable side process, since it can potentially
increase the risk of induction of cancer and heritable diseases and it decreases the image
quality. This dose needs to be estimated for regulatory purposes and for an assessment of
patient’s risks and benefits. Moreover, therapeutic nuclear medicine procedures and epi-
demiological studies require personalized dose estimations. According to the commonly used
framework, personalized internal dosimetry requires the development of individual-specific
pharmacokinetic models, which describe the distribution and excretion of the administered
radiopharmaceutical, as well as personalized anatomical models, which facilitate radiation
transport simulations in the human body for internal dosimetry. These models are usually
not viable in clinical routine though, due to high time and effort requirements. Consequently,
reference doses, which can be substantially different from personalized doses, are typically
applied to individuals. This thesis aims at investigating how the reliability of internal dose
estimates for individual patients can be increased by practically viable methods.
Methods: Personalized compartmental pharmacokinetic models were established for five
healthy volunteers and the inter-individual variability in pharmacokinetics was analyzed.
The effect of blood activity on organ doses was evaluated by computing organ doses in two
ways – with and without blood as a distinct source region. A reference polygon-surface
phantom was scaled to fit a set of selected dimensions of one slim and one overweight
individual. The scaled dimensions comprised the distance between the iliac crest and the
clavicles, total height, front-to-back distance and width of the rib cage. It was subsequently
investigated whether the dose differences originating from inter-individual variations in
anatomy can be captured by the developed scaling. Finally, variance-based sensitivity
analysis was applied for the first time to internal dosimetry. This allowed to quantify the
variances in organ doses caused by inter-individual differences in pharmacokinetics and
anatomy. The implemented sensitivity analysis facilitated ranking of the input factors
according to their impact on these variances.
Results: A substantial effect of blood activity on absorbed doses for highly vascular non-
source regions was shown. Adjusting the reference polygon-surface phantom enabled partly
capturing inter-individual anatomic variability and, consequently, decreasing the error
in estimated organ doses caused by differences in anatomy. Based on the results of the
sensitivity analysis it follows that the accurate determination of the time-integrated activity
coefficients accompanied by the estimation of individual source region masses and the usage
of an appropriate blood distribution in a patient’s body have great potential to decrease
the variance of internal doses. For organs located in close proximity to the source regions
the cross-fire specific absorbed fractions have an impact as well.
Conclusion: Measurement protocols for pharmacokinetic and dosimetric studies should
include the assessment of activity in blood samples and blood should subsequently be
considered as a distinct source region in internal dose calculations. It is feasible and
practically achievable to improve dose estimates by scaling the reference polygon-surface
phantom to selected dimensions of individuals. Alternatively, these dimensions could be
considered in selecting the phantom that best matches to the individual patient. In this
thesis the powerful variance-based sensitivity analysis was successfully adapted to internal
dosimetry in nuclear medicine applications. It allows to identify the input factors, which
have the highest impact on the variance of dose coefficients. An accurate determination
of these input factors has the great potential to reduce the uncertainties of organ dose
coefficients in nuclear medicine in the most effective way. The implemented and evaluated
methods as well as the developed programs can be used to enhance the reliability of organ
dose assessment for individual patients in nuclear medicine applications.
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Introduction
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Many diagnostic and therapeutic procedures in medicine rely on the application of ionizing
radiation. This radiation can be emitted by external sources, i.e. those located outside the
patient’s body, or it can be ejected by internally administered radioactive substances. An
example of the modalities with externally applied radiation is the usage of X-ray sources for
a widely known diagnostic modality like computed tomography (CT). Another example is
the external beam radiotherapy – application of electrons, X-rays, γ-radiation (e.g. 60Co),
protons or ions for cancer treatment. Diagnostic and therapeutic procedures, which employ
radioactive substances, are commonly combined under the term “nuclear medicine”. These
substances are administered to the patient in form of radiopharmaceuticals – radioactive
tracers labeled with biological compounds. The biochemical properties of the latter define
the clinical purpose of the radiopharmaceutical. As a result of the administration of
radiopharmaceuticals, the patient’s body emits photon radiation, which is externally
detected. In contrast to CT, which is applied to visualize the anatomy of the patient,
nuclear medicine modalities are employed to investigate the physiological function of
organs, tissues or other studied systems. For this reason the nuclear medicine diagnostic
applications are often called functional imaging. To enable an external radiation detection in
diagnostic nuclear medicine applications, radiation that can penetrate substantial soft-tissue
thicknesses is used. Thus, X- and γ-emitting radionuclides are employed in such imaging.
The therapeutic applications in nuclear medicine are commonly denoted as radionuclide
therapy. Radionuclide therapy is used for treatment of cancer, metastatic bone pain and
neuroendocrine tumors, for radiosynovectomy (a treatment of synovial inflammation and
related arthritis) etc. To locally sterilize cancer cells by self-irradiation and avoid the
irradiation of surrounding normal tissues, in radionuclide therapy radionuclides emitting
short range radiation such as electrons, β-rays or α-particles are used [1–3]. Nuclear
medicine applications are available nowadays in many clinics worldwide and are extensively
used for both, diagnostics and therapy.
As mentioned above, the use of nuclear medicine modalities is associated with an
administration of radiation to the patient. The administered radiation deposits energy in a
patient’s body. Consequently, besides the patient’s benefit from the diagnosis or therapy,
these procedures are associated with undesirable radiation doses, which could potentially
increase the risk of inducing cancer and heritable diseases. For the regulatory purpose
and to facilitate an assessment of risks and benefits for a patient, these doses need to be
estimated. Due to the operating principles of nuclear medicine applications, the associated
doses cannot be determined by direct measurements. Thus the internal dosimetry relies on
computational methods.
The commonly used framework of internal dosimetry was developed and formulated
by the Committee on Medical Internal Radiation Dose (MIRD) [4]. It relies on the
knowledge of the spatial distribution of an injected radiopharmaceutical in the patient’s
body and the values called specific absorbed fractions (SAFs) [5]. The spatial distribution,
metabolism and excretion of the administered substance in the patient’s body is often
described mathematically by pharmacokinetic models [6–8]. Alternatively, it can be given
as integrated activities, accumulated in source regions – anatomical regions that accumulate
considerable amount of activity, higher than the general level of activity in the body.
Integrated activities, normalized by the injected activity, are given in units of time and
often called time-integrated activity coefficients ã (rS). The specific absorbed fraction
Φ (rT ← rS, E) is defined as a fraction of energy E emitted from the source region rS, which
is absorbed in the target region rT , normalized by the target region mass. It is specific
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to a radiation type and energy and the combination of the source rS and the target rT
regions. If rT = rS, i.e. the dose is deposited in a target region from radiation contained
in the target region itself, the corresponding dose is called the self-absorption dose. The
dose from the cross-fire denotes a dose deposited in a tissue rT from radiation coming from
the radionuclides contained in another tissue rS (rT 6= rS). Specific absorbed fractions
Φ (rT ← rS, E) are usually derived by Monte Carlo calculations. For a certain type of
radiation and energy the amount of radiation released by a source region and deposited in
a target region is affected by the relative locations and compositions of the source and the
target. Thus the geometries where the Monte Carlo radiation transport is to be simulated
should mimic the patient’s anatomy. For this purpose digital models of the human anatomy,
called anatomical models or human computational phantoms, are developed. In summary,
the determination of internal organ doses involves several modeling steps: pharmacokinetic
modeling, anatomical modeling with subsequent radiation transport simulations and the
dose computation according to the model promulgated by the MIRD committee.
Some situations, mainly radionuclide therapy and epidemiological studies, require per-
sonalized medical dosimetry [9–11]. For example, even the same radiopharmaceutical
activities administered to different patients may result in different doses delivered to the
regions of interest. Since the delivered doses define the therapeutic success, their individual
estimation and adjustment, if needed, potentially increase the success of the therapy. Indi-
vidualized dosimetry can affect the outcome of epidemiological studies and, therefore, it
is also important in this case. Personalized dose assessment in diagnostics can facilitate
the reduction of late negative effects of the radiation. However, it is often omitted, due
to the relatively low associated doses. Individualized dosimetry is required for a proper
treatment planning, which is a routine practice in e.g. external beam radiation therapy, but
is often disregarded in radionuclide therapy. To this end, the framework described above
would require personalized modeling at each step. The collection of human data, required
for the calculation of individual time-integrated activity coefficients ã (rS), is not always
done in the clinical routine though. With a lack of robust automatic segmentation tools,
the construction of individual-specific anatomical model is not viable for each patient due
to the very time-consuming manual work required. Consequently, personalized modeling
is often neglected and reference pharmacokinetic models along with anatomical models
that mimic a reference standard anatomy are applied to individuals instead. In fact, doses
computed in this way correspond to the used model and not to the investigated individual.
The neglect of the inter-individual variability in pharmacokinetics and anatomy, which can
potentially amount to a high value [12–16], can lead to substantial uncertainties of the
estimated doses in nuclear medicine applications. The importance of the quantification
of these uncertainties is recognized by various authors [17–19]. Besides the uncertainty
analysis, a key procedure used to assess the quality of a model-based study is sensitivity
analysis [20]. It is a study of the relative importance of a variability of different input
factors on the uncertainty of model output. In some works, e.g. [21], sensitivity analysis is
applied to pharmacokinetic models only. Whereas little work has been done to apply it to
all modeling steps involved in internal dosimetry.
The objective of this thesis is to evaluate and apply advanced modeling procedures
required for personalized internal dosimetry, to analyze the inter-individual variability in
the pharmacokinetics and anatomy, to quantify the uncertainties in the organ doses caused
by this variability and to investigate the effect of input factors on the output doses by the
application of a variance-based global sensitivity analysis. As a practical outcome, the
4
global sensitivity analysis of this thesis will reveal what substantially affects the variance of
the organ doses and, consequently, how this variance can be reduced in the most effective
way. The main steps taken to fulfill the aim of this thesis are outlined in the following
section.
5

Structure and outline of the thesis
This section summarizes the main steps taken to fulfill the aim of this thesis – to investigate
the viability and accuracy of personalized dosimetry in nuclear medicine applications in
practice of clinical PET. Throughout this thesis various types of advanced modeling for
personalized dosimetry in nuclear medicine applications were implemented and evaluated.
This is subdivided into six parts as follows:
 Part I “Fundamentals of nuclear medicine techniques” summarizes operating
principles and applications of nuclear medicine modalities in general and positron-
emission tomography in particular in chapter 1. Chapter 2 recapitulates the main
concepts of internal dosimetry. These include the systems formulated by the Com-
mittee on Medical Internal Radiation Dose for the computation of absorbed dose
coefficients from internally administered radiopharmaceuticals. Two formalisms are
presented in chapter 2: the general framework of internal dosimetry and the special
case of urinary bladder dosimetry.
 Part II “Pharmacokinetic modeling” presents the first type of advanced modeling
needed for internal dosimetry. Its fundamentals and mathematical formalism are
summarized in chapter 3. The inputs required to establish a pharmacokinetic model
along with the challenging aspect of considering blood in such a model are also
introduced in chapter 3. Experimental data employed in this thesis for establishing
pharmacokinetic models, the used methods and the proposed approach to model
blood contents of organs and tissues are described in chapter 4. The developed
pharmacokinetic models and the evaluated effect of blood on the internal organ doses
are presented and discussed in chapter 5.
 Part III “Anatomical modeling” presents the second type of modeling required in
the framework of internal dosimetry. The background of the development of digital
models mimicking human anatomy, their construction and applications are given
in chapter 6. The method proposed, implemented and evaluated in the scope of
this thesis to capture the inter-individual differences in anatomy for the purpose of
internal dosimetry is described in chapter 7. Chapter 8 presents the newly developed
anatomical models and evaluates the feasibility to reduce the inter-individual anatomic
differences with less effort than that needed for the segmentation of an individual
anatomical model.
 Part IV “Uncertainty and sensitivity analysis” deals with two key procedures
required for the evaluation of a model-based study – uncertainty and sensitivity
analyses. The fundamentals of these procedures are summarized in chapter 9. The
details of the global variance-based sensitivity analysis implemented in this thesis,
along with an uncertainty analysis, are provided in chapter 10. Chapter 11 presents
the computed uncertainties of organ dose coefficients. As an outcome of the sensitivity
analysis, the effect of input factors on the variance of organ dose coefficients is shown
7
in chapter 11. The main results, obtained using the materials and methods of Part I –
Part IV are presented and discussed here.
 Part V “Summary and conclusion” summarizes this thesis in chapter 12 and gives
its outcomes and conclusions in chapter 13.
 Part VI “Appendix” contains additional figures from sections 8.3 and 11.3 not
included in the main text of the thesis. It is followed by the lists of figures and tables,
the lists of abbreviations, acronyms and symbols as well as the bibliography, the list
of publications, the acknowledgment and the curriculum vitae.
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Part I.
Fundamentals of nuclear medicine
techniques
9

This part recapitulates the commonly used nuclear medicine modalities and the main
principles of their work in chapter 1. Since the clinical data employed in this work correspond
to a radiopharmaceutical used in positron-emission-tomography, this particular modality is
described in detail in section 1.3. In chapter 2 the main concepts of internal dosimetry are
recapitulated. The formalism is originally presented in the pamphlet 21 [4] of the Committee
on Medical Internal Radiation Dose. A special case of the internal dose computation is the
urinary bladder dosimetry. The Committee on Medical Internal Radiation Dose developed
and promulgated in the revised pamphlet 14 [22] a dynamic model to be used for the urinary
bladder dosimetry. The main concepts of this model are also summarized in chapter 2.
11

1. Nuclear medicine modalities
Radioactive decay modes are recapitulated in the following. Principles of intra-operative
probes, organ uptake probes and gamma cameras are summarized in the following section 1.1.
The most common nuclear medicine modalities are Single Photon Emission Computed
Tomography (SPECT) and Positron Emission Tomography (PET). The main principles of
SPECT are outlined in section 1.2. The description of PET is given in detail in section 1.3.
This chapter is partly based on the book “Clinical nuclear medicine” by H.-J. Biersack and
L.M. Freeman [1]. As it is discussed in the following sections, nuclear medicine images can
be planar or represent a three-dimensional geometry, depending on the modality and the
used instrumentation. All these applications are based on the concept of administration
of radioactive substances (radiopharmaceuticals) to a patient and subsequent external
detection of radiation emitted by the administered substances.
Radioactivity of some atomic nuclei is caused by their structural instability [1]. The
process by which a structurally unstable nucleus transforms to a more stable nucleus is
called radioactive decay. The typical radioactive decay mode for nuclei of elements with
high atomic number Z is an emission of an α-particle (a nucleus of 42He):
A
ZX
0 →A−4Z−2 Y
2− +42 He
2+ (1.1)
Nuclei with low Z increase their stability via β−-, β+-decay or electron capture. β−-decay
occurs for the nuclei that have a high neutron-to-proton ratio N/Z. During this process a
neutron is converted to a proton and an electron, and an anti-neutrino ν̄ is ejected:
A
ZX→ AZ+1Y + e− + ν̄ (1.2)
where A is the mass number, A = Z +N . Small nuclei with a low N/Z ratio transform to
structurally more stable nuclei by a β+-decay, i.e. a conversion of a proton to a neutron
and generating a positron e+ and a neutrino ν:
A
ZX→ AZ−1Y + e+ + ν (1.3)
Alternatively to a β+-decay, an electron capture can occur:
A
ZX + e
− → AZ−1Y + ν (1.4)
Another type of radioactive decay is γ-decay. In this process a nucleus makes a transition
from a higher energy state to a lower energy state. The energy difference is released in a
form of a γ-ray. γ-decay often follows an α- or β-decay, if a proton or a neutron inside the
daughter nucleus jumps to an excited state and subsequently relaxes back down to ground
state via a γ-decay. The number of protons Z and neutrons N (N = A− Z) remains the
same in this process:
A
ZX
∗ → AZX + γ (1.5)
where X∗ and X are the excited atom and the relaxed state of the initial excited atom,
respectively.
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A number of radioactive decays per unit time is described by the physical quantity
activity. It is usually given in units “becquerel” Bq. 1 Bq corresponds to one decay per
second. An important property of nuclear medicine images is the possibility or impossibility
of their accurate quantification. Quantification of images in nuclear medicine means the
determination of e.g. activity concentrations e.g., in [kBq·cm-3] from the reconstructed
images. Quantitative images facilitate dosimetric calculations and the accuracy of the image
quantification limits the accuracy of the computed doses. To generate quantitative data in
nuclear medicine, it is necessary to compensate for the attenuation of the radiation emitted
by the administered radiopharmaceutical, which occurs between the emission point and the
detector (mainly in the patient’s body), and to correct the detected data for scatter. The
latter means to consider that the radiation detected in nuclear medicine imaging undergoes
scattering, mainly Compton scattering [23], and, as a result, it changes direction and looses
energy. Various scatter correction techniques are described e.g. by H. Zaidi [23].
1.1. Intra-operative probes, organ uptake probes and
gamma cameras
Intra-operative probes are portable hand-held devices with a relatively small field-of-view
that are mainly used to detect tumors or metastases in regional lymphatic nodes during a
surgical treatment of cancer. These devices are commonly employed for identification of
sentinel lymph nodes and, thus, assist in decision making regarding the volume of operative
intervention. Intra-operative probes are usually either scintillation- or semiconductor-
detector-based [1].
Organ uptake probes are used for measuring the uptake of radionuclides in body organs,
mainly in thyroid. These are portable systems that consist of a wide-aperture, a gantry, a
collimator, a scintillator crystal thallium-doped sodium iodine (NaI(Tl)), a photomultiplier
tube, an energy discriminator and associated electronics [1]. Measurements with such
systems are usually accompanied by a measurement of a standard known activity to
facilitate an automatic radioactive decay correction.
Gamma cameras or scintillation cameras are devices employed to measure X- and γ-
radiation emitted by radionuclides. In contrast to intra-operative probes or organ uptake
probes, gamma cameras have a large detector area that enables simultaneous and fast
data collection over a large body region. One or more flat crystal detectors of various
thicknesses coupled to a two-dimensional (2D) array of photomultiplier tubes are used
in gamma cameras. The principle of mechanical collimation is utilized in these systems.
Predominantly only radiation traveling perpendicular to the detector surface can pass
through the parallel-hole, diverging hole or pinhole collimator and reach the crystal. Any
radiation falling to e.g. parallel-hole collimator at an oblique angle will be stopped by the
collimator septa (walls between the holes of the collimator) usually composed of lead [1].
Gamma camera collimators can be designed to be more sensitive to certain photon energies.
The location of the scintillation within a crystal is determined from the voltage signals from
the 2D array of photomultipliers, since the intensity of the signal inversely varies with the
distance between the scintillation and the photomultiplier [1].
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Besides the standard scintigraphy examinations gamma cameras are employed for a
specific nuclear medicine procedure called radionuclide angiography. The latter is applied
for testing of the heart function. In this application a radioactive tracer, e.g. 99mTc, is used
to label red blood cells. The purpose of radionuclide angiography is the evaluation of blood
flow and organ function and it is specifically used for cardiac imaging. A gamma camera is
used in this case to obtain a series of heart images at different phases of the cardiac cycle.
All nuclear medicine modalities described above, i.e. intra-operative probes, organ uptake
probes and gamma cameras allow obtaining planar (2D) images. In contrast to these
modalities, tomographic SPECT and PET scanners are used to get a three-dimensional (3D)
data. Main principles of their functionality are outlined in the following sections 1.2 and 1.3.
1.2. Single photon emission computed tomography
(SPECT)
SPECT imaging is based on the detection of radiation released by single-photon-emitting
(γ-rays and X-rays) radionuclides. The typical radionuclides used in SPECT include 99mTc,
67Ga, 123I, 131I and 111In [24]. They are usually administered via an injection into the
bloodstream and are labeled with biological compounds, whose biochemical properties
define the distribution of the administered substance. SPECT systems are usually based
on a gamma camera rotating around a patient. Thus the mechanical collimation principle
described in section 1.1 for gamma cameras is also applied here. As in a typical tomographic
modality, in SPECT multiple projection images are acquired at various angles around the
patient with usually 360o of arc (except for cardiac studies, where typically a 180o data
collection is used). The projection images are subsequently reconstructed to transverse
tissue-section images (slices) with filtered backprojection or iterative reconstruction methods
[25]. SPECT images are usually not absolutely quantitative in practice, since the correction
for photon attenuation and scattering is challenging for this modality and is often omitted.
Nonetheless, recent developments show the possibility to obtain a quantitative SPECT
image in the combined systems like e.g. SPECT and computed tomography – SPECT/CT
[26]. Bailey and Willowson [26] describe the main challenges of applying the correction for
photon attenuation in SPECT, the requirements for quantitative emission tomography and
the proposed steps needed for quantitative SPECT reconstruction.
1.3. Positron-emission-tomography (PET)
1.3.1. Operating principles of PET imaging
The following outline of the main principles of Positron Emission Tomography (PET) imaging
is partly based on the book “PET: physics, instrumentation and scanners” by M.E. Phelps
[27] and a review article by P. Zanzonico [28]. PET is a widely used nuclear medicine imaging
technique. It involves the use of radiation administered in a form of radiopharmaceuticals
[28]. These radiopharmaceuticals are positron-emitting radionuclides labeled with biological
compounds [27]. Often intravenous administration is used, in some rare cases, e.g. in
the studies of gastrointestinal drug absorption with 18F-labeled fluorodeoxyglucose (18F-
FDG) – oral administration. The clinical purpose of a radiopharmaceutical depends on
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the biochemical properties of the biological compound. The radionuclides commonly used
in PET imaging include 18F, 11C, 15O, 124I, 13N, 82Rb and some others which are usually
produced in a cyclotron. These radionuclides have a neutron-to-proton ratio N/Z smaller
than that of the stable nuclides, i.e. they are “proton rich”. The excess of protons can be
eliminated either via β+-decay, or via electron capture. Electron capture is the dominant
process in nuclides with high Z while β+-decay is the dominant process in low Z nuclides. In
case of electron capture, a proton in the nucleus is transformed into a neutron by capturing
an orbital electron (usually K shell electrons) and emitting a neutrino ν (see equation 1.4
on page 13). An emission of a positron e+ is needed for the basic principle of PET imaging
(described later in this subsection). Since it does not occur as a result of electron capture,
in PET imaging usually those radionuclides that decay predominantly by β+-emission are
used. In this case a proton transforms into a neutron by ejecting a positron e+ and a
neutrino ν. As an example, the β+-decay of 18F is given in the following equation:
18
9 F → 188 O + e+ + ν (1.6)
The fraction of decays that occur for 18F by β+-emission is approximately 97 %. The
emitted positrons e+ are not monoenergetic, since the released energy is shared between
the daughter nucleus, ν and e+. The maximum kinetic energy of e+ is radionuclide-specific.
For 18F the maximum kinetic energy of e+ is equal to 633.5 keV.
After losing the kinetic energy in inelastic interactions with atomic electrons and almost
at rest, the emitted e+ annihilates with an electron e− of the tissue. The spatial distance
between the emission of e+ and the annihilation depends on positron range, which is in order
of a few mm in human tissue [29]. Thus the annihilation occurs in a very short distance
from the place where the β+-emission took place. During the annihilation, the mass of the
electron and the positron is converted into electromagnetic energy, which is released (in
the vast majority of cases) in the form of two so-called annihilation photons. Due to the
conservation of momentum and energy the annihilation photons carry an energy of 511 keV
each and are emitted simultaneously in almost opposite directions. The high energy of the
emitted photons allows them to escape from the body with a high probability and thus,
enables the detection of these coincidence photons outside the body of the patient. This is
the main principle of PET imaging. It is schematically shown in figure 1.1. The interaction
of the emitted radiation with tissue as well as the detection principle are discussed in
sections 1.3.2 and 1.3.3, respectively.
1.3.2. Interaction of emitted radiation with matter
Two types of radiation are to be considered in PET imaging: positrons ejected in β+-decay
of the used radionuclide and high-energy photons emitted as a result of annihilation of
the positron with an electron of the tissue. Positrons quickly lose their kinetic energy in
inelastic interactions with atomic electrons. The annihilation occurs when the kinetic energy
is almost zero, i.e. when the positron is almost at rest. The distance that positrons travel
in tissue prior to annihilation, also called positron range, depends on the energy of the
ejected e+ and is, thus, radionuclide-specific. For 18F the maximum positron range in water
is ≈ 0.2 cm [30]. The calculation of positron range for common PET radionuclides was
done by e.g. C.S. Levin and E.J. Hoffman [29]. Due to multiple scattering the trajectories
of positrons are not straight and, therefore, the Continuous Slowing Down Approximation
(CSDA) range is always higher than the projected range. The CSDA range of positrons
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Figure 1.1. Concept of PET imaging: administration of β+-emitting radionuclide, its decay,
annihilation of the emitted e+ with e− and the subsequent external detection
of the coincidence annihilation photons. The range of e+ is not to scale but for
clear illustration.
with kinetic energy of 600 keV in water is equal to 0.2265 g/cm2 (the data are taken from
http://physics.nist.gov/PhysRefData/Star/Text/ESTAR.html). The e+ range effect
is one of the factors limiting the resolution of the PET image. Other limiting factors are
discussed in section 1.3.3.
In contrast to the energy of the emitted e+, the energy of annihilation photons does not
depend on the radionuclide, since the annihilation occurs almost at rest and the masses
of e+ and e− are converted to the energy of the photons. This energy is equal to the rest
mass of e− (or e+), which is 511 keV. The annihilation photons subsequently travel in
tissue and interact with it. The quantity related to the probability dW of a particle moving
perpendicularly in a thin layer of tissue dx to undergo a certain type of interaction is called
cross section σ [31]:
dW = dx
n
V
σ = dx N σ (1.7)
where n is the number of scattering centers in an arbitrary volume V of material and N is
the concentration of scattering centers per unit volume in material. Cross sections that
correspond to a particular interaction type are called partial cross sections, whereas the sum
of all partial cross sections is denoted as the total cross section σtot. A beam of particles
loses intensity as it traverses material. This intensity loss is referred as attenuation. Often
a simple exponential attenuation law is applied to describe an attenuation of a narrow
beam of monoenergetic uncharged particles that incidents perpendicularly on material.
“Narrow-beam” geometry means that any scattered or secondary radiation is not considered.
For the change dI in the beam intensity I after passing thickness dx of material it can be
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written:
dI = −µ I dx (1.8)
where the coefficient of proportionality µ is the probability that an individual particle
undergoes interaction in a unit thickness of material. After dividing both sides of equation 1.8
by intensity I, integrating it and solving the resulting equation with respect to I one gets:
Ix = I(x) = Const e
−µx (1.9)
Assuming the initial beam intensity I0 = I(x = 0), from equation 1.9 it follows that
Const = I0:
Ix = I0 e
−µx (1.10)
Equation 1.10 is called exponential attenuation law and µ is the linear attenuation coefficient,
e.g. in [cm-1] if dx is in [cm]. Linear attenuation coefficient µ divided by density ρ of the
attenuating material is denoted as mass attenuation coefficient µ/ρ, e.g. in [cm2/g]. From
the definition of µ/ρ and equation 1.7 it follows:
µ
ρ
=
1
ρ
n
V
σtot =
1
ρ
ρV
V A
NA
σtot =
NA
A
σtot (1.11)
where NA ≈ 6.02 · 1023 mol-1 is Avogadro’s number and A is the atomic mass number of
the attenuator.
The mass attenuation coefficients for photons in water are shown in figure 1.2. At the
photon energy E = 511 keV the interactions to be considered are incoherent (Compton)
scattering, coherent (Rayleigh) scattering and photoelectric absorption (effect). The mean
free path, i.e. the average distance between two sequential interactions, of 511 keV photons
in water λ is 10.42 cm.
Figure 1.2. Photon mass attenuation coefficients in water, [cm2/g]. The mass attenuation
coefficients data are taken from www.nist.gov.
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Compton scattering Incoherent (Compton) scattering is an inelastic scattering of a
photon on a free electron. An electron is considered to be free, if the energy of the photon
is much higher than the binding energy of the electron. As a result of this scattering the
photon deflects from its original direction and a fraction of its energy is transferred to a
kinetic energy of the recoiling electron Ee:
Ee = Eγ − E ′γ =
Eγ
1 +
mec
2
2Eγ sin
2(θ/2)
(1.12)
In equation 1.12 Eγ is the initial energy of the photon and E
′
γ is the energy of the photon
after the Compton scattering, me and c are the electron mass and the speed of light,
respectively, and θ is the angle at which the photon is scattered.
The anisotropy of the scattering increases with increasing initial energy of the incident
photon Eγ . The electronic cross section of the Compton scattering does not depend on the
characteristics of the medium. The corresponding atomic cross section σC is proportional
to atomic number Z and is inversely proportional to the energy of the photon:
σC ∝
Z
Eγ
(1.13)
Rayleigh scattering Coherent (Rayleigh) scattering is a scattering of photons by bounded
atomic electrons. In this process the atom is not ionized or excited, so no energy transfer
occurs. The probability of Rayleigh scattering is higher at low energies of the photons and
for materials with high atomic number Z:
σR ∝
Z2
E2γ
(1.14)
Photoelectric effect In the photoelectric effect a photon is absorbed by the atom, a part
of the photon energy is spent on the binding energy of the electron shell and the rest of the
energy of the photon is entirely transferred to an orbital electron. This process is possible
if the energy of the incident photon is higher than the binding energy of the electron shell.
The electron gets enough energy to escape the atom and is called a photoelectron. The
kinetic energy of the photoelectron (Te) can be written as:
Te = Eγ − Ii − En (1.15)
where Eγ is the energy of the incident photon, Ii is the ionization energy of the electron shell
i (i = K,L,M, ...) and En is the recoil energy of the nucleus, which is usually negligible.
The photoelectric effect is more probable for the electron shell closest to the nucleus,
i.e. K shell (≈ 80 %), and due to the conservation of momentum the photoelectron is
emitted in almost the same direction as that of the incident photon. The cross section
of the photoelectric effect στ strongly depends on the atomic number Z of the absorbing
material and the energy of the incident photon Eγ , which is equal to 511 keV for annihilation
photons:
στ ∝
Zn
E
7/2
γ
(1.16)
with n varying from 3 to 5.
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After the photoelectron is emitted, the vacancy in the electron shell of the atom is filled
with an electron from a higher electron shell. The energy difference is typically ejected as
a characteristic X-ray photon. This process is called X-ray “fluorescence”. The typical
energies of the K-shell fluorescence X-rays range from a few keV (for the elements with
atomic numbers 11–30, i.e. from 11Na to 30Zn) to a few tens of keV for heavier atoms.
For the elements from 4Be to 10Ne the corresponding energies amount to a few hundreds
of eV. Thus the characteristic X-rays are rapidly absorbed in the medium as well as the
photoelectrons. Another process, which is a competing process to the ejection of the
characteristic X-rays, is the Auger effect. When the vacancy in the electron shell is filled
with an electron from a higher energy level, the excess of energy can be transferred to
another electron. As a result, this electron, called Auger electron, is ejected from the atom.
The kinetic energy of the Auger electron is equal to the difference between the electron
transition into the vacancy and the binding energy of the electron shell, from which the
Auger electron was ejected.
1.3.3. Radiation detection in PET imaging
Due to the high energy of annihilation photons, they can leave the body of the patient
with a high probability and thus can be detected externally. As it was mentioned above,
the annihilation photons are emitted with an angle of approximately 180o to each other.
Therefore, if the detected photons can be localized, the line joining the detection points
goes through the annihilation site. Since the annihilation occurs almost locally, this event
line also approximately goes through the location where the atom of the radionuclide was in
the body. To localize exactly where the radioactive nucleus was in the body, the principle of
computed tomography is used. According to it, the annihilation photon pairs along the lines
that traverse the patient (lines of response) at various angles are measured. The set of lines
of response is resorted and re-binned into the projection dataset [1,23]. Subsequently, filtered
back-projection or iterative image reconstruction algorithms are employed to compute the
transverse tissue-section images. The contiguousness of the transverse-section images in
PET (as well as in SPECT) enables a rearrangement of the reconstructed voxels, so that
coronal, sagittal, or oblique images can be obtained.
In fact e+ and e− are not completely at rest when they annihilate. Consequently, due
to the conservation of momentum, the annihilation photons are emitted not exactly at
180o to each other. This is called non-collinearity and it results in a small error in locating
the line of annihilation. Along with the positron range effect mentioned in section 1.3.2,
non-collinearity limits the spatial resolution achievable in PET and causes a blurring in the
reconstructed image.
The energy of the annihilation photons is independent of the used radionuclide and is
always equal to 511 keV. Due to this property PET scanners are optimized to efficiently
detect 511 keV photons. The detectors must also localize the annihilation site with good
accuracy. The latter is one of the important factors that define the spatial resolution of the
resulting image. The detectors with an energy resolution ability, e.g. inorganic scintillating
detectors with an energy resolution of about 10–15% are used in PET scanners, so that
the photons, which scattered in the body and lost some of their energy in these inelastic
interactions can be identified and typically rejected. Since coincident photon pairs need to
be detected, an important property of the detectors is their time resolution. This is the
ability to estimate the time interval between the detection of two photons. In order to avoid
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the undesirable rejection of annihilation photon pairs, a time window in PET scanners
is usually set higher than the time resolution of the detectors and is typically 4–18 ns
[27]. Because each annihilation photon has always the energy of 511 keV and one pair of
annihilation photons corresponds to one β+-decay, the coincidence detection of this photon
pair facilitates the quantification of PET imaging. Applying necessary corrections makes
PET imaging absolutely quantitative. The required corrections include e.g. normalization
(correction for non-uniformity of measured count rates for the same activity), calibration
of the detection efficiency, correction for the count loss due to a deadtime of scintillators,
subtraction of randoms from the detected coincidence counts, scatter and attenuation
corrections [1]. Thus, activity concentrations of the injected radiopharmaceutical can be
determined from the PET image.
As mentioned above, the most frequently used detectors in PET scanners are scintillation
detectors. These detectors convert a part of the particles’ (in case of PET imaging –
annihilation photons) energy deposited in the material of the scintillator into visible light.
How much of the deposited energy is converted to scintillation photons is defined by the
scintillation efficiency. Scintillators typically used in PET imaging are inorganic crystalline
scintillators. Their relatively large effective Z and density yield a high stopping power
of photons in the material of the scintillator. Typical scintillation crystals utilized in the
design of current PET systems are e.g. BGO (Bi4Ge3O12) or LSO (Lu2SiO5). The densities
of BGO and LSO are 7.13 and 7.4 g/cm3, respectively, whereas effective Z is 75 for BGO
and 66 for LSO [23]. The latter crystal is usually doped with cerium Ce. Consequently,
in the Ce-doped LSO additional electron orbitals (activation centers) between the valence
and the conduction bands of molecular orbitals are created. The incident photons interact
with the material of the scintillator and secondary electrons are produced. These electrons
excite and ionize the atoms of the scintillator. Some of the electrons have sufficient energy
to jump through the forbidden gap to the conduction band, where they migrate till they
drop to the excited-state orbitals of the activation center. The holes in the valence band
also effectively migrate to the ground-state orbitals of the activation center. Eventually, an
electron from the excited-state orbital of the activation center drops down and fills the hole
at the ground-state orbital of the activation center. The excess energy is released in a form
of a scintillation photon, which passes through the crystal and strikes a photocathode. As
a result of a photoelectric effect in the material of the photocathode, an electron is ejected
into a vacuum space of a photo-multiplier tube. The electrons in the photo-multiplier tube
are accelerated by the voltage and knock out from a set of dynodes a number of other
electrons, which create a measurable electronic signal at the anode of the photo-multiplier.
The height of the generated pulse is proportional to the energy absorbed in the scintillator.
Usually a whole ring of scintillators (detector elements) is used in PET scanners. According
to the principle described above, each photon striking a detector element results in a pulse,
generated by the detector element. The timed pulse sequences generated by each detector
element are compared and those occurred within a short time-window are considered to
be coincident. The number of coincidence events correspond to the number of detected
β+-decays and the underlying radionuclide activity can be reconstructed and quantified
with the data correction and image reconstruction techniques above mentioned.
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2. Dosimetry in nuclear medicine
The standard model of organ absorbed dose computation proposed by the Committee on
Medical Internal Radiation Dose (MIRD) is described in reference [4] and summarized in
the following text. According to this model, the absorbed dose coefficient d (rT ) in the
target region rT is calculated as:
d (rT , TD) =
∑
rS
∫ TD
0
a (rS, t)S (rT ← rS, t) dt (2.1)
where a (rS, t) denotes the fraction of administered activity in the source regions rS at
time t after administration of a radiopharmaceutical, normalized to a unit of administered
activity A0. The values of a (rS, t) are usually calculated by numeric solution of a system
of differential equations, defined by an employed pharmacokinetic model (cf. section 4.3).
TD is the dose-integration period which is theoretically infinite.
The values S (rT ← rS, t) are specific to the radionuclide and to the considered human
computational phantom. They are defined as:
S (rT ← rS, t) =
∑
i
EiYiΦ (rT ← rS, Ei, t) (2.2)
with Φ (rT ← rS, Ei, t) =
φ (rT ← rS, Ei, t)
MrT
(2.3)
Ei, Yi are mean energy and yield of radiation i; φ (rT ← rS, Ei, t) and Φ (rT ← rS, Ei, t) are
absorbed fraction and specific absorbed fraction (SAF) [5], respectively. φ (rT ← rS, Ei, t)
is defined as the fraction of radiation i with energy Ei emitted from rS at time t that is
absorbed in rT . MrT denotes the mass of the target region, which in general can also be
time-dependent (MrT (t)). The time-dependence of the mass MrT (t) is to be considered if
e.g. rT is a tumor region, since MrT (t) varies during the irradiation period.
For β-emitters, where the continuous β-spectrum is to be considered, the summation in
equation 2.2 is replaced by the following integral:
S (rT ← rS, t) =
∫ E0
0
P (E)E Φ (rT ← rS, E, t) dE (2.4)
In equation 2.4 E0 is the maximum (end-point) energy of the β-spectrum; P (E) is the
number of β-particles emitted at the energy E per MeV per nuclear transformation. If for
the combination of rS and rT , where rS 6= rT , φ (rT ← rS, E0, t) is negligible, equation 2.2
for the mean energy of β-spectrum can be used instead of equation 2.4.
If the time-dependence of S (rT ← rS, t) can be neglected, equation 2.1 can be written as:
d (rT , TD) =
∑
rS
S (rT ← rS)
∫ TD
0
a (rs, t) dt
=
∑
rS
S (rT ← rS) ã (rS, TD) (2.5)
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where ã (rS, TD) is the time-integrated activity coefficient in the source region rS, given in
units of time.
In dosimetric calculations for radiopharmaceuticals the list of source regions usually
includes the so-called rest of body (RoB). rRoB comprises the total body, excluding other
source regions, which are explicitly considered in a pharmacokinetic model. Thus, for
different agents that have various mechanisms of distribution in a human body and,
consequently, different lists of source regions, rRoB does not remain the same anatomical
region. Therefore, it is not robust to derive the values S (rT ← rRoB) via direct Monte
Carlo calculations for this source region. The common practice is to compute S (rT ← rRoB)
from the corresponding values for the total body as a source (rTB) and other rS 6= rRoB:
S (rT ← rRoB) =
MrTBS (rT ← rTB)−
∑
rS 6=rRoB MrSS (rT ← rS)
MrRoB
(2.6)
where MrS and MrTB denote the masses of source regions and total body, respectively.
MrRoB is the mass of rest of body rRoB. The definition of rRoB results in the following
equation for MrRoB :
MrRoB = MrTB −
∑
rS 6=rRoB
MrS (2.7)
Using equations 2.5 and 2.6 for the case of time-independent S (rT ← rS) the absorbed
dose coefficient in the target region rT is computed as follows:
d (rT , TD) =
∑
rS 6=rRoB
ã (rS, TD)S (rT ← rS)
+ ã (rRoB, TD)
MrTBS (rT ← rTB)−
∑
rS 6=rRoB
MrSS (rT ← rS)
MrRoB
 (2.8)
A special case in internal dosimetry is the reconstruction of absorbed dose to the urinary
bladder wall. For renally excreted radiopharmaceuticals a notable fraction of the injected
activity is accumulated in urinary bladder content. Thus a high contribution to the dose
absorbed in urinary bladder wall comes from the radiation emitted by urinary bladder
contents. It was demonstrated elsewhere [32] that absorbed dose to urinary bladder wall
depends on the volume of bladder content and the thickness of the bladder wall. The
phantom-specific values of Φ(UBwall ← UBcont) are derived with Monte Carlo calculations in
the geometry of the respective phantoms. They correspond to the bladder volume segmented
in the phantom and to the thickness of the bladder wall, which is often limited by the
voxel size. Hence, the changes in the volume of the bladder content and the corresponding
thickness of the wall with bladder filling and emptying are neglected, if computing the
absorbed dose according to equation 2.5. To account for these limitations a dynamic urinary
bladder model was developed in [22].
According to the dynamic bladder model [22], the volume of bladder contents V (t)
is defined as (time t = 0 correspond to the time when the radiopharmaceutical was
administered):
V (t) =

V0 +
t∫
0
U (t′) dt′, for 0 ≤ t < T1
Vr +
t∫
Tn−1
U (t′) dt′, for Tn−1 ≤ t < Tn
(2.9)
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V0 [ml] and Vr [ml] are, respectively, the initial bladder-content volume and the residual
bladder-content volume after the voiding. Ti [min] is the time between the administration
of the radiopharmaceutical and the i-th voiding, e.g. T1 [min] is that of the first voiding.
U(t) [ml/min] stands for the urine production rate.
Thomas et al. [22] define the activity of the bladder contents normalized to the injected
activity A0 as follows:
a (UBcont, t) =
A (t)
A0
= e−λt
m∑
j=1
αj
(
1− e−λjt
)
−
n∑
i=1
(
1− Vr
V (Ti)
)
A (Ti) e
−λ(t−Ti) (2.10)
where λ is the physical decay constant, n is the number of voidings, V (Ti) and A (Ti)
denote the bladder volume and the activity in the bladder contents right before the i-
th voiding at t = Ti, respectively. αj and λj are biologic parameters for the bladder
contents, which are radiopharmaceutical-specific. The values of αj and λj for commonly
used radiopharmaceuticals are summarized in reference [22]. Thomas et al. [22] stated
that for radiopharmaceuticals that are excreted solely via the urinary path, αj and λj
can be estimated from the total body retention data. These data are fitted to a sum of
exponential functions, where the number of the exponential functions (= parameter m in
equation 2.10) is defined by the modeler based on the retention data. For example, if total
body time-activity data are in agreement with a double-exponential function, it can be
written:
a (rTB, t) = e
−λt (α1e−λ1t + α2e−λ2t) (2.11)
and m = 2 in this case. From equations 2.10 and 2.11 it can be seen that the first term of
equation 2.10 represents the input of activity from the total body to the bladder content.
Whereas the second term of equation 2.10 is the voided bladder content activity, i.e. this
term corrects the activity accumulated in the bladder contents for the activity that is
excreted at each voiding time Ti.
S (UBwall ← UBcont, t) is dependent on V (t) and can be derived by Monte Carlo calcu-
lations for various volumes of the bladder contents V (t). Such simulations were done by
Andersson et al. [33] for photon and electron sources. Knowing the time-dependent activity
of bladder contents from equation 2.10 and the time-dependent bladder-content volume
from equation 2.9, the absorbed dose coefficient for urinary bladder wall from activity
accumulated in bladder contents can be calculated according to equation 2.1:
d (UBwall, TD) =
∫ TD
0
a (UBcont, t)S (UBwall ← UBcont, V (t)) dt (2.12)
To compute the bladder-wall dose from all considered sources, equations 2.12 and 2.8 are to
be used for the contributions from bladder content and other source regions, respectively.
For comparison values similar to effective dose were computed in this thesis. For the
sake of convenience, they are denoted as effective dose (or effective dose coefficients). The
effective doses calculated in section 5.2 are not age- and sex-averaged, in contrast to the
definition of effective dose given by the International Commission on Radiological Protection
(ICRP) [34]. They were computed for individual phantoms as weighted average of the
individual organ equivalent dose conversion coefficients using tissue weighting factors from
ICRP Publication 103 [34].
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Part II.
Pharmacokinetic modeling
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In chapter 3 a short summary of the classes of mathematical models used in kinetic studies
as well as the general equations describing a lumped deterministic model (compartmental
model) are given. It is followed by the description in chapter 4 of materials and methods
used for the development of compartmental pharmacokinetic models in this work. In
chapter 5 the newly developed compartmental pharmacokinetic models along with the
model predictions are presented with emphasis on the effect of blood activity on internal
organ doses. Materials, methods and results of this part were also summarized and published
by Zvereva et al. [35] in the paper related to one specific issue in internal dosimetry – the
way of considering blood activities in dosimetric studies.
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3. Fundamentals of pharmacokinetic
modeling
The material in this chapter is recapitulated partly based on the books of Godfrey [36],
Phelps, Mazziotta and Schelbert [37] and Carson, Cobelli and Finkelstein [38].
Carson, Cobelli and Finkelstein [38] review the commonly used classes of mathematical
models describing kinetic and metabolic processes. The models can be lumped or distributed.
Both of these model classes can be linear or nonlinear, stochastic or deterministic. In a
linear model the variables and their derivatives are present only in a linear combination.
Stochastic models include probabilistic effects, when e.g. describing some processes on a
cellular level. In the lumped models the distributed entity is assumed to be homogeneous, e.g.
a metabolite in plasma. In fact a metabolite in plasma has gradients of concentration, but
in a lumped model it is considered to be one compartment with homogeneously distributed
substance. Mathematically a lumped model leads to ordinary differential equations. Such a
simplified representation is adequate in many cases. Where it is not appropriate to neglect
the distribution effects like, e.g. blood flow, diffusion, chemical reactions, the distributed
models are employed. Mathematically the distributed effects are usually described by
partial differential equations.
An example of a lumped deterministic model frequently used in kinetic or metabolic
studies is a compartmental model. Such model consists of a finite number of well-mixed
homogeneous subsystems (compartments) that exchange with each other and with the
environment [36]. The kinetics of substances in a compartmental model is usually described
by a system of first-order differential equations. The general form of compartmental
equations is based on mass-balance equations for such system and the flux of an investigated
entity from each compartment to other sites. Godfrey [36] gives these equations for a system
with p compartments as follows:
dxi
dt
= fi0 +
p∑
j=1
j 6=i
fij −
p∑
j=1
j 6=i
fji − f0i, i = 1,2,...,p (3.1)
In this equation xi is the amount (or concentration) of the substance of interest in com-
partment i, fij is the flow rate to compartment i from compartment j. The flow rates
fi0 and f0i are from the environment to compartment i and from compartment i to the
environment, respectively. In pharmacokinetic studies for radiopharmaceuticals used for
PET imaging fi0 and f0i correspond to injection and excretion, respectively.
The most commonly used compartmental models are linear and time-invariant [36]. In
such models the flow rates are proportional to the amount of substance in a compartment
from which the substance flows to other sites. The constant of proportionality is often
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denoted as a rate constant. Considering this assumption, equation 3.1 can be written as:
dxi
dt
= ui (t) +
p∑
j=1
j 6=i
kijxj −
p∑
j=1
j 6=i
kjixi − k0ixi, i = 1,2,...,p (3.2)
The rate constants kij represent parameters of a compartmental model and “establishing”
a compartmental model means the estimation of the rate constants.
3.1. Input data to establish a personalized
pharmacokinetic model
In PET imaging pharmacokinetic models describe the distribution of the injected radio-
pharmaceutical in the body of the patient over time and the excretion of the injected
substance. In the compartmental equations 3.2 used for describing these processes, xi is the
activity accumulated in the source region i. Since PET imaging is absolutely quantitative,
as it is discussed in section 1.3, these activities can be obtained from the PET image.
Radiopharmaceuticals in PET imaging are usually administered intravenously. Thus, the
parameter ui (t) in equations 3.2 is present usually only in the corresponding equation for
the blood compartment. The exact shape of the input function ui (t) is defined by the
type of administration, e.g. bolus (instant injection) or infusion (prolonged administration),
and is, therefore, usually known. Since the distribution of the injected substance in the
human body is a dynamic process, the activity values in the considered compartments
need to be determined over time to allow the estimation of the model parameters. This
practically means that for the set up of a personalized pharmacokinetic model a series of
activity measurements in various regions of interest has to be done for the patient. The
number and the frequency of the measurements as well as the list of regions of interest to be
measured depends on the expected complexity of the compartmental model. For this reason
usually the development of the measurement protocol is accompanied by the evaluation
of the model identifiability. The model is globally identifiable if a unique solution of the
system of equations 3.2 exists under the assumption that noise is not present.
3.2. Simulation, Analysis, and Modeling Software II
(SAAM II)
Simulation, Analysis, and Modeling Software II (SAAM II) [39] is a software package for
tracer and pharmacokinetic analysis. Compartmental and numerical modules are available
in SAAM II. The compartmental module can be used to create a visual representation of
a model in the graphical user interface. The program creates subsequently a system of
ordinary differential equations from the graphically specified compartmental model structure.
The numerical module allows direct specification of algebraic equations describing the model.
Three integration methods are implemented in SAAM II. This includes the Rosenbrock
integrator, the Runge-Kutta integrator as well as the Pade integrator. In this thesis the
Rosenbrock integrator was employed. Depending on the investigated problem, one of
these integrators can be specified by the user. The values of unknown model parameters
are estimated by minimizing the objective function, which in SAAM II is the extended
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least-squares maximum likelihood function [39]. A detailed description of SAAM II package
is given by Barrett et al. [39] and in the SAAM II User’s Guide.
3.3. Blood in pharmacokinetic modeling
As described in section 3.1, the input data, required for setting up a compartmental
pharmacokinetic model, include time-resolved activities in the considered organs and tissues.
Since most of radiopharmaceuticals in nuclear medicine are administered intravenously,
they are distributed to other body tissues via blood. Right after the injection a large
amount of tracer activity is contained in the blood and might remain in the blood during
a substantial time, depending on the speed of the clearance of the injected agent from
the blood. To consider the fraction of activity in the ROI that is associated with the
circulating blood, ICRP [7] and Legget and Williams [40] recommend using the blood
distribution model. ROI activities are obtained from registered PET and CT images. For
each organ or tissue the measured radiotracer activity represents the sum of the activity
in the organ or tissue parenchyma and the activity in the blood content of this organ
or tissue. The blood is distributed throughout the organs in vessels. The diameters of
the vessels go down to 4–9 micrometres for capillary [41], which is much smaller than
the spatial resolution of both PET and CT. Therefore, the activity in organ parenchyma
and organ blood cannot be discriminated. Only the total activity in organ parenchyma
and organ blood is measurable. Consequently, usually these aggregate values, i.e. the
measured activities in organ parenchyma and organ blood together, are used to establish a
pharmacokinetic model. Aggregate measured activities might substantially differ from the
corresponding activities in organ parenchyma for highly vascular organs and tissues. This
circumstance might considerably affect the estimated model parameters.
Activities in blood contents of body organs and tissues were employed in some established
pharmacokinetic models for various purposes. For example, pharmacokinetic models of some
short-lived radionuclides summarized in ICRP publication 53 [7], were derived based on the
blood distribution model. Sgouros [42] corrected the activity of red bone marrow biopsy
samples for blood contamination. Bigler and Sgouros [43] derived cumulated activities of
oxygen in blood in various tissues according to the blood volume of each tissue. Little
work has been done though to sub-divide the aggregate activities obtained from PET
images into activities in organ parenchyma and organ blood in pharmacokinetic models.
Such sub-division of the measured activities facilitates the calculation of activity in organ
parenchyma and organ blood, which, as described above, cannot be obtained by direct
measurements.
Knowing activities in organ parenchyma and organ blood, two concepts of organ dose
computation can be applied. According to concept-1, activities in source organ parenchyma,
with blood as a distinct source region are to be used. In concept-2 blood is not considered
to be a distinct source region and the aggregate measured activities in perfused organs, i.e.
in organ parenchyma and organ blood content together, are employed. Concept-2 is the
conventional one. The majority of the recent publications, related to dosimetric character-
isation of new diagnostic and therapeutic agents [44–46], derive the dosimetry using the
computer program OLINDA/EXM [47]. OLINDA/EXM does not utilize specific absorbed
fractions for blood as a source Φ (rT ← rBlood, E, t). Thus the computed doses in this case
correspond to the concept-2. It is of a high interest to evaluate and compare concept-1
and concept-2, since the way of considering blood activity in the dose calculation might
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considerably influence the resulting organ doses. This is true even for relatively low activity
concentrations in the blood because they can amount to high integral activity due to the
large blood volumes (5300 ml and 3900 ml for reference male and female, respectively) [48].
In this thesis a new method for modeling separately activities in parenchyma and blood
contents of source regions was proposed, implemented and evaluated. The dosimetric
influence of defining blood as a distinct source region, i.e. blood contents of various organs
and blood vessels, was also examined. The related findings are presented later in sections 4.4
and 5.2, respectively.
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pharmacokinetic model development
4.1. Patients
In this work five sets of activity data were used. They were obtained from five healthy
volunteers (three women, two men) administered with a radiopharmaceutical for PET/CT
imaging. The employed radiopharmaceutical (S)-4-(3-18F-fluoropropyl)-L-glutamic acid
(18F-FSPG) is designated for the diagnosis of cancer. This novel agent was recently described
by Smolarz et al. [44] and is not yet clinically approved. For convenience, the following
nomenclature for naming the volunteers will be used here and in the consecutive text:
1101/94, 1102/94, 1103/94, 1104/94, 1105/94. Non-image information (age, height, weight
of the volunteers) and the injected activities (IA) are presented in table 4.1.
1101/94
female
1102/94
female
1103/94
male
1104/94
female
1105/94
male
Age, years 58 64 57 63 51
Height, cm 170 170 189 160 168
Weight, kg 90 95 106 65 65
IA, MBq 283 316 275 330 295
Table 4.1. Volunteers details and injected activities (IA) [35].
4.2. Measurements
The PET images, blood and urine samples were acquired at the Nuclear Medicine De-
partment of Klinikum rechts der Isar of Technische Universität München as part of the
characterization of this agent [44]. The ethics committee approval had been granted.
18F-FSPG was administered intravenously via a catheter placed in the antecubital vein.
Another catheter was placed in the antecubital vein of the other arm to allow blood sampling.
PET scans were obtained with Biograph 64 TruePoint PET/CT scanner (Siemens Medical
Solutions). The imaging protocol comprised seven sequential scans. The description of it is
given by Zvereva et al. [35] and Smolarz et al. [44]. The frequency of the scans was higher
at the beginning in order to resolve the high-gradient part of the time-activity curves. The
total body scan started instantly after the tracer administration and the other six scans
were done from the top of the head to the mid-thigh starting at approximately 15, 20, 30, 40,
150 and 240 minutes after injection. The first scan comprised 12 bed positions, with each
bed position being one minute long. It was followed by four scans of seven bed positions
(one minute per bed position). The two last scans comprised a total of seven bed positions,
four minutes long each. Blood samples were collected at approximately 5, 10, 15, 20, 30, 45,
60, 90, 180 and 240 minutes after injection. Blood samples of volunteer 1102/94 were not
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taken because of technical reasons. Activities of the blood samples were measured with a
well counter detector (Wallac) with respect to a reference, which was calibrated in the well
counter (Capintec). To do the cross calibration between the imaging system and the well
counter, a phantom filled with a known activity measured in the well counter (Capintec)
was included in the PET scans. Smolarz et al. [44] compensated the off-image activity in
the partial body scans. Urine samples were collected at approximately 50, 125, 180, 225 and
265 minutes after the tracer administration. Individual voiding times and the volumes of
the voided urine were recorded. Various regions of interest (ROI) were considered: kidneys,
urinary bladder contents, heart, thyroid, salivary glands, pancreas, stomach wall, liver and
spleen [44]. The activity concentrations for the ROIs were determined from the PET images.
After segmenting the registered CT images, Smolarz et al. [44] defined the organ volumes
and, subsequently, calculated absolute activity values in these regions.
4.3. Development of personalized pharmacokinetic
models
The activity data used in this work to establish a compartmental pharmacokinetic model
for radiopharmaceutical 18F-FSPG included the physical decay of 18F. Half-life of 18F is
T1/2 = 109.771 min. The activities obtained from PET images corresponded to the times
at which the respective PET scans were obtained, and not to the injection time. The
measured activities in blood corresponded to the times at which the blood samples were
taken. Therefore it was necessary to account for the radioactive decay of 18F in the model.
For this purpose an additional loss from each compartment in the model equal to the decay
constant λ of 18F was included. The compartmental pharmacokinetic model structure
proposed in this work for 18F-FSPG is presented in figure 4.1. Note that the transfer rates
mimicking the physical decay of 18F are not shown in figure 4.1, since they are not the
unknown model parameters. Their values were fixed to λ = ln 2
T1/2
= 0.0063 min-1.
Figure 4.1. Compartmental pharmacokinetic model structure for 18F-FSPG [35].
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To establish the compartmental model shown in figure 4.1 relative activities in % of
injected activity were employed, i.e. activity in Bq normalized to the injected activity
in Bq and given in %. These values are denoted as activity coefficients in the following
text. A system of first-order linear ordinary differential equations was used to describe
the distribution and the excretion of 18F-FSPG. Model structural identifiability was tested
against the measured data (PET images, blood samples) using the computer program
DAISY (Differential Algebra for Identifiability of SYstems) [49]. The model is globally
identifiable if a unique solution of the system of differential equations describing the model
can be found with the available input and output data under a condition that noise is not
present. The considered ROIs included kidneys, bladder, heart, thyroid, salivary glands,
pancreas, stomach wall, liver and spleen [44]. These organs were initially implemented
into the proposed model as compartments connected to the central blood compartment.
In addition to the mentioned ROIs Smolarz et al. [44] considered bone marrow for two
volunteers. For the other three volunteers the uptake by the bone marrow was not above
the general activity level in the body and was not measured. To keep the same consistent
model structure, bone marrow was not considered as a distinct source region in this work.
Sub-compartments for liver and spleen were added to the model to better fit the measured
data, analogously to, e.g., ICRP [50] and Giussani et al. [51], who introduced two liver
sub-compartments. Sub-compartments 1 and 2 represent, respectively, short- and long-term
retention of 18F-FSPG. Liver-2 and spleen-2 are defined on a kinetic rather than a biological
basis. To describe the urinary excretion of 18F-FSPG initially the kidney-bladder model
reported by the ICRP [50] was adopted. It includes the direct transfer from blood to the
urinary bladder and the slower transfer to the bladder through the urinary path. During
the model fit, the transfer rate representing the direct flow from the blood to the bladder
content could not resolve the relatively slow experimentally measured uptake of 18F-FSPG
by bladder. Thus, for 18F-FSPG the fast transfer from blood to bladder was removed. To
model the observed fast renal clearance and the slow uptake by bladder, an additional
compartment was introduced between kidneys and bladder. Physiologically it represents
the urine flow through the ureter (figure 4.1). The activity of 18F-FSPG in ureter can be
also seen in the PET images in figure 4.2.
Figure 4.2. PET image of volunteer 1104/94 showing activity of 18F-FSPG in urine, which
is produced in kidneys and flows through ureter to bladder content. 18F-FSPG
was injected via an intravenous catheter placed in the antecubital vein of the
right arm. Since this image corresponds to the PET scan obtained right after
the administration of 18F-FSPG, a large amount of activity can still be seen in
the blood vessels of the right arm.
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One compartment, defined as rest of body (RoB), was added to the model to account
for the radiotracer activity transported to the organs and tissues that were not explicitly
considered in the compartmental pharmacokinetic model. The activity coefficients of
RoB were calculated via the subtraction of organ activity coefficients from the total body
data. One common model structure was used for all volunteers; however, personalized
model parameter sets were estimated based on the individual PET images and measured
blood samples. A system of linear first-order ordinary differential equations was used to
mathematically describe the kinetics of 18F-FSPG. All necessary nomenclature is given in
table 4.2. The system of differential equations 4.2 for the model developed in this work (see
figure 4.1) is given in the end of this section.
Activity coefficient in respective
compartment of the model
Symbol Measured activity
coefficient†
Symbol
Blood x1 Blood-per-ml y1
Other kidney tissue x2 } Kidneys y2Urinary path x3
Ureter x4 — —
Heart x5 Heart y5
Liver-1 x6 } Liver y6Liver-2 x62
Rest of body x7 Rest of body
? y7
Pancreas x8 Pancreas y8
Spleen-1 x9 } Spleen y9Spleen-2 x92
Urinary bladder content x10 Urinary bladder content y10
Stomach wall x13 Stomach wall y13
Salivary glands x33 Salivary glands y33
Thyroid x34 Thyroid y34
Known injected activity
coefficient‡
u1
Table 4.2. Symbols used in the system of differential equations for the model shown in
figure 4.1. Kidneys, liver and spleen are represented by two sub-compartments,
which were defined on a kinetic rather than a biological or anatomical basis.
Thus the separate determination of the activity in the sub-compartments was
not possible and the whole organs were measured instead. This represented by
one entry in the two rightmost columns for kidney, liver and spleen.
†Activity coefficient is a measured activity given in % of injected activity.
?Rest of body data were not measured, but calculated instead.
‡Normalized to injected activity, it is always equal to 100 %.
Exact voiding times of the volunteers were recorded. This enables a volunteer-specific
modeling of the urinary excretion. The volume and the activity of the collected urine
samples were also measured, however, the available data for the activities in the urine
samples were not conclusive and, therefore, analogously to [44], not used in the modeling.
In this work the bladder-content activities determined from the PET images were employed
instead. Some published bladder models [22] account for the residual urine volume following
voiding. To account for the residual urine volume in this work, an additional equation was
included at every time-point of the voiding cycle:
xafter10 = x
before
10 (1− fri) (4.1)
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where xbefore10 denotes the activity coefficient in the urinary bladder-content compartment
right before the voiding and xafter10 – right after the voiding; fri is the voiding fraction of
voiding i with 0 ≤ fri ≤ 1. The values fri were included as additional unknown parameters
into the compartmental pharmacokinetic model. Although the amount of voided activity
could be determined from the total measured activities in the urine samples, these were not
used in the modeling due to the above mentioned reasons.

dx1
dt
= u1 − (k34,1 + k33,1 + k2,1 + k3,1 + k9,1 + k6,1 + k8,1 + k5,1 + k13,1 + k7,1)x1
+k1,34x34 + k1,33x33 + k1,2x2 + k1,9x9 + k1,6x6 + k1,8x8 + k1,5x5 + k1,13x13
+k1,7x7 − λx1
dx2
dt
= k2,1x1 − k1,2x2 − λx2
dx3
dt
= k3,1x1 − k4,3x3 − λx3
dx4
dt
= k4,3x3 − k10,4x4 − λx4
dx5
dt
= k5,1x1 − k1,5x5 − λx5
dx6
dt
= k6,1x1 − k1,6x6 − k62,6x6 − λx6
dx62
dt
= k62,6x6 − λx62
dx7
dt
= k7,1x1 − k1,7x7 − λx7
dx8
dt
= k8,1x1 − k1,8x8 − λx8
dx9
dt
= k9,1x1 − k1,9x9 + k9,92x92 − k92,9x9 − λx9
dx92
dt
= k92,9x9 − k9,92x92 − λx92
dx10
dt
= k10,4x4 − λx10
dx13
dt
= k13,1x1 − k1,13x13 − λx13
dx33
dt
= k33,1x1 − k1,33x33 − λx33
dx34
dt
= k34,1x1 − k1,34x34 − λx34
(4.2)
The duration of the measurements covered 4.5 hours, and not the entire modeled time-
period of 1000 minutes (≈ 17 hours). To account for the urinary excretion of activity after
the last recorded voiding, a scheme used by the MIRD committee [22] was considered:
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3-hours voiding intervals following the last measured voiding and a 6-hours nighttime gap
beginning at midnight with an extra voiding right before midnight. Due to the absence of
experimental data later than 4.5 hours after the injection these later voidings were assumed
to be complete, i.e. the values fri = 1 were fixed. Since the bladder-content activities were
determined from the PET images, they were available at the time-points when the PET
scans were taken. If more than one voiding took place between the two sequential PET
scans, it was possible to estimate only the latest voiding fraction fri in this time-period.
The indeterminable fri in this time-period were fixed to one (complete voiding).
The coefficient λ in the system of differential equations 4.2 is the decay constant of 18F,
as described on page 36. The system of differential equations 4.2 was numerically solved in
the software SAAM II (Simulation, Analysis, and Modeling Software II) [39] described in
section 3.2. The equation 4.1 describing the bladder voiding, i.e. full or partial emptying
of compartment x10 at the voiding times, was added as a “change conditions” option of
SAAM II. The fitting was done simultaneously for all transfer rates. All transfer rates were
adjustable.
4.4. Proposed method for modeling blood contents of
organs and tissues
To consider that aggregate activities obtained from the PET images comprise the activities
of organ parenchyma and organ blood, each measured organ activity was associated with
the respective organ compartment and a fraction of the blood compartment. For each
source organ and tissue the attributed blood fraction was equal to the blood content of
the respective organ or tissue given as a fraction of the total blood volume. The remaining
blood activity was included into the RoB. The blood compartment was associated with the
measured activity coefficients-per-ml in blood samples multiplied by the total blood volume
(5300 ml and 3900 ml for reference male and female [48], respectively). Thus for each source
region except blood in concept-1 (see section 3.3) the measured activity coefficients were
considered as follows:
ymeasuredrSi
= yparenchrSi
+RBF rSi y
measured,ml
1 TBV (4.3)
where ymeasuredrSi
is the activity coefficient (in % of IA) obtained from the PET images in the
source region rSi ; y
parench
rSi
is the activity coefficient in the parenchyma of rSi (in % of IA);
RBF rSi is the regional blood fraction in rSi , i.e. blood content of rSi given as fraction of the
total blood; ymeasured,ml1 and TBV are the measured activity coefficient in blood-per-ml (in
% of IA/ml) and the total blood volume (in ml), respectively. Reference values of regional
blood fractions RBF rSi and total blood volumes TBV reported by ICRP [48] were used
(see table 4.3), because individual data for the studied volunteers were not available. ICRP
publication 89 [48] does not provide the blood contents for salivary glands. Mass fractions
of blood in salivary glands were evaluated as average of the mass fractions of blood in
some other tissues (namely: fat, brain, stomach/oesophagus, small intestine, large intestine,
kidneys, liver, skeletal muscle, pancreas, red marrow, skin, thyroid, lymph nodes, gonads,
adrenals, and urinary bladder). Blood contents for salivary glands were evaluated from the
mass of salivary glands, mass fractions of blood in salivary glands and the total mass of
blood.
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Regions of interest
for 18F-FSPG
Adult female Adult male
Kidneys 2.000% 2.000%
Heart? 8.950% 9.078%
Bladder content 0.000% 0.000%
Spleen 1.400% 1.400%
Pancreas 0.600% 0.600%
Liver 10.000% 10.000%
Stomach wall 1.000% 1.000%
Thyroid 0.060% 0.060%
Salivary glands‡ 0.244% 0.257%
Rest of body 75.746% 75.605%
Total body 100.000% 100.000%
Blood 100.000% 100.000%
Table 4.3. Reference blood contents of considered regions of interest (in % of total blood
volume TBV ) from ICRP publication 89 [48].
TBV is equal to 3900 ml and 5300 ml for reference adult female and reference
adult male, respectively [48].
?Mainly heart content. Includes the inner part of the heart wall, though.
‡Is not taken from ICRP [48], but calculated as described in the text.
Using the nomenclature from table 4.2 on page 38 and the values of RBF rSi from table 4.3
as an example for reference adult female, equations 4.3 for 18F-FSPG can be written as
follows: 
y1 =
x1
3900
y2 =x2 + x3 + 2.00 · 10−2x1
y5 =x5 + 8.95 · 10−2x1
y6 =x6 + x62 + 10.00 · 10−2x1
y7 =x7 + x4 + 75.74 · 10−2x1
y8 =x8 + 0.60 · 10−2x1
y9 =x9 + x92 + 1.40 · 10−2x1
y10 =x10
y13 =x13 + 1.00 · 10−2x1
y33 =x33 + 0.24 · 10−2x1
y34 =x34 + 0.06 · 10−2x1
(4.4)
For male volunteers the values of RBF rSi for reference adult male were employed. The
available sets of time-activity coefficients yrSi were used as an input in the SAAM II software.
In the graphical user interface of the SAAM II, yrSi were associated with the corresponding
compartment, with a fraction of the compartment or with several compartments (see
figure 4.3). Based on this visual graphical representation, the equations 4.4 were created by
the SAAM II software, analogously to the system of differential equations 4.2. Equation 4.1
(see page 38) was used as “change conditions” for bladder-content compartment x10.
The resulting pharmacokinetic model fits along with the estimated model parameters
and the computed internal organ doses are presented in the next chapter 5.
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Figure 4.3. Graphical user interface of SAAM II. Black circles and arrows represent the
model compartments and the considered transfer ways of 18F-FSPG, respectively.
Red circles show how experimentally measured data were associated with the
compartments in the pharmacokinetic model.
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5. Developed pharmacokinetic models
and blood effect
5.1. Developed individual pharmacokinetic models
The developed model structure for the considered radiopharmaceutical 18F-FSPG [44]
was presented in figure 4.1 on page 36. With the available experimental data the model
structure was globally identifiable – as tested with the software DAISY (Differential Algebra
for Identifiability of SYstems) [49]. Table 5.1 shows estimated model parameters for five
volunteers. Voiding fractions fri were also estimated with the SAAM II software [39] as
explained in section 4.3. They are summarized in table 5.2.
A subset of the resulting compartmental pharmacokinetic model predictions along with
the measured data is presented in figure 5.1 [35]. It was assumed that at t = 0 (injection
time) 100% of the injected activity was distributed in blood. A fraction of blood activity,
corresponding to regional blood volumes, was attributed to the source regions (except
the urinary bladder contents), resulting in non-zero activities in these regions at t = 0.
Although such immediate uptake is physiologically not entirely meaningful, this does not
have a notable influence on the time-integrated activity coefficients ã (rS, TD) due to the fast
experimentally observed uptake. Within a few minutes after the tracer administration the
uptake of 18F-FSPG reached its maximum in all source regions except the urinary bladder
contents. Hence these assumptions are considered to be appropriate and not critical for the
resulting model fits.
The retention of activity in the liver of volunteer 1102/94 was considerably higher
compared to the other volunteers. The uptake in pancreas for volunteers 1102/94, 1104/94
and 1105/94 was similar, while for volunteer 1103/94 the maximum uptake in pancreas was
approximately only half of that value, followed by a slower decline of activity in this organ.
Different accumulation and release of activity in the stomach walls of the volunteers was
observed (see figure 5.1). It can be seen that the model prediction for spleen of volunteer
1105/94 does not describe the experimental data precisely. The probable reason of this is
the variability in the blood fractions RBFspleen in the spleen. The reference fraction of blood
attributed to the spleen of volunteer 1105/94 was higher than the respective individual
RBF
1105/94
spleen . Consequently, the model could not be precisely fitted to the experimental data
at the earlier times, at which the amount of 18F-FSPG in the blood was still substantial.
18F-FSPG showed relatively fast release from the body via the urinary excretion pathway.
After the first voiding, 30–40 % of the injected activity was excreted. However, such a renal
clearance results in substantial doses from 18F-FSPG for kidneys and urinary bladder wall.
Besides the model predictions for the perfused organs, shown in figure 5.1, the model
predictions for the organ parenchyma were also obtained. An example of the time-activity
curves derived for the organ parenchyma is presented in figure 5.2.
By the integration under the modeled time-activity curves the time-integrated activity
coefficients ã (rS, TD) were computed for all considered source regions rS. The activity in
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Compartmental pharmacokinetic model parameters, [min-1]
Parameter*,‡ 1101/94 f 1102/94 f 1103/94 m 1104/94 f 1105/94 m Mean ± SD
k1,2 Other kidney tissue→Blood 4.20E-02 1.70E-02 4.00E-02 5.80E-02 4.50E-02 4.0E-02 ± 1.3E-02
k1,5 Heart
†→Blood 4.30E-02 1.40E-02 3.60E-02 8.40E-02 1.30E-02 3.8E-02 ± 2.6E-02
k1,6 Liver1→Blood 3.30E-02 5.40E-03 3.90E-02 8.50E-02 6.70E-03 3.4E-02 ± 2.9E-02
k1,7 Rest of body→Blood 2.50E-02 0.00E+00 2.20E-02 2.10E-02 1.10E-02 1.6E-02 ± 9.1E-03
k1,8 Pancreas→Blood 1.50E-02 1.10E-02 2.00E-02 1.70E-02 1.50E-02 1.5E-02 ± 3.1E-03
k1,9 Spleen1→Blood 8.30E-02 2.00E-02 8.40E-02 1.70E-01 0.00E+00 7.2E-02 ± 6.1E-02
k1,13 Stomach wall→Blood 2.00E-02 4.30E-02 5.10E-02 1.80E-01 1.20E-02 6.1E-02 ± 6.1E-02
k1,33 Salivary glands→Blood 4.40E-02 1.50E-02 4.40E-02 3.90E-02 1.40E-02 3.1E-02 ± 1.4E-02
k1,34 Thyroid→Blood 8.90E-02 3.10E-02 4.80E-01 1.00E-01 2.40E-01 1.9E-01 ± 1.6E-01
k2,1 Blood→Other kidney tissue 3.70E-02 2.80E-02 3.40E-02 4.40E-02 2.50E-02 3.3E-02 ± 6.8E-03
k3,1 Blood→Urinary path 5.30E-02 7.60E-02 5.60E-02 5.70E-02 4.60E-02 5.8E-02 ± 1.0E-02
k4,3 Urinary path→Ureter 9.30E-01 9.40E-01 1.00E+00 1.00E+00 4.40E-01 8.7E-01 ± 2.2E-01
k5,1 Blood→Heart† 3.70E-03 2.20E-03 4.90E-03 2.40E-03 2.50E-04 2.7E-03 ± 1.6E-03
k6,1 Blood→Liver1 1.10E-02 8.20E-03 1.00E-02 1.60E-02 2.00E-03 9.4E-03 ± 4.6E-03
k7,1 Blood→Rest of body 7.00E-02 6.40E-03 8.10E-02 6.50E-02 1.70E-02 4.8E-02 ± 3.0E-02
k8,1 Blood→Pancreas 4.50E-03 4.20E-03 2.70E-03 5.60E-03 3.10E-03 4.0E-03 ± 1.0E-03
k9,1 Blood→Spleen1 2.40E-03 1.20E-03 2.00E-03 4.00E-03 1.20E-05 1.9E-03 ± 1.3E-03
k10,4 Ureter→Bladder content 8.80E-02 2.90E-02 6.80E-02 1.50E-01 1.20E-01 9.1E-02 ± 4.2E-02
k13,1 Blood→Stomach wall 2.10E-03 1.90E-03 1.90E-03 1.30E-02 4.60E-04 4.0E-03 ± 4.8E-03
k33,1 Blood→Salivary glands 5.40E-04 1.90E-04 5.30E-04 3.70E-04 1.00E-04 3.5E-04 ± 1.8E-04
k34,1 Blood→Thyroid 8.00E-04 2.30E-04 3.50E-03 7.30E-04 7.60E-04 1.2E-03 ± 1.2E-03
k62,6 Liver1→Liver2 2.90E-03 0.00E+00 1.80E-03 5.70E-03 9.30E-04 2.3E-03 ± 2.0E-03
k92,9 Spleen1→Spleen2 1.40E-03 1.20E-03 0.00E+00 3.40E-03 0.00E+00 1.2E-03 ± 1.2E-03
Table 5.1. Estimated model parameters [min-1] [35].
SD is standard deviation.
*Parameter k9,92 (Spleen2 → Spleen1) is not shown in table 5.1 because the
estimated value of it was equal to zero for all five volunteers. This can be
explained by too long retention of the radiopharmaceutical 18F-FSPG in the
compartment Spleen2 compared to the time of the measurements (≈ 4 hours).
‡Blood volumes were not estimated, but fixed to the reference values, reported
in ICRP Publication 89 [48] – 3900 ml and 5300 ml for reference female and
male, respectively.
†The source region Heart comprised the heart content and only the inner part of
the heart wall.
Serial number
of voiding fraction 1101/94 f 1102/94 f 1103/94 m 1104/94 f 1105/94 m
1 1.0? 1.0? 1.0? 1.0? 1.0?
2 1.0 0.9 0.8 1.0? 1.0?
3 1.0? 1.0? 0.6 0.1 0.8
4 0.9 1.0 1.0? 1.0? 0.8
5 —– 1.0? —– 0.1 —–
6 —– —– —– 1.0? —–
Table 5.2. Estimated‡ voiding fractions [35].
‡Where it was not possible to estimate the voiding fractions, they were fixed to
the value one – complete voiding. The fixed voiding fractions are marked?.
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Figure 5.1. Resulting compartmental pharmacokinetic model fits for subjects 1101/94-
1105/94. The lines are model predictions, discrete points are measured data.
For kidneys, liver, pancreas, stomach wall and spleen measured data, obtained
from PET images, represent activity coefficients of organs along with the activity
coefficients of blood flowing through them [35].
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Figure 5.2. Example of resulting compartmental pharmacokinetic model fits for perfused
organs and organ parenchyma of subject 1101/94. The solid lines correspond
to activity coefficients of perfused organs, i.e. to activity coefficients of organs
along with the activity coefficients of blood flowing through them. The dashed
lines correspond to the activity coefficients of organ parenchyma.
the ureter compartment was attributed to the rest of body rRoB. The ureter was hence a
part of the source rRoB. For each source region except urinary bladder content, blood and
total body, two sets of the time-integrated activity coefficients ã (rS, TD) were computed.
They correspond to the organ parenchyma and to the perfused organ, i.e. including the
activity of the regional blood content. Specifically, to compute the values of ã (rS, TD)
for perfused organs, the integration was done under the time-activity curves shown in
figure 5.1. To obtain the corresponding values of ã (rS, TD) for organ parenchyma, the
dashed time-activity curves, e.g. for volunteer 1101/94 those from figure 5.2, were employed.
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5.2. Effect of blood activity on dosimetric calculations
All computed ã (rS, TD) are summarized in table 5.3.
The integration period TD was set to 1000 min despite it theoretically being infinite.
For the kinetics of 18F-FSPG considering 1000 minutes was sufficient because at the time
t = 1000 min after the tracer administration only 0.001 %–0.015 % of injected activity
remained in the body. To test how the time-integrated activity coefficients ã (rS, TD)
change with increasing the modeled time-period TD, their values were recalculated with
TD = 10
5 min. The values of ã (rS, TD) increased by 0.25 % at most for spleen of one
of the volunteers, if employing TD = 10
5 min instead of TD = 1000 min. ã (rS, TD) for
most source regions remained unaffected by the increase of the integration time. Since
ã (rS, TD) = ã (rS, TD = 1000), the following notation will be used from now on: ã (rS).
5.2. Effect of blood activity on dosimetric calculations
Organ doses were computed according to the formalism described in chapter 2. To evaluate
the effect of blood activity on the organ doses, the calculations were done according to two
concepts. The definition of the concepts is given in section 3.3 on page 33. In concept-1
activities of organ parenchyma were employed, i.e. organs without blood content, and blood
was a distinct source region. According to concept-2, activities in perfused organs were
used, i.e. with their blood contents, the rest of blood activity (besides the part distributed
in the source organs) was attributed to the rest of body rRoB. Thus the organ doses were
computed with the two sets of activity data summarized in tables 5.4 and 5.5 for concept-1
and concept-2, respectively.
The source region “Heart” comprised the heart content and only the inner part of the
heart wall. When considering a distinct blood source (concept-1), the heart content (being
pure blood) is part of this source and should not be considered separately in addition.
Therefore the heart source in concept-1 is only the heart wall, and, consequently, the specific
absorbed fractions for the heart wall are to be used. When considering perfused organs
(concept-2), the heart source should consist of both the heart wall source and the heart
content source. This means that two different sets of the specific absorbed fractions are
to be used – for the heart wall and for the heart content. The heart contents comprise
481 ml and 349 ml of blood for reference male and female, respectively. Therefore the
time-integrated activity coefficient of the heart content ã (heart content) can be calculated
by multiplying the known ã (blood-per-ml) by 481 ml (for male volunteers) or 349 ml (for
female volunteers). ã (heart wall) is then calculated by subtracting ã (heart content) from
the time-integrated activity coefficients for the entire heart.
In this section the values of specific absorbed fractions Φ (rT ← rS, E) of ICRP reference
voxel phantoms [52–54] were used for computation of the dose. Φ (for convenience the
argument is omitted in the following) were not adjusted to organ masses of the volunteers
to keep the computations consistent, i.e. to use the reference values for both, regional
blood volumes and organ volumes/masses. This is a source of uncertainty, though. The
inter-individual differences in organ volumes and regional blood volumes may enhance or
reduce the investigated effect of blood.
The employed values of Φ summarized in the studies [52–54] were originally simulated
for organs with blood – Φw. This corresponds to concept-2. The values of Φ corresponding
to organ parenchyma – Φw/o – are needed for concept-1. These can be deduced from Φw
considering the following. The probability that a particle is absorbed in any constituent of an
organ is proportional to its mass and its mass-energy absorption coefficient µen/ρ for photons
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5.2. Effect of blood activity on dosimetric calculations
Time-integrated activity coefficients ã (rS), [s]
Source region 1101/94 f 1102/94 f 1103/94 m 1104/94 f 1105/94 m
Kidneys 5.90E+02 7.33E+02 5.30E+02 5.13E+02 5.51E+02
?Heart wall 5.40E+01 6.09E+01 7.68E+01 1.81E+01 1.18E+01
Bladder content 1.17E+03 9.75E+02 1.35E+03 1.15E+03 1.24E+03
Spleen 2.36E+01 2.97E+01 1.45E+01 2.29E+01 1.71E+00
Pancreas 1.51E+02 1.46E+02 6.88E+01 1.64E+02 1.42E+02
Liver 2.66E+02 4.05E+02 1.87E+02 2.18E+02 1.51E+02
Stomach wall 5.71E+01 2.26E+01 2.21E+01 4.98E+01 2.39E+01
Thyroid 6.11E+00 3.55E+00 4.85E+00 4.58E+00 2.91E+00
Salivary glands 7.83E+00 5.11E+00 7.20E+00 5.59E+00 4.65E+00
Rest of body 2.02E+03 1.81E+03 2.46E+03 1.89E+03 1.24E+03
Blood, total 7.27E+02 5.79E+02 6.73E+02 6.92E+02 9.38E+02
Table 5.4. Time-integrated activity coefficients used in the dosimetry according to concept-1
for volunteers 1101/94-1105/94 (18F-FSPG).
Concept-1: source organs parenchyma, blood is a separated source.
?This source region comprised the heart content and only the inner part of the
heart wall. The way it was considered in concept-1 is described in the text.
Time-integrated activity coefficients ã (rS), [s]
Source region 1101/94 f 1102/94 f 1103/94 m 1104/94 f 1105/94 m
Kidneys 6.05E+02 7.45E+02 5.43E+02 5.27E+02 5.70E+02
?Heart content 6.50E+01 5.18E+01 6.11E+01 6.19E+01 8.51E+01
?Heart wall 5.41E+01 6.09E+01 7.69E+01 1.81E+01 1.18E+01
Bladder content 1.17E+03 9.75E+02 1.35E+03 1.15E+03 1.24E+03
Spleen 3.37E+01 3.78E+01 2.39E+01 3.25E+01 1.48E+01
Pancreas 1.56E+02 1.49E+02 7.29E+01 1.68E+02 1.47E+02
Liver 3.39E+02 4.63E+02 2.54E+02 2.87E+02 2.45E+02
Stomach wall 6.44E+01 2.84E+01 2.88E+01 5.67E+01 3.33E+01
Thyroid 6.55E+00 3.90E+00 5.25E+00 4.99E+00 3.47E+00
Salivary glands 9.61E+00 6.53E+00 8.93E+00 7.28E+00 7.06E+00
Rest of body 2.58E+03 2.25E+03 2.97E+03 2.41E+03 1.95E+03
Table 5.5. Time-integrated activity coefficients used in the dosimetry according to the
concept-2 for the volunteers 1101/94-1105/94 (18F-FSPG).
Concept-2: perfused source organs, i.e. with their blood contents, circulating
blood is included into rest of body.
?This source region “Heart” comprised the heart content and only the inner part
of the heart wall. The way it was considered in concept-2 is described in the
text.
or continuous slowing down approximation (CSDA) ranges for electrons. This is valid for
the self-absorption and the cross-fire. The self-absorption and the cross-fire are defined in
the introduction (see part on page 4). The National Institute of Standards and Technology
(NIST) provides µen/ρ and CSDA ranges in various materials (http://www.nist.gov).
According to these data, µBlooden /ρ ≈ µTissue,Soften /ρ (equal within the precision accuracy of
10−5) for the photon energy of 500 keV. The percent differences between CSDABlood and
CSDAT issue,Soft amount to 0.75 % and 0.70 % for the electron energies of 250 and 600 keV,
respectively. Thus the differences in µen/ρ and CSDA ranges between perfused organs and
organ parenchyma are negligible in the considered energy range. Note the relation between
the specific absorbed fraction Φ and the absorbed fraction φ: Φ = φ/MrT . Therefore
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5. Developed pharmacokinetic models and blood effect
assuming a homogeneous mixture of blood and parenchyma in source regions, for the
absorbed fraction φ it can be written:
φw/o
φw
≈
MrTw/o
MrTw
(5.1)
According to the definition of Φ it follows that:
Φw/o =
φw/o
MrTw/o
≈ φw
MrTw/o
·
MrTw/o
MrTw
=
φw
MrTw
= Φw (5.2)
Thus Φ for all combinations of source and target regions, except source region rest of body,
are approximately the same for both concepts, i.e. for organs with and without blood.
To calculate organ doses, an in-house software “Esoterik”, developed at the Helmholtz
Zentrum München (HMGU), was used. It utilizes pre-calculated Φ for several gamma-ray
energies and for detailed beta spectra from ICRP Publication 107 [55]. 18F is a positron-
emitter with mean energy of 249.8 keV. The pre-calculated Φ for the corresponding electron
energies and a photon energy of 511 keV (annihilation photons) were used. Values defined
in chapter 2 on page 25 and denoted as effective dose coefficients were also computed in
this thesis. The resulting absorbed dose coefficients, effective dose coefficients and the
corresponding relative differences of concept-1 compared to concept-2 are given in table 5.6.
For all source organs, except heart and spleen, no substantial differences between the
two concepts were observed with maximum differences of 6.6 % and 4.6 % for liver and
thyroid, respectively. The doses for heart wall and spleen slightly increased in concept-1
compared to concept-2 (18.5 % and 11.3 % at maximum, respectively). For most of the
target organs, that are not sources, absorbed dose coefficients were higher in concept-1 (up
to 92 % for lungs). Consequently, the effective dose coefficients in concept-1 were higher for
all volunteers with a mean difference of 5.2 % (median 4.4 %, maximum 10.0 %).
The comparison of organ absorbed dose coefficients between concept-1 and concept-2
revealed notably higher doses in concept-1 for many organs. This was mostly observed for
target organs with substantial blood fraction that are not sources, i.e. they are part of
rRoB. For these target regions, the blood activity being attributed to the organs, according
to regional blood fractions RBFrSi (see table 4.3 on page 41) (concept-1), leads to a higher
dose than if the blood activity would be homogeneously distributed in the rest of body
rRoB (concept-2).
For most of the source organs no substantial differences between the two concepts were
noticed. This was expected because, on the one hand, ã (rS), and, therefore, the self-
absorption (see page 4 for the definition), decreased in concept-1 due to the subtraction of
the activities in organ blood contents. On the other hand, a blood activity corresponding
to RBFrSi was present in concept-1 in all source organs. Thus, the subtracted activities
were effectively “placed back” to the source organs, compensating the self-absorption and
leading to the same dose as for concept-2, disregarding other cross-fire (see page 4 for the
definition), i.e. not considering the contribution to the absorbed dose from the radiation
contained in another region. The observed differences in absorbed dose coefficients for
heart wall and spleen are due to the cross-fire from the blood being inside the neighboring
non-source organs, e.g. lungs (for heart wall and spleen), oesophagus (for heart wall), colon
and small intestine (for spleen).
The greatest impact of considering blood as a source region in dosimetry of 18F-FSPG was
observed for lungs, small intestine, colon, oesophagus, thymus and extrathoracic airways.
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5. Developed pharmacokinetic models and blood effect
These organs are considered in the computation of effective dose. The aforementioned
organs were not source regions, though. They received the dose as cross-fire contribution,
which for 18F is expected to be lower than the self-absorption because the low-energy e+ are
predominantly absorbed in source regions themselves. Consequently, the difference of the
two approaches on effective dose was found to be up to 10 %. Due to high mass fractions
of blood in liver, kidneys and spleen, a substantial impact of blood activity in dosimetric
calculations for these organs is expected in case of other radiopharmaceuticals as well, if
liver, kidneys and spleen are not sources. The effect of blood on dosimetric calculations is
expected to be even more pronounced for radiopharmaceuticals with slower clearance from
the blood than the one of 18F-FSPG.
A considerable influence of the blood even for a radiopharmaceutical with a rapid clearance
from the blood, such as 18F-FSPG, was shown (see table 5.6). This suggests that blood should
be introduced as a separate compartment in most compartmental pharmacokinetic models
and considered as a distinct source region in dosimetric calculations. Hence, blood samples
should be included in all pharmacokinetic and dosimetric studies for radiopharmaceuticals
if possible.
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Part III.
Anatomical modeling
53

This part describes the development of models mimicking human anatomy and needed
for internal dosimetry. Specifically, the feasibility of reducing the difference in the estimated
doses in nuclear medicine caused by anatomical differences between a patient and the
reference person was evaluated. Three existing generations of anatomical models, their
construction and application are presented in chapter 6. This is followed by the description
of the proposed method of reducing the difference in internal doses between the patient
and the reference phantom in chapter 7. The steps taken to obtain the new anatomical
models are also described in chapter 7. Chapter 8 presents the newly developed phantoms
and the results of the evaluation of the proposed approach aimed at the development
of non-personalized anatomical models which facilitate overall reliable dose estimates for
individual patients.
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6. Three generations of anatomical
models, their construction and
applications
Models of human anatomy along with radiation transport codes are extensively used for
the computation of radiation doses in medical imaging, radiotherapy, nuclide therapy and
radiation protection. A detailed review of the developments in computational phantom
research is given in e.g. reference [56]. There are three distinct generations of these phantoms
currently in use: stylized mathematical models, voxel models and models based on boundary
representation (BREP) geometries. The latest include the phantoms defined with Non-
Uniform Rational B-Splines (NURBS) and polygon surfaces. The models mimicking the
human anatomy are used in radiation protection for the reconstruction of radiation doses
to workers or public. In medical imaging (radiology and nuclear medicine) they are used for
estimation of the doses associated with these modalities and for the optimization of these
procedures. Whereas in radiation therapy, especially in radionuclide therapy, anatomical
models are employed for computing the dose distributions inside the patient’s body. The
latter is especially important, since the therapeutic procedures are associated with high
doses and these doses cannot be determined by direct measurements. The dose calculation
in the patient’s body is essential for treatment planning. As a routine procedure in external
radiotherapy, the dose distributions are computed based on the tomographic images of
the patient and thus they represent an individual anatomy of the patient. This is usually
not the case in nuclide therapy though. In nuclide therapy the anatomy of a patient is
approximated by an employed anatomical model, which theoretically can be individual.
In routine nuclide therapy and nuclear medicine applications in general the personalized
anatomical models are not frequently used due to the complexity of the construction of
these models. This will be discussed in more detail in the following sections.
6.1. General methods to construct a human
computational phantom
The construction of stylized mathematical phantoms, voxel phantoms and BREP phantoms,
their advantages and drawbacks are given in the following subsections 6.1.1, 6.1.2 and 6.1.3,
respectively.
6.1.1. Stylized mathematical phantoms
This is the first and the oldest generation of human computational phantoms. Stylized
mathematical phantoms are based on the surfaces defined by quadratic equations (planar,
cylindrical, conical, elliptical, toroidal, spherical surfaces). They were first developed for
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internal dosimetry of workers and patients. This is a very simplified representation of
human anatomy, since the used mathematical equations can capture only the most general
features of organ shapes and positions. The first mathematical model of an average adult
man was developed at Oak Ridge National Laboratory (ORNL) and adopted by the MIRD
committee [57]. It is shown in figure 6.1. Based on this model, Cristy and Eckerman
[58] created a family of stylized mathematical models, which is included in the clinically
used software for internal dosimetry - OLINDA/EXM [47]. All currently available stylized
mathematical phantoms are described in the review paper by Xu [56].
Figure 6.1. First stylized mathematical phantom MIRD-5 [57].
The main advantage of these models is their simplicity. They facilitated the first Monte
Carlo radiation transport simulations in geometry mimicking human anatomy. The lack
of anatomical realism limited the use of the stylized models though, and resulted in the
development of the next generation of anatomically realistic phantoms.
6.1.2. Voxel phantoms
Voxel phantoms are composed of three-dimensional arrays of voxels and are segmented from
individual tomographic images, i.e. CT images or magnetic resonance (MR) images. Since
these models are constructed based on the tomographic data of real persons, the human
anatomy is mimicked very realistically. One of the first voxel phantoms was constructed
at the HMGU for pediatric patients [59] and currently the HMGU model library includes
various voxel models of adult males, adult females and children [60]. An example of a voxel
model of seven years old female individual constructed at HMGU is given in figure 6.2.
The methods of constructing a voxel model from tomographic images are described in
detail elsewhere [56, 61] and recapitulated here. Tomographic data consist of a set of slices,
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Figure 6.2. Voxel phantom of the seven years old female individual “Child” from HMGU
model library (courtesy of Helmut Schlattl).
where each slice is a two-dimensional representation of the anatomy in a transverse (most
commonly), coronal or sagittal “cut”. Being interpolated between two sequential slices,
each pixel of the tomographic data forms a three-dimensional voxel. The user needs to
identify for each voxel the anatomical structure, where it belongs to. This process is called
segmentation. It is the most time-consuming step in the construction of a voxel model,
because the user needs to define the anatomical boundaries between all organs and tissues
of interest based on the original two-dimensional slices and with a lack of robust automatic
segmentation tools this process is usually done manually. As a result of the segmentation
step, binary files of the considered organs and tissues are created and each structure is
assigned with a unique organ identification number (OIN). Subsequently, all binary files
are combined to a complete model. Each voxel in the model is identified as belonging to a
specific anatomical structure according to the value of its OIN. For Monte Carlo calculations,
the density and the elemental composition are specified for each organ or tissue.
From the described procedure it can be seen that it is very time-consuming. Additionally,
the construction of a voxel model for the individual patient requires individual CT or MR
images of sufficiently large body coverage and adequate resolution to realistically represent
even small organs and tissues.
Voxel-based computational phantoms provide a high level of anatomic realism. They are
limited in their flexibility though. Such phantoms can be modified only by increasing or
decreasing the dimensions of each voxel or adding or removing voxel layers comprising an
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organ or e.g. adipose tissue. Selective adjustment or scaling of various body parts of a voxel
phantom by different factors cannot be easily done. Thus, despite realistically mimicking
human anatomy, they are limited in representing individuals and various body postures,
unless segmented from individual tomographic images of the desired posture. Xu [56]
summarized the majority of voxel phantoms currently developed by various institutions.
6.1.3. Phantoms based on boundary representation geometries
Phantoms based on boundary representation (BREP) geometries belong to the latest third
generation of human computational models. They are based upon NURBS or polygon
surfaces – the methods widely used in the computer graphics community for creating 3D
graphical objects or for movie animation.
NURBS models consist of anatomical structures defined with Non-Uniform Rational B-
Spline surfaces. This method offers a common mathematical representation of the shapes of
different complexity. The main features and properties of NURBS curves are recapitulated
in the following, partly based on the book “The NURBS book” by Piegl and Tiller [62].
NURBS surfaces are described by a tensor product of two NURBS curves. For the sake of
simplicity the mathematical definition is explicitly given here only for NURBS curves.
A NURBS curve is defined by three main element groups: a set of weighted control points,
knots and basis functions, which are defined for each control point. A NURBS curve of
degree k is mathematically defined as follows:
C (u) =
n∑
i=0
Ni,k (u)ωiPi
n∑
i=0
Ni,k (u)ωi
, u ∈ [a, b] (6.1)
where Pi (i = 0, 1, ..., n) are the control points, ωi are the weights and Ni,k (u) are the
B-spline basis functions of degree k.
Denote a sequence of real numbers sorted from the smallest to the highest value by u.
The vector u and its elements ui are the knot vector and knots, respectively. u is used
to specify where exactly the control point Pi affects the curve C (u). It effectively splits
C (u) into intervals where the respective control points have an effect on the curve. In
NURBS curves these intervals are not equal in length. Moving Pi or changing the weight
ωi influences the shape of only a part of the curve C (u) on the interval u ∈ [ui, ui+k+1].
This property facilitates the localized deformation of the NURBS curve by changing the
positions of selected control points. The basis functions determine for each control point
how strongly it influences the curve. The i-th B-spline basis function Ni,k (u) of degree k is
defined as follows [62]:
Ni,k (u) =
u− ui
ui+k − ui
Ni,k−1 (u) +
ui+k+1 − u
ui+k+1 − ui+1
Ni+1,k−1 (u) (6.2)
with
Ni,0 (u) =
{
1, if ui ≤ u < ui+1
0, otherwise
(6.3)
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Knowing Ni,k (u) from equations 6.2 and 6.3 and the weights ωi, rational basis functions
Ri,k (u) can be calculated:
Ri,k (u) =
Ni,k (u)ωi
n∑
j=0
Nj,k (u)ωj
(6.4)
Equation 6.1 then becomes:
C (u) =
n∑
i=0
Ri,k (u)Pi, u ∈ [a, b] (6.5)
NURBS surfaces are continuous in the first derivative, which provides “smooth” surfaces,
in contrast to polygon meshes (see next paragraph). This fact potentially allows easier
deformation of NURBS surfaces compared to polygon surfaces. NURBS surfaces can form
various complex objects. This facilitates the accurate representation of organs and tissues in
such phantoms and can realistically mimic human anatomy. The relatively easy deformation
facilitates the modeling of various body postures or movements with NURBS surfaces.
Figure 6.3 shows widely used NURBS-based 4D XCAT phantoms of adult male and adult
female [63].
Figure 6.3. Anterior views of the male (left) and the female (right) 4D XCAT phantoms [63].
Image courtesy of Paul Segars.
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Polygon surfaces or polygon meshes are another BREP modeling method, alternative
to the NURBS surfaces described above. A polygon mesh consists of three types of
fundamental entities: vertices, edges and faces. The vertices are points in space defined
by their coordinates. The connections between two vertices are denoted as edges. The
face is defined either as a closed set of the edges or as a connection of several vertices
together (clockwise or counter-clockwise). Each face has a minimum of three vertices.
Those faces with only three vertices form triangular faces, which are commonly used in
the polygon-mesh modeling. Figure 6.4 shows a triangular torso mesh (with vertices) of a
polygon-surface adult male phantom. Polygon meshes are very robust and can be used to
represent geometries of arbitrary complexity. This makes the polygon meshes beneficial and
more convenient compared to the NURBS surfaces for realistic modeling of very complex
structures, e.g. human skeletal system or muscles. At the same time, analogously to the
NURBS, these models keep the ability to be relatively easily deformed, scaled or adjusted.
In literature BREP models are sometimes denoted as hybrid models, since they preserve
the flexibility of the simple stylized mathematical models and the anatomical realism of the
voxel models. These properties make this generation of human computational phantoms
the current state-of-the-art of anatomical modeling.
Figure 6.4. Triangular torso mesh of a polygon-surface adult male phantom. The displayed
white points are the vertices of the polygon mesh.
6.2. Reference human computational phantoms
Reference computational phantoms of adult male and adult female [53] were adopted by the
ICRP and the International Commission on Radiation Units and Measurements (ICRU) as
standard benchmarked models of adults. These models are consistent with reference organ
and tissue masses, body dimensions and body masses given in ICRP [48]. The reference
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ICRP phantoms [53] are widely used in dosimetric calculations from different types of
internal and external exposures for the purpose of radiation protection. These voxel models
were developed from the computed tomographic data of real persons by M. Zankl and
colleagues [53,64] at the HMGU. One of the main motivations for the development of these
phantoms was to adopt the models that realistically mimic human anatomy, compared to the
employed at that time stylized mathematical phantoms. The over-simplified representation
of the human anatomy in the stylized models resulted in deviations in the doses computed
based on these models, as reported by various researches [65, 66]. The voxel phantoms
described in the ICRP publication 110 [53] are currently the official models of reference
adults. Lately the limitations of these models were recognized though [67]. The limitations
are caused by relatively big voxel dimensions, which e.g. for the reference computational
phantom of adult male are equal to 2.137×2.137×8.000 mm3. Thus the small anatomical
structures cannot be realistically represented with such voxel size. This drawback can be
overcome with the latest generation of human computational phantoms – BREP-based
models. Additionally, the BREP phantoms offer high flexibility and facilitate the modeling
of different body postures and movements, needed in some specific situations for the
reconstruction of the radiation doses. Hence, the ICRP committee decided to convert the
reference voxel models of adult male and adult female to the polygon-surface format. This
is an ongoing project at the Department of Nuclear Engineering of Hanyang University in
Seoul. The development of various anatomical structures in the polygon-surface format is
described in the publications [67–70]. The original voxel ICRP reference computational
phantom of adult male and the currently available polygon-surface version of this model
are described in the following subsections 6.2.1 and 6.2.2, respectively.
6.2.1. Reference voxel ICRP adult male phantom
Voxel ICRP adult male reference computational phantom, denoted as RCP-AM, was
constructed from another whole-body voxel phantom Golem [71], which closely resembled
the height and the weight of reference adult male, given by ICRP [48]. The height and the
weight of Golem were equal to 176 cm and 69 kg, respectively, compared to the corresponding
reference values of 176 cm and 73 kg. Various minor adjustments were applied to Golem to
fit the individual organ masses and the total body mass to the reference values from ICRP
publication 89 [48]. It was achieved by voxel scaling and adding or subtracting voxels from
individual organs and adipose tissue. The detailed procedure is described elsewhere [53,64].
A total number of 138 regions were segmented in RCP-AM.
6.2.2. Reference polygon-surface ICRP adult male phantom
Polygon-surface ICRP adult male reference computational phantom, denoted analogously
to RCP-AM, as P-RCP-AM, was constructed from its voxel counterpart by Yeom and
colleagues [67]. P-RCP-AM [67], used in this thesis, is not the final version, since it is
currently under development [68–70]. For this reason some complex structures, e.g. muscles,
are not present in P-RCP-AM. In total 111 regions were segmented in this phantom.
Figure 6.5 shows the two ICRP reference models of adult male – the voxel phantom
RCP-AM and the polygon-surface phantom P-RCP-AM.
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Figure 6.5. Two reference phantoms of adult male: voxel (left) and polygon-surface (right).
Note that the image on the left is a surface rendered representation of RCP-AM
(courtesy of Helmut Schlattl).
6.3. Rationale for individual anatomical models
The reference computational phantoms, described in section 6.2, were originally developed
for the purpose of prospective radiation protection. Various authors, e.g. in the publications
[13,56], recognized the need for individualized dosimetry for medical dose tracking. The
use of reference anatomical models is limited in medical imaging and therapy applications,
because anatomical variations among individuals are disregarded if reference phantoms are
employed. These anatomical variations can notably contribute to the uncertainty of the
estimated organ doses [13].
To account for anatomical differences between individuals, many groups created families
of human computational phantoms. They are constructed via segmentation from available
individual tomographic data (voxel phantoms) or obtained via scaling the BREP phantoms
in terms of body height and weight [60,65,72–85]. To match an individual with a library
of available phantoms for the purpose of dosimetric calculations often such parameters
as total body height, weight or body mass index (BMI) are used. This usually does not
reflect the organ topology of the investigated individual though. Thus it could cause high
differences between the real person-specific doses and the ones obtained for the available
not-person-specific computational phantom. Zhang et al. [86] investigated the differences
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in organ doses, effective doses, and risk indices in CT examinations for adults, caused by
the employment of four types of computational phantoms for dose reconstruction. This
included the extended cardiac-torso (XCAT) family [63], the reference voxel phantoms
described in the ICRP Publication 110 [53] and two stylized mathematical phantoms. The
study of Zhang et al. [86] revealed considerable differences in organ doses from CT even
in case of closely matched weight, height and organ masses of the investigated phantoms.
Other authors also quantified and showed notable differences in some individual organ dose
conversion coefficients for external irradiation [60, 65] and specific absorbed fractions or
organ absorbed dose coefficients for internal irradiation [14–16], caused by the variations in
organ masses and locations in different computational phantoms.
The application of individualized phantoms has the potential to improve the accuracy of
medical dosimetric calculations. This is especially important for medical dose estimation
in therapeutic applications. Individualized anatomical models can be constructed via a
direct segmentation from tomographic data. There are factors precluding this though. As
described in detail in subsection 6.1.2, the accurate segmentation of an individual-specific
phantom in nuclear medicine is difficult due to the very time-consuming manual work
necessary. Another shortcoming of the segmentation of individual phantoms is the need of
individual tomographic images of sufficient resolution and body coverage, which are usually
not available in routine nuclear medicine procedures.
The objective of this part of the thesis was to study the second modeling step needed
for the personalized dosimetry in nuclear medicine applications – anatomical modeling.
Specifically, the aim was to investigate whether the differences between the patient-specific
absorbed doses and those evaluated for non-personalized models can be efficiently reduced
with less effort than would be required were the modelers to segment an individual-specific
phantom.
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7. Adjustment of reference model to
individuals and Monte Carlo
calculation of specific absorbed
fractions
As it is discussed in chapter 6, the goal of anatomical modeling is to develop models
mimicking human anatomy, which facilitate simulations of radiation transport in the
geometry of human body. These simulations enable the modelers to calculate the specific
absorbed fractions Φ (rT ← rS, E) defined on page 23 and needed for internal dosimetry (see
chapter 2). Since Φ (rT ← rS, E) are phantom-specific, it follows that only individualized
anatomical models facilitate personalized internal dosimetry. The accuracy of dosimetry in
general and the accuracy of mimicking individual patient anatomy in particular depend on
the application and on the available resources. As it was mentioned in the introduction
(page 4), the accurate segmentation of a complete individual-specific phantom is difficult
and most commonly not viable for each patient in the routine nuclear medicine practice.
The limiting factors for this were discussed in section 6.3. In this thesis an approach,
alternative to the segmentation of an individual-specific model, was proposed and applied.
The approach is that an anatomical model is developed not by the segmentation from
individual tomographic data, but it is derived by the adjustment of a reference phantom to
some individual-specific characteristics instead. The proposed approach has a potential to
overcome two main shortcomings of the segmentation of the patient-specific phantom or
the direct dosimetry on the patient-specific CT. First, only the source regions are to be
contoured, in contrast to the contouring all regions of interest needed for patient-specific
dosimetry. With a lack of automated segmentation tools, the latter is difficult and requires
an experienced radiologist to be involved. Additionally, most soft tissues are difficult to
distinguish in PET/CT images. Doses for not contoured regions cannot be calculated. The
second shortcoming of the patient-specific methodology is the need of individual CT or MR
images of sufficiently large body coverage and adequate resolution to realistically represent
even small organs and tissues. Such tomographic data are not always available. Therefore,
the proposed approach can be useful in those scenarios where the segmentation of the
patient-specific phantom or the direct dosimetry on the patient-specific CT is not possible.
The viability and the accuracy of the proposed approach are evaluated in chapters 7–8.
Since in this thesis the human computational phantoms are employed for internal dosimetry,
the goodness of the adjusted phantom is evaluated depending on how accurate the computed
doses are and how close they are to the real personalized doses.
In nuclear medicine investigations, patient’s organs and tissues receive radiation doses
due to the accumulation of an administered radiopharmaceutical in the source regions,
defined on page 3. There are two components of an organ absorbed dose: the self-absorption
dose (for source regions only) and the dose from the cross-fire from other source regions.
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The self-absorption and the cross-fire are defined in the introduction (page 4). Organ
self-absorption is dominated by organ mass, as demonstrated in the MIRD Pamphlet 11
[87], which provides a guidance on how patient-specific scaling of Φ (rT ← rS, E) is to be
done. This scaling requires only the mass of the target (= source) region and is, hence,
otherwise independent of the organ topology of an individual. The cross-fire (except the
cross-fire from blood and total body), on the contrary, is influenced by the organ topology.
To distinguish the impact of the individual organ topology on the computed absorbed
dose coefficients, the self-absorption and the cross-fire components of the respective organ
absorbed dose coefficients are given and compared separately in this thesis.
7.1. Adjustment of reference phantom to
individual-specific characteristics
As it is described in subsection 6.1.2, voxel-based computational phantoms are limited
in their flexibility. Thus, as a base model in this work the polygon-surface ICRP male
reference phantom [67], described in subsection 6.2.2 was used. As a BREP model (see
subsection 6.1.3), the polygon-surface phantom can be relatively easily modified and
deformed. As mentioned in subsection 6.2.2, the polygon-surface ICRP male reference
phantom (P-RCP-AM) used here is not the final version and various complex anatomical
structures of this model are currently under development [68–70].
7.1.1. Selected individuals
Two voxel models were selected from the HMGU model library to represent individual
target patients. The biggest available model Visible Human [65] and the smallest available
model Irene [65,72,88] were chosen to test the approach on the individuals with potentially
large differences in the anatomy. These models are shown in figure 7.1.
Overweight individual The Visible Human model used here was segmented from the CT
images obtained from the National Library of Medicine’s Visible Human Project. This
phantom is a partial-body phantom covering the head to mid-thigh. It is described in
detail by Zankl et al. [65]. The BMI of Visible Human is equal to 31.9 kg/m2. The Visible
Human phantom has been constructed from an individual who had only one testicle. This
circumstance resulted in a testes mass lower than the reference value (25.5 g compared
to 35 g). However, for the radiopharmaceutical under consideration (see chapter 4) the
testes are not a source region. Hence, the testes dose is only due to cross-fire irradiation.
Consequently, this lower target region mass does not have an impact on the estimated
doses.
Slim individual Irene has been constructed from the CT images of a patient, covering the
whole body. The BMI of Irene is equal to 19.2 kg/m2. The detailed description of this
phantom is given elsewhere [65,72]. Despite the employed polygon-surface reference model
being male, the female model Irene was chosen since no male model with similarly small
BMI is available in the HMGU model library. Thus the doses for gender-specific organs
could not be compared between Irene and the polygon-surface reference model adjusted
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Figure 7.1. Voxel phantoms Visible Human (left) [65] and Irene (right) [65, 72, 88], denoted
here as Pat1 and Pat2, respectively. Images courtesy of Helmut Schlattl.
to Irene. The comparison of the doses for other target regions appears to be appropriate
though.
For the sake of simplicity and to emphasize that Visible Human and Irene represent
individual patients in this thesis, they were denoted in the consecutive text as Pat1 and Pat2,
respectively. The height, body weight, number of segmented regions and voxel dimensions
of Pat1 and Pat2 are given in table 7.1.
Phantom Height,
[cm]
Weight,
[kg]
Number of segmented
regions
Voxel dimensions,
[mm3]
Pat1 (=Visible Human) 180.0
(125.0)?
103.2
(89.1)?
131 0.908×0.941×5.000
Pat2 (=Irene) 163.0 51.1 62 1.875×1.875×5.000
Table 7.1. Selected properties of employed individual phantoms Pat1 and Pat2.
?Pat1 is a partial-body phantom. The values in parentheses correspond to the
available part of the phantom, without parentheses to the actual height and
weight of the individual they were based on.
For each selected individual (Pat1 and Pat2), three models approximating the individual
anatomy were considered. These included the voxel (RCP-AM) and the polygon-surface
(P-RCP-AM) ICRP adult male reference phantoms (see section 6.2) and the adjusted
reference model P-RCP-AM.
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7.1.2. Adjusted dimensions
The following dimensions of P-RCP-AM were adjusted to the corresponding individual
characteristics of Pat1 and Pat2: distance between the iliac crest and the clavicles, total
height, front-to-back distance and width of the rib cage (both on the level of the xiphoid
process). These dimensions are shown in figure 7.2. The dimensions of the rib cage
correspond to those of the skeleton, not the external body dimensions. It is expected that
the dimensions of the skeleton correlate with the relative locations of the organs inside
the rib cage better than those of the external body, especially for overweighed individuals
with a thick layer of subcutaneous fat. The front-to-back distance and the width of the
rib cage (skeleton) can be estimated by subtraction of the approximate thickness of the
subcutaneous fat from the corresponding external body dimensions. Alternatively, the rib
cage dimensions can be determined easily from a CT or MR scan which usually accompanies
the actual PET diagnosis. The two new phantoms, matched to Pat1 and Pat2, are indicated
as Pat1M and Pat2M, respectively. Table 7.2 summarizes all abbreviations used for naming
the phantoms in this thesis.
Figure 7.2. Adjusted dimensions of polygon-surface ICRP adult male reference computa-
tional phantom P-RCP-AM.
The selected set of adjustments was restricted to individual characteristics which are
usually relatively easily measurable in real persons. The head of the phantoms was not
scaled in any dimension. The expected variability in the size of a head is not high. In this
feasibility study only the dimensions with high expected variability are considered. Since
the female individual Pat2 is represented by the male model Pat2M with only limited set of
adjustments made, waist to hip ratio is not matched, bone size and muscle distribution are
different. Additionally, gender-specific organs as uterus, gonads or prostate are excluded
from the analysis.
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Description Used
abbreviations
Voxel ICRP adult male reference computational phantom [53] RCP-AM
Polygon-surface ICRP adult male reference computational phantom [67] P-RCP-AM
Visible Human [65] (patient 1) Pat1
Irene [65,72,88] (patient 2) Pat2
Phantom obtained via adjustments of polygon-surface ICRP adult male
reference computational phantom to fit selected characteristics of Visible Human
Pat1M
Phantom obtained via adjustments of polygon-surface ICRP adult male
reference computational phantom to fit selected characteristics of Irene
Pat2M
Table 7.2. Abbreviations used for indicating the computational models in this thesis.
All adjustments were made in the 3D modeling software Rhinoceros® 4.0 (McNeel North
America, Seattle, WA), which provides powerful tools for, e.g., creating and editing NURBS
curves, surfaces and polygon meshes. The adjustments were applied in three main steps,
which are schematically shown in figure 7.3. At the first step the distance between the
iliac crest and the clavicles and the total height were matched. This was achieved by
scaling the rib cage, the spine, the clavicles, the sternum, the scapulae, the arms and all
the organs inside the rib cage on the level of thoracic and lumbar spine, including the
small intestine and the colon in superior-inferior directions by a factor needed to match
the distance between the iliac crest and the clavicles. For convenience, prior to the first
scaling step, the pelvis along with the legs, the bladder, the prostate, the testes and the
inguinal lymphatic nodes were moved in inferior direction, as shown in figure 7.3. After
matching the distance between the iliac crest and the clavicles the phantom was re-unified.
If needed, the first scaling step was followed by a scaling of the legs in inferior direction
to match the total height. At the second step all the aforementioned organs, except the
arms, were scaled together with the rib cage in anterior-posterior direction to fit the outer
front-to-back distance of the rib cages of Pat1 and Pat2. At the third step the scaling
in lateral dimension was applied to match the outer width of the rib cages of the target
individuals. The arms were not scaled at this step, but moved laterally to fit the scaled
thorax. The scaling was done with the Scale 1D command. Organ intersections were then
found with the MeshIntersect command (Rhinoceros® 4.0) and eliminated by applying
some minor adjustments of the intersecting organs with the Smooth command and/or Mesh
Edit and Mesh Repair Tools of Rhinoceros® 4.0. The scaling and the repair of the skin
mesh required more manual manipulations, which are not shown in figure 7.3. Scale 1D
command, Mesh Edit and Mesh Repair Tools along with Smooth command were employed
to scale and repair the skin mesh. No further adjustments of individual organ positions
and sizes of Pat1M and Pat2M to match the corresponding values of Pat1 and Pat2 were
applied.
7.2. Monte Carlo radiation transport calculations
It is generally difficult to analytically solve the radiation transport equation (Boltzmann’s
transport equation) in an arbitrary medium and geometry. Consequently, stochastic Monte
Carlo methods are commonly used to solve it numerically. In Monte Carlo simulations each
particle ejected at a given position and with a given momentum and energy by the source
is followed step-wise from one interaction to another until either the particle leaves the
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considered medium or the energy of the particle becomes smaller than the user-specified
minimum energy (cut-off energy) and the particle is locally absorbed. Thus in Monte Carlo
simulations each particle’s history is a random sequence of interactions. The probabilities
of various interaction types are defined by the cross-sections of the corresponding processes.
Based on these probabilities the type of interaction is randomly defined for each interaction
event. As a result, the particle can loose its kinetic energy, it can be absorbed or deflected
from its original direction or secondary particles can be produced. The state of the particle
after the underwent interaction is described by its energy, position and direction of flight.
All these variables are defined from the corresponding probability density functions. Using
Monte Carlo techniques various values, e.g. the energy deposited in the medium, can be
scored. Due to the random nature of this method, the results are affected by statistical
uncertainties. The latter decreases with 1/
√
Nhist with increasing number of simulated
particles Nhist. Thus the number of followed particles is usually very high, e.g. Nhist ∼ 107
for photons and electrons in this thesis (see subsection 7.2.2 for more details). The value of
Nhist is usually selected based on the acceptable statistical uncertainty, which depends on
the geometry as well as type and energy of the simulated particles. With Nhist →∞ the
scored value converges to its true value.
7.2.1. EGSnrc
The Monte Carlo code EGSnrc [89] with a user code developed at the HMGU was employed
in this work to calculate the specific absorbed fractions (SAFs) for homogeneous volume
sources of monoenergetic photons and electrons. The radiation transport code EGSnrc
[89] is an updated version of the EGS4 code, described by Nelson et al. [90]. It facilitates
the Monte Carlo simulation of electron and photon transport in various materials. The
detailed description of EGSnrc is given elsewhere [89]. The main elements and features are
recapitulated here.
EGSnrc is written in Mortran3 [89] – a string processor that produces Fortran77 code. The
dynamic range of photon energies in EGSnrc lies between 1 keV and several hundred GeV.
The corresponding values for electron kinetic energies are between a few tens of keV
and a few hundred GeV. An improved condensed history algorithm for simulation of
electron transport was implemented in EGSnrc [91]. Several other features were provided or
improved in EGSnrc compared to the original EGS4 code. These included the production
and transport of fluorescence photons from K, L, M shells and Auger electrons, bound
Compton scattering as well as the Compton scattering on “free” electrons [89]. The cross-
sections for photoelectric effect, Rayleigh scattering and pair production used in the EGSnrc
code are in accordance to the NIST/XCOM database [92] (https://www.nist.gov/pml/
xcom-photon-cross-sections-database). Note that pair production is not a possible
process for the photon energy of 511 keV (the energy of annihilation photons in PET)
considered in this thesis (see subsection 7.2.2).
The user code is a program written to employ EGSnrc for the simulations of radiation
transport in the specific defined geometry and for the case-specific source. The user code
consists of a MAIN program and three subroutines: HOWFAR, HOWNEAR and AUSGAB.
The MAIN program calls two subroutines, HATCH and SHOWER that are part of the
EGSnrc code itself. The HATCH subroutine does all necessary initializations and reads
the material data. The latest are created by PEGS4 code, which is a stand alone utility
program used in EGSnrc. PEGS4 prepares the material dependent cross section datasets
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needed for the simulations, according to the user-specified media list and the elemental
compositions of the considered organs and tissues. After the call to HATCH, MAIN calls
the subroutine SHOWER. One call to SHOWER generates one particle history with the
specified parameters. MAIN can also include macros to control functions in EGSnrc. The
subroutines HOWFAR and HOWNEAR determine the problem-specific geometry, AUSGAB
is used to score and save the results. The user code along with necessary parts of EGSnrc
are converted with the Mortran3 string processor to a large complete Fortran77 program.
This needs to be compiled to create an executable program. The user code employed in
this thesis has been previously utilized and benchmarked in various works to compute dose
conversion coefficients for public, occupational and medical exposures [73,88]. The photon
cut-off energy was set to 2 keV. The electron cutoff energy was equal to 20 keV, except for
initial kinetic energies less than 50 keV, which were followed down to 2 keV.
7.2.2. Geometry, radiation types and energies
SAFs for monoenergetic photons and electrons were calculated in the geometry of the six
computational phantoms from table 7.2 on page 72. A total of 18 electron energies, ranging
from 10 keV to 1 MeV, and one photon energy of 511 keV were considered. The simulated
energies were selected to cover the beta spectra of 11C- and 18F-labeled compounds, which
are commonly used in PET, and the energy of annihilation photons. For photon internal
sources and for electron internal sources in the energy range of 10 keV – 600 keV, 4 · 107
histories were simulated per source region and energy. For electron energies of 800 keV and
higher the number of simulated histories was reduced to 107 for the sake of computational
time. The considered internal sources were homogeneously distributed in the source regions
of the radiopharmaceutical employed in this thesis – 18F-FSPG (see chapter 4 on page 35).
These included total blood, heart wall, heart contents, kidneys, liver, pancreas, salivary
glands, spleen, stomach wall, total body, thyroid and urinary bladder content. Target
regions included all organs and tissues segmented in the phantoms. The source region “total
blood” comprised blood vessels, if present in the phantom, and blood contents of organs
and tissues.
As it was shown in section 5.2 and in the paper by Zvereva et al. [35], blood is an
important source region in the internal organ dose calculation. The available Mortran3
programs for the phantoms Pat1 and Pat2 were modified to include organ blood contents
into the total blood. For this purpose mass fractions of blood in different organs and tissues
are required. Nadler’s formula [93] was applied to calculate the total blood volumes for
Pat1 and Pat2. Total blood masses were computed with the blood density from ICRU
Report 46 [94] and ICRP Publication 110 [53] (1.06 g/cm3). Using the resulting total blood
masses, reference blood fractions in various anatomical regions from ICRP Publication 89
[48] and the organ masses of Pat1 and Pat2, mass fractions of blood were calculated for
organs and tissues of the aforementioned phantoms.
Media elemental compositions and densities from ICRP Publication 110 [53] were used
for organs and tissues of P-RCP-AM, Pat1M and Pat2M. Since muscles were not present
in the phantom P-RCP-AM and, consequently, in Pat1M and Pat2M, subcutaneous fat
and skeletal muscle were considered together as only one tissue (residual tissue) in these
phantoms. The elemental composition and the density of the residual tissue were adjusted
to correspond to a mixture of muscles and adipose (66 % and 34 %, respectively, for the
parenchyma mass fractions).
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7.3. Voxelization of polygon-surface models
Since the EGSnrc user code utilizes a voxel geometry, all considered polygon-surface
phantoms had to be voxelized. Using the software Binvox developed by Patrick Min, all
polygon-surface organs have been transferred into individual organ voxel models with
1×1×1 mm3 voxel size. The Binvox software is an open source program and is available
at http://www.patrickmin.com/binvox/. It is a command-line program and utilizes the
parity-count and the ray-stabbing methods developed and described by Nooruddin and
Turk [95] for turning the polygonal 3D models into the voxelized format. The parity-
count method facilitates the production of the true interiors of the voxel models. In the
parity-count algorithm multiple parallel rays going through the polygon-surface model are
produced. For instance, for a model with dimensions N ×N ×N voxels, N ×N rays, each
passing through N voxel centers, are needed. The algorithm counts the number of times
each ray intersects the polygons of the model. According to the number of intersections,
each voxel is classified as being located inside or outside of the model. The parity-count
algorithm works well for watertight manifold models. For the models with cracks or holes
in the surfaces it might have limitations, though. It might lead to unexpected results
and holes in the model interior, if the chosen rays do not intersect the polygons of the
model, while passing through the holes or cracks in its surface. Increasing the number of
projections for the employed rays can solve this issue [95]. The successful voxelization of
models with several inter-penetrating subparts is difficult with parity-count method. For
this reason, Nooruddin and Turk [95] proposed the ray-stabbing algorithm. Analogously to
the parity-count algorithm, the orthographic projections of the polygon-surface model are
used here. According to the ray-stabbing algorithm, only the first and the last intersections
of the rays with the polygons of the model are kept. The voxels lying between these two
extreme intersection depth are interpreted as located inside the model, and otherwise they
are stored as located outside of the model. The combination of these algorithms is utilized
in Binvox software.
Various formats of the input 3D models are supported by Binvox, the most common
format is Wavefront OBJ. The input polygon-surface model is first normalized in the Binvox,
so that it fits to a unit cube with an origin at (0.0, 0.0, 0.0) in Cartesian coordinates. The
unit cube is subsequently voxelized. The voxelized output models are provided in .binvox
file format. It has a a short ASCII header, followed by the binary data. The header gives
the dimensions of the voxel grid along with the scaling and translation factors needed to fit
the model to a unit cube with an origin at (0.0, 0.0, 0.0). The binary data consists of pairs
of value byte and count byte. The value byte can have values equal to 0 or 1, where the
value 1 means the presence of a voxel belonging to the model, and the value 0 otherwise.
The count byte provides the number of times the preceding value byte is repeated.
By executing Binvox for each considered anatomical structure, given in the polygon-
surface format, the binary file with the voxelized version of the corresponding organ or
tissue is produced. The resulting individual organ voxel models were subsequently combined
to complete phantoms using an in-house IDL-based (IDL®, Exelis Visual Information
Solutions, Inc., version 8.2.1) program. For the sake of simplicity, here and in the following
the same abbreviations are used for denoting the polygon-surface models and their voxelized
versions, since only the latter were employed for the Monte Carlo calculations. The voxel
size of 1×1×1 mm3 was selected as a trade-off between the realism of the resulting voxelized
anatomical structures and the memory required to store the voxel model.
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7.4. Internal dosimetry for the developed anatomical
models
Five sets of time-integrated activity coefficients ã (rS), derived in part II were employed here
to compute absorbed organ dose coefficients for the six computational phantoms shown in
table 7.2 on page 72. The dose calculations were done according to the formalism described
in chapter 2 and concept-1 defined in section 3.3, i.e. for the case of blood being a distinct
source region. The used sets of activity data are given in table 5.4 on page 49.
Absorbed-dose coefficients were calculated five times (i.e. once for each set of activity
data of five volunteers) for each of the models Pat1, RCP-AM, P-RCP-AM and Pat1M. The
specific absorbed fractions SAFs of RCP-AM, P-RCP-AM and Pat1M were mass-scaled to
the correspond to the organ masses of Pat1. The mass scaling is described in details in
the next subsection. For each set of activity data the dose differences between RCP-AM,
P-RCP-AM and Pat1M relative to Pat1 were computed. Average, maximum and minimum
values of these differences are reported. The same procedure was done for the models Pat2,
RCP-AM, P-RCP-AM and Pat2M with SAF scaled to the masses of Pat2. The healthy
volunteers (see table 4.1) were the source of the activity data only, i.e. their activity data
served as surrogate for Pat1 and Pat2.
In the scope of this thesis a MATLAB-based (MATLAB, version 8.0.0.783 (R2012b), The
MathWorks, Inc., Natick Massachusetts, 2012) program was developed to calculate organ
absorbed-dose coefficients, according to the MIRD system [4] recapitulated in chapter 2.
The detailed β-spectrum of 18F from ICRP Publication 107 [55] and a single photon energy
at 511 keV (annihilation photons) were considered for the dosimetric calculations. The
SAFs for the considered radiation types and energies were derived with the Monte Carlo
calculations, as described in section 7.2.
7.4.1. Mass-correction of specific absorbed fractions
Whole-body anatomical models
The MIRD formalism [4] assumes reference mass values for the organs (source and target)
and the total body. MIRD Pamphlet 11 [87] provides guidance on how patient-specific
scaling of reference radionuclide S values (and eventually specific absorbed fractions SAFs)
is to be done for the electron and photon component of the emission spectrum. Based
on this guidance and results of extensive analysis of the mass dependences of photon [16]
and electron [52] SAFs, the SAFs derived for RCP-AM, P-RCP-AM, Pat1M and Pat2M
were mass-corrected. This was done to transfer the simulated values to the investigated
patients (Pat1 and Pat2), who have organ masses differing from those of RCP-AM, P-RCP-
AM, Pat1M and Pat2M. The mass-dependences of the SAFs for whole-body phantoms,
demonstrated by Petoussi-Henss et al. [16] and Zankl et al. [52], include the self-irradiation
(rT = rS) for both, photons and electrons, and the case of total body rTB source of
electrons with the target rT being a part of it. If rT = rS, the SAFs for electrons are
inversely proportional to the mass of the target MrT (= MrS) and the SAFs for photons are
proportional to the (MrT )
− 2
3 (= (MrS)
− 2
3 ). The corresponding mass-corrections of SAFs
were applied in this case to account for the differences in MrT (= MrS) between Pat1 and
Pat2 and the models approximating them. Before the SAFs for electrons were explicitly
derived from particle transport calculations, an approximation given by ICRP publication 30
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[96] was commonly used. According to it, the SAFs for all internal organs as targets and a
total body source rTB are approximately equal to the inverse of the total body mass MrTB
[96]. The validity of this approximation has also been demonstrated by Zankl et al. [52].
The SAFs derived for a total body source of electrons and internal organs as targets were
corrected in this way to account for differences in MrTB of RCP-AM, P-RCP-AM, Pat1M
(Pat2M) relative to Pat1 (Pat2).
Partial-body anatomical model
As mentioned in subsection 7.1.1, the Visible Human phantom (Pat1) is a partial-body
phantom, from head to mid-thigh. Thus the SAFs simulated for this model had to be
adjusted to correspond to a whole-body model. The above summarized corrections of the
SAFs derived for partial-body phantoms are based on the analysis done by Maria Zankl
(private communication). Several cases had to be considered. If rS and rT are both entirely
inside the partial-body model, the SAFs of the whole-body model would not differ from
those of the partial-body model. Hence, the same mass-correction as for the whole-body
models was applied in this case. The second case is for total body rTB as a source and rT
being entirely inside the partial-body model. As mentioned above, the electron SAFs in
this case are approximately equal to 1/MrTB [52, 96]. Hence, the SAFs evaluated with a
phantom comprising only a part of the body are overestimated and should be corrected, so
that they correspond to the inverse mass of the total body of the whole person, rather than
to the mass of the phantom only. The same is applied here for photons. If the source is
another extended region (6= rTB) that is partly outside the partial-body phantom, e.g. total
blood or muscles, and the target is entirely inside the phantom, the SAFs are inversely
proportional to the total mass of rS. Thus, the SAFs simulated for partial-body phantoms
should be corrected in this case to account for the missing mass of the extended source
region. If rS is entirely inside the phantom and rT is an extended region that is only partly
inside the available part of the phantom, e.g. total body, skin and muscles, the reciprocity
principle, introduced by Cristy and Eckerman [58] for photons and confirmed for electrons
by Zankl et al. [52], suggests that the situation is the same as when rT is entirely inside the
partial-body phantom and rS is not. Hence, the SAFs are inversely proportional to the total
mass of rT . The SAFs evaluated for partial-body phantoms should be corrected for the
missing target mass. If both, rS and rT extend beyond the phantom, electron and photon
SAFs are inversely proportional to the highest mass (rS or rT ). Thus, the SAFs simulated
for a partial-body phantom had to be corrected for the missing mass of a heavier region
(rS or rT ). All the aforementioned cases of mass-correction of the SAFs were implemented
in the in-house MATLAB-based program developed in the scope of this thesis and applied
for internal dosimetry in the following.
7.4.2. Considered target regions
Absorbed organ dose coefficients were computed simultaneously for all target regions
segmented in the considered phantoms. In Pat1 breast was not segmented. Hence for
breast in Pat1 the total breast of the RCP-AM was used. Heart wall of Pat1 and Pat2 was
surrogated by heart (wall and content). Pat2 is a computational phantom representing a
female individual whereas P-RCP-AM and, consequently, Pat2M represent male individuals.
Thus, the doses for gonads, uterus or prostate cannot be compared. As it was mentioned
in subsection 7.2.2, subcutaneous fat and skeletal muscle were considered together as one
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tissue in P-RCP-AM, Pat1M and Pat2M. Thus the skeletal muscle in these models was
surrogated by residual tissue in the dose computation.
7.4.3. Special case of urinary bladder dosimetry
The dynamic bladder model developed by Thomas et al. [22] and described in chapter 2
was used to compute the absorbed dose coefficient for bladder wall from the source region
bladder content. For applying this model, SAFs for the bladder content as source and
bladder wall as target are required for different bladder content volumes. However, the
SAFs simulated for the computational phantoms in this work correspond to a fixed volume
of the bladder contents (e.g. 39.3 and 24.3 cm3 for Pat1 and Pat2, respectively). Thus
they do not reflect the dependence of the absorbed dose to urinary bladder wall on the
bladder-contents volume as demonstrated by Smith et al. [32]. Hence, for the urinary
bladder dosimetry the SAF values obtained from the models were not used. The values
calculated by Andersson et al. [33] were employed instead.
The application of the dynamic bladder model [22] requires the following parameters: bio-
logic parameters for the bladder contents – αj and λj , which are radiopharmaceutical-specific
(see chapter 2 for more details), initial bladder-content volume V0 [ml], residual bladder-
content volume Vr [ml], the voiding schedule and the urine production rate U (t) [ml/min].
Since 18F-FSPG, used in this thesis, is a novel radiopharmaceutical, the aforementioned
biologic parameters for 18F-FSPG are not available in the literature. Hence, the volunteer-
and radiopharmaceutical-specific αj and λj were estimated in the scope of this work. The
values of αj and λj were derived from the total body retention curves. The latter were ob-
tained via the regression of the available activity data for 18F-FSPG to a double-exponential
function (see equation 2.11 on page 25) using SigmaPlot® (SigmaPlot® Version 12.3, Systat
Software Inc., San Jose, CA). The estimated volunteer-specific values of αj and λj are
summarized in table 7.3.
1101/94
female
1102/94
female
1103/94
male
1104/94
female
1105/94
male
α1 5.86E-01 1.44E-01 7.50E-01 6.09E-01 4.18E-01
λ1 5.50E-03 7.00E-04 6.30E-03 6.00E-03 5.90E-03
α2 4.17E-01 8.92E-01 2.69E-01 4.00E-01 6.31E-01
λ2 2.06E-02 1.46E-02 2.92E-02 3.39E-02 3.16E-02
Table 7.3. Estimated volunteer-specific biologic parameters αj and λj of dynamic bladder
model formulated by Thomas et al. [22], with radiopharmaceutical 18F-FSPG.
Thomas et al. [22] used various initial bladder-content volumes, ranging from 10 ml
to 500 ml. The initial bladder-content volumes for the volunteers, to whom 18F-FSPG
was administered, were not defined within the study of Smolarz et al. [44]. Thus the
values V0 = 10 ml, analogously to Andersson et al. [33], and Vr = 10 ml as in the
study of Thomas et al. [22] were used here. Smolarz et al. [44] recorded the exact
voiding times and the volumes of the voided urine at every time-point of the voiding cycle.
This facilitated the estimation of U (t) and the usage of the volunteer-specific voiding
schedules in the implemented dynamic bladder model. Smolarz et al. [44] followed the
volunteers up to 4.5 hours after the administration of 18F-FSPG, whereas in this thesis a
dose integration period of ≈ 18.0 hours was used. In the time period 4.5-18.0 hours post
administration a regular 3-hours voiding intervals were assumed with an extra voiding just
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before midnight, a night-time gap between midnight and 06:00 o’clock and urine production
rates, corresponding to the normal hydration state (1.0 and 0.5 ml/min during the day and
the night, respectively), analogously to Thomas et al. [22]. The estimated volunteers-specific
urine production rates U (t) are given in table 7.4.
Volunteer U1(t) U2(t) U3(t) U4(t) U5(t) U6(t) U7(t) U8(t) U9(t) U10(t) U11(t)
1101/94 11.7 2.2 7.3 8.8 1.0 1.0 0.5 1.0 1.0 — —
1102/94 2.9 1.0 0.2 2.2 0.7 1.0 0.5 1.0 1.0 — —
1103/94 6.2 3.3 3.4 6.6 1.0 1.0 0.5 1.0 1.0 — —
1104/94 6.4 3.0 4.9 7.2 3.8 3.4 1.0 1.0 0.5 1.0 1.0
1105/94 3.2 4.2 15.6 10.1 6.8 1.0 0.5 1.0 1.0 — —
Table 7.4. Estimated volunteer-specific urine production rates Ui(t) [ml/min], before void-
ing i.
A MATLAB-based program was developed in the scope of this thesis to compute the
absorbed dose coefficient for urinary bladder wall. The program accounts for the dependence
of SAF on the bladder content volume by employing the SAF calculated by Andersson et al.
[33] for different volumes of bladder contents. It uses the activity accumulated in urinary
bladder contents, according to the dynamic bladder model, as described above. This dose
was summed with the bladder wall dose coefficient from other source regions to obtain the
total absorbed dose coefficient for urinary bladder wall from all source regions.
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comparison of their organ doses
8.1. Developed anatomical models
Two phantoms were developed in this work via adjustments of polygon-surface ICRP
adult male reference computational phantom P-RCP-AM [67] to fit selected dimensions
of one overweight (Pat1) and one slim individual (Pat2), as described in subsection 7.1.2.
The resulting phantoms, matched to Pat1 and Pat2, are denoted as Pat1M and Pat2M,
respectively. Figure 8.1 shows P-RCP-AM along with Pat1M and Pat2M. It can be seen
from figure 8.1 that the adjusted phantoms Pat1M and Pat2M retain their anatomic realism.
The adjusted dimensions are summarized in table 8.1. Table 8.2 contains selected properties
of the six employed phantoms.
Figure 8.1. P-RCP-AM with the selected dimensions and the result of its adjustment to
Pat1 and Pat2 (from left to right).
As discussed in section 7.3, P-RCP-AM, Pat1M and Pat2M were converted to voxel
models with 1×1×1 mm3 voxel size. The voxelization of the polygon-surface models
potentially introduces the limitation of the voxelized models to realistically represent very
small (< 1 mm in at least one dimension) anatomical structures. Nonetheless, the used voxel
size is notably smaller than in the models segmented directly from the tomographic images
(see e.g. table 8.2) and was sufficient for retaining the anatomical realism of most of the
organs. This can be seen in figure 8.2, which shows a representable subset of four slices of the
voxelized P-RCP-AM. The grey values in the images correspond to the organ identification
numbers of the phantom P-RCP-AM. The contours of the organs of P-RCP-AM are smooth
(see figure 8.2) and the voxel size of 1×1×1 mm3 is sufficient for realistic representations
of most of the organs, i.e. those where no dimension is smaller than 1 mm. This can also
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Adjusted dimension Pat1 Pat1M Difference,
%
Pat2 Pat2M Difference,
%
Distance between the iliac
crest and clavicles
46.0 46.2 0.4% 40.0 39.7 -0.8%
Front-to-back distance
of the rib cage
23.6 23.7 0.3% 15.0 15.1 0.5%
Width of the rib cage 32.7 32.7 0.1% 23.6 23.6 0.2%
Height 180.0 180.2 0.1% 163.0 162.4 -0.4%
Table 8.1. Selected dimensions of Pat1 and Pat2 [cm] and the corresponding matched
dimensions of Pat1M and Pat2M [cm]. The differences are given in % of the
original dimensions of Pat1 and Pat2.
Phantom Height,
[cm]
Weight,
[kg]
Number of segmented
regions
Voxel dimensions,
[mm3]
Pat1 180.0
(125.0)‡
103.2
(89.1)‡
131 0.908×0.941×5.000
Pat2 163.0 51.1 62 1.875×1.875×5.000
RCP-AM 176.0 73.0 138 2.137×2.137×8.000
P-RCP-AM 176.4 73.6 111 1.000×1.000×1.000
Pat1M 180.2 95.6 111 1.000×1.000×1.000
Pat2M 162.4 51.1 111 1.000×1.000×1.000
Table 8.2. Selected properties of all considered computational phantoms.
‡Pat1 is a partial-body phantom. The values in parentheses correspond to the
available part of the phantom, without parentheses to the actual height and
weight of the individual.
be seen in figure 8.3 showing the rendered voxelized P-RCP-AM, Pat1M and Pat2M. The
voxelization can be theoretically done with even smaller voxel sizes. The limiting factors
in this case are the available computer RAM to store the phantom and the increasing
calculation time of the Monte Carlo simulations when decreasing the voxel size.
Figure 8.2. A subset of four slices of P-RCP-AM. The voxel size is 1×1×1 mm3. Grey
values correspond to the organ identification numbers.
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Figure 8.3. Rendered voxelized models P-RCP-AM, Pat1M and Pat2M (from left to right).
The models preserved their anatomical realism after the applied voxelization.
8.2. Performed Monte Carlo calculations
The number of simulated particle histories for different energies and radiation type was
previously given in subsection 7.2.2. Since the probability to hit a target organ is decreasing
with increasing source-to-target distance and decreasing target volume, the statistical
uncertainties of the performed Monte Carlo calculations notably depend on the absolute
values of the absorbed fractions (AF). For the target regions located distant from the source
only a small fraction of energy released from the source can reach the target. This results in
low AF and higher statistical uncertainties. For the calculations done here, the coefficients of
variation for AF ≥ 10−3 were below 0.5 %, in most cases even below 0.25 %. For the values
10−4 ≤ AF < 10−3, the coefficients of variation were below 1.5 %, for 10−5 ≤ AF < 10−4
the coefficients of variation amounted to 2.5 % at most, and for 10−6 ≤ AF < 10−5 they
were below 10 %.
8.3. Comparison of computed organ doses between
selected individuals and the developed matched
models
To distinguish the impact of the individual organ topology on the computed organ absorbed
dose coefficients, the self-absorption and the cross-fire components of the respective organ
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absorbed dose coefficients are given separately in the following. For each set of activity data
from the five volunteers the dose differences between RCP-AM, P-RCP-AM and Pat1M
relative to Pat1 and RCP-AM, P-RCP-AM and Pat2M relative to Pat2 were computed.
Average, minimum and maximum values of these relative differences for the cross-fire
components of the organ dose coefficients were calculated. Note that this part of the thesis
focuses on the cross-fire absorbed dose coefficients, since only they are affected by the
relative positions of organs in the anatomical models.
As described in subsection 7.4.3, for the bladder wall dosimetry the initial bladder content
volume was set to V0 = 10 ml. The absorbed dose coefficient for bladder wall from the
cross-fire from bladder content decreases with increasing V0. The bladder wall absorbed dose
coefficients were computed in this thesis in addition with V0 = 200 ml. They decreased by
4 – 22 %, if employing an initial bladder content volume V0 = 200 ml instead of V0 = 10 ml.
The relative differences in the bladder wall absorbed dose coefficients between the patients
and the models approximating them are not substantially affected by the different initial
bladder content volumes. The results summarized in the following subsections 8.3.1 and
8.3.2 refer to V0 = 10 ml, since this presents the conservative approach.
8.3.1. Self-absorption component of absorbed dose coefficients
The source regions for the radiopharmaceutical 18F-FSPG comprise stomach wall, liver,
thyroid, salivary glands, heart wall, kidneys, urinary bladder-contents, pancreas, spleen and
blood. Due to the accumulation of activity in these regions and relatively low energies of the
emitted radiation in case of 18F (Emax (β
+) = 633.5 keV and E (γ) = 511 keV), the doses
received by the source regions are predominately due to the self-absorption. The calculated
absorbed dose coefficients due to the self-absorption along with the deviation in % from
the respective values calculated for Pat1 and Pat2 and the absolute contributions of the
self-absorption to the total organ absorbed dose coefficients are presented in figure 8.4. Note
that the absorbed dose coefficients from figure 8.4 are computed with one set of activity
data, i.e. with that for volunteer 1101/94 (see table 5.4 on page 49). The corresponding
figures obtained using the four sets of activity data for volunteers 1102/94–1105/94 are
similar and hence not presented here but included in appendix A.1 instead. Except for heart
wall and stomach wall, no substantial differences in the self-absorption dose coefficients
are observed. The expected high contribution of self-absorption to total absorbed dose
coefficients, especially for kidneys and pancreas can be seen in figure 8.4.
8.3.2. Cross-fire component of absorbed dose coefficients
The subset of the calculated absorbed dose coefficients from cross-fire along with the
deviations in % from those calculated for Pat1 and Pat2 employing one set of activity
data for volunteer 1101/94 are presented in figure 8.5 and figure 8.6, respectively. The
corresponding figures for the four sets of activity data for volunteers 1102/94–1105/94
are similar to those of figure 8.5 and figure 8.6 and, therefore, are not presented here but
included in appendix A.2 instead. Note that the same set of activity data is used for
figure 8.4, figure 8.5 and figure 8.6. The total absorbed dose coefficients for source organs
include the contribution from the self-absorption in addition to the corresponding dose
coefficients shown in figures 8.5 and 8.6. The self-absorption is dominated by the organ mass
and is otherwise independent of the anatomy of an individual. For the target regions that
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Figure 8.4. Calculated self-absorption components of absorbed dose coefficients, differences
in % relative to the corresponding values for Pat1 (a) and Pat2 (b) and absolute
contributions of the self-absorption to the total absorbed dose coefficients. The
total height of the bars on the upper row corresponds to the total organ absorbed
dose coefficients, the filled areas to the self-absorption components. The SAFs
estimated with RCP-AM, P-RCP-AM and Pat1M (Pat2M) for organs where
source is equal to target were adjusted according to the masses of the patient
Pat1 (Pat2), as described in subsection 7.4.1.
are not sources the absorbed dose coefficients in figures 8.5 and 8.6 are the total absorbed
dose coefficients for these regions.
Tables 8.3 and 8.4 show the differences in the calculated absorbed dose coefficients from
cross-fire for Pat1 and Pat2, respectively, and the models approximating Pat1 and Pat2. The
values given in tables 8.3 and 8.4 are computed as average, minimum and maximum within
dose differences calculated for five sets of activity data. For the majority of organs of Pat1M
(table 8.3) and Pat2M (table 8.4) the deviations in cross-fire absorbed dose coefficients from
the ones calculated for Pat1 and Pat2 are lower than the respective dose differences between
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the target phantoms Pat1 and Pat2 and the reference phantoms (RCP-AM, P-RCP-AM).
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Figure 8.5. Calculated cross-fire components of the organ absorbed dose coefficients for
Pat1 and different models approximating it. The dose differences in the upper
panel are given relative to Pat1.
The computed differences are similar for all activity datasets of the volunteers. No
substantial differences in absorbed dose coefficients for urinary bladder wall were observed.
The breast of RCP-AM was used as a surrogate for the breast of Pat1. Hence, no differences
between Pat1 and RCP-AM befall in this case, while the differences between Pat1 and
Pat1M are below 18.1 %. For Pat1 the relative differences in cross-fire absorbed dose
coefficients of liver, extrathoracic airways, kidneys, pancreas and eyes decreased from about
30.0 – 40.0 % for the reference phantoms RCP-AM and P-RCP-AM to less than 10.0 % for
the matched phantom Pat1M. For oesophagus, brain, adrenals, heart wall, spleen, thymus
and spinal cord the cross-fire dose differences between Pat1 and the reference phantoms
amount to approximately 40.0 %, while the corresponding differences between Pat1 and
Pat1M are below 15.0 %. For Pat1 the relative differences in absorbed dose coefficients
of gall bladder wall amount to 80.6 % and 75.5 % on average with respect to RCP-AM
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Figure 8.6. Calculated cross-fire components of the organ absorbed dose coefficients for
Pat2 and different models approximating it. The dose differences in the upper
panel are given relative to Pat2.
and P-RCP-AM, respectively. The corresponding differences relative to Pat1M are below
30.0 % on average. For active bone marrow, thyroid and salivary glands the calculated
relative dose differences between Pat1M and Pat1 are only half of those between reference
phantoms and Pat1. For lungs the computed dose differences decreased on average from
21 – 24 % between Pat1 and reference phantoms to -3 % between Pat1 and Pat1M. The
relative differences in the calculated cross-fire absorbed dose coefficients for stomach wall
and small intestine wall amount, respectively, to 12.4 % and 14.0 % on average between
Pat1 and Pat1M. The corresponding differences between Pat1 and both reference phantoms
are within 54.7 % and 57.9 % on average. Better agreement was observed between Pat1 and
the reference phantoms (RCP-AM and P-RCP-AM) in the absorbed dose coefficients for
gonads, prostate, skeleton and colon wall. Absorbed dose coefficients for all organs, except
gonads and gall bladder wall agree between Pat1 and Pat1M within 25.0 % (table 8.3).
For Pat2 the differences in the cross-fire absorbed dose coefficients for kidneys, pancreas,
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RCP-AM P-RCP-AM Pat1M
Mean Min Max Mean Min Max Mean Min Max
Bladder wall 0.6% 0.3% 0.7% 0.5% 0.3% 0.7% 0.2% 0.1% 0.3%
Prostate -10.2% -11.1% -9.8% -12.8% -13.6% -12.4% -15.3% -16.2% -14.9%
Adrenals 38.7% 31.5% 46.9% 40.1% 32.7% 48.4% 3.3% -1.9% 11.4%
Gall bladder wall 80.6% 67.8% 88.7% 75.5% 64.4% 83.7% 29.4% 23.2% 35.6%
Colon wall 8.6% 5.8% 10.3% 11.0% 7.2% 13.1% -17.2% -18.4% -16.4%
Pancreas? 32.8% 29.7% 37.2% 32.8% 30.4% 36.8% -6.5% -8.7% -2.9%
Spleen? 39.9% 30.9% 47.3% 43.2% 33.0% 51.7% 6.6% -0.6% 12.2%
Small intestine
wall
57.9% 47.7% 65.8% 45.3% 34.4% 54.2% 14.0% 5.5% 22.9%
Lungs 20.8% 20.1% 21.6% 23.7% 22.2% 25.3% -3.1% -4.6% -1.0%
Stomach wall? 51.4% 49.6% 54.3% 54.7% 52.3% 58.2% 12.4% 9.4% 14.5%
Oesophagus 36.0% 30.1% 44.0% 32.7% 26.4% 40.4% 8.5% 3.8% 12.2%
Liver? 40.9% 39.8% 41.8% 44.3% 43.0% 45.7% 2.2% 0.8% 4.6%
Bone marrow 38.1% 32.7% 46.3% 35.2% 30.2% 43.3% 14.5% 11.4% 19.2%
Kidneys? 37.7% 36.4% 40.0% 41.9% 39.8% 45.0% 4.2% 2.3% 5.9%
Gonads -20.6% -26.5% -18.3% -20.8% -26.3% -18.5% -28.4% -34.1% -26.2%
Skeleton, total -3.3% -4.4% -2.6% -3.6% -4.5% -3.0% -11.7% -13.3% -10.9%
Spinal cord 34.5% 33.4% 36.6% 36.8% 35.3% 39.7% 14.0% 13.5% 15.0%
Heart wall? 42.3% 38.2% 49.7% 41.1% 37.1% 49.2% 8.9% 5.2% 15.0%
Breast, total 0.0% 0.0% 0.0% 4.5% 4.0% 5.5% -16.4% -18.1% -14.1%
Thymus 34.6% 32.5% 38.2% 33.4% 31.2% 35.6% 10.9% 9.6% 12.4%
Muscle tissue 23.1% 22.4% 24.8% 31.7% 29.0% 35.4% 18.5% 16.8% 20.6%
Extrathoracic
airways (ET)
19.7% 19.2% 20.7% 25.1% 24.0% 27.9% 3.2% 0.9% 4.5%
Skin, total 12.7% 9.5% 14.6% 11.9% 9.1% 13.3% -5.7% -10.9% -2.8%
Eyes 18.7% 15.9% 20.1% 27.2% 25.0% 28.5% 4.9% -1.9% 8.4%
Eye lenses 10.3% 7.8% 11.7% 14.4% 8.4% 17.6% -9.9% -17.6% -5.9%
Thyroid? 50.7% 46.8% 57.1% 51.5% 47.3% 58.5% 18.9% 16.8% 21.4%
Brain 29.4% 29.1% 30.3% 31.5% 30.4% 34.2% 11.7% 10.3% 12.4%
Salivary glands? 15.7% 15.5% 16.1% 20.7% 19.8% 22.5% -9.2% -10.6% -8.2%
Table 8.3. Relative differences in the organ absorbed dose coefficients from cross-fire, cal-
culated for three models approximating Pat1, compared to the corresponding
doses of Pat1 (five sets of activity data were used).
?These are the source organs for 18F-FSPG.
For AF ≥ 10−4 the coefficients of variation were 1.5 % at most,
for 10−5 ≤ AF < 10−4 the coefficients of variation were below 2.5 %. For more
information on statistical uncertainties of performed Monte Carlo calculations
see section 8.2.
brain, small intestine wall, thymus, and eye lenses relative to the corresponding dose
coefficients for Pat2M are approximately lower by a factor of two compared to the differences
in the respective dose coefficients between Pat2 and the reference phantoms. As a general
finding for all sets of activity data, the relative differences in the absorbed dose coefficients
for lungs, stomach wall (cross-fire), adrenals, extrathoracic airways and spinal cord decreased
from approximately 30.0 % between RCP-AM, P-RCP-AM and Pat2 to less than 10.0 %
between Pat2M and Pat2. The absorbed dose coefficient for eyes and muscles in Pat2M
agrees with the corresponding value in Pat2 within 5.6 %. For liver and salivary glands
the calculated relative cross-fire dose differences between Pat2M and Pat2 are only one
third of those between reference phantoms and Pat2, for skin and eyes only one tenth.
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RCP-AM P-RCP-AM Pat2M
Mean Min Max Mean Min Max Mean Min Max
Bladder wall -0.9% -1.1% -0.5% -1.0% -1.2% -0.5% -0.4% -0.5% -0.2%
Adrenals -25.4% -29.4% -19.8% -24.7% -28.7% -19.0% -2.8% -8.0% 3.6%
Gall bladder wall -8.2% -13.1% -3.6% -11.0% -15.2% -7.5% 19.4% 9.9% 23.8%
Pancreas? -38.1% -38.7% -37.1% -38.1% -38.9% -37.3% -16.9% -18.2% -15.8%
Small intestine
wall
-29.4% -33.8% -24.5% -34.8% -38.2% -30.9% -18.1% -22.9% -13.6%
Spleen? -21.9% -26.3% -18.0% -20.1% -25.1% -16.0% 3.3% -4.0% 7.8%
Stomach wall? -29.8% -31.6% -24.7% -28.1% -29.9% -22.9% -6.7% -8.9% -0.8%
Colon wall -15.5% -17.4% -13.8% -13.9% -16.4% -12.0% 10.2% 5.9% 12.4%
Liver? -34.4% -35.2% -34.0% -32.8% -33.4% -32.4% -10.0% -10.8% -9.4%
Lungs -28.0% -33.5% -25.1% -26.5% -31.5% -23.9% -7.2% -11.0% -4.7%
Kidneys? -38.0% -38.9% -35.8% -36.0% -36.8% -33.7% -14.6% -16.0% -11.3%
Spinal cord -25.3% -28.4% -22.2% -24.1% -26.9% -21.3% -7.9% -9.4% -5.4%
Oesophagus -4.7% -6.5% -2.8% -6.9% -8.3% -5.4% 17.1% 14.0% 19.0%
Thymus -26.9% -29.5% -23.1% -27.5% -29.9% -23.8% -12.7% -16.3% -8.3%
Bone marrow 0.7% -2.1% 6.4% -1.3% -4.3% 4.3% 17.9% 14.1% 26.3%
Heart wall? -5.1% -13.5% -0.3% -5.8% -14.7% -0.5% 18.5% 8.3% 24.5%
Muscle tissue -24.7% -27.7% -22.2% -20.2% -22.3% -18.8% -4.2% -5.0% -3.5%
Skeleton, total -8.9% -10.9% -6.5% -9.2% -11.2% -6.7% 7.3% 4.6% 12.0%
Breast, total -7.0% -9.7% -3.2% -3.5% -6.7% 1.4% 19.2% 13.2% 28.0%
Extrathoracic
airways (ET)
-25.5% -29.9% -23.3% -22.7% -26.3% -21.0% -4.8% -6.2% -4.1%
Eyes -27.1% -32.2% -24.4% -22.7% -27.6% -20.2% -2.6% -5.6% -1.0%
Eye lenses -28.4% -33.7% -25.6% -26.2% -33.3% -22.4% -12.4% -17.6% -9.5%
Skin, total -15.5% -16.9% -14.5% -16.3% -17.4% -15.6% -0.9% -1.6% 0.3%
Brain -13.4% -14.4% -13.0% -12.4% -12.4% -12.3% 6.7% 5.7% 9.2%
Thyroid? -7.5% -11.9% -5.4% -7.0% -11.1% -5.1% 17.5% 14.5% 18.9%
Salivary glands? -42.1% -42.6% -41.6% -39.7% -40.9% -38.1% -16.3% -17.9% -13.9%
Table 8.4. Analogue to table 8.3 the relative differences in the organ absorbed dose coeffi-
cients from cross-fire, calculated for three models approximating Pat2, compared
to the corresponding doses of Pat2 (five sets of activity data were used).
?These are the source organs for 18F-FSPG.
For AF ≥ 10−4 the coefficients of variation were 1.5 % at most,
for 10−5 ≤ AF < 10−4 the coefficients of variation were below 2.5 %. For more
information on statistical uncertainties of performed Monte Carlo calculations
see section 8.2.
For the cross-fire absorbed dose coefficients for active bone marrow, breast, oesophagus,
thyroid, gall bladder wall and heart wall better agreement was observed between Pat2 and
reference phantoms, though. Absorbed-dose coefficients from cross-fire for all considered
organs and tissues of Pat2M, except the active bone marrow and breast agree with the
ones of Pat2 within 25.0 % (table 8.4). As mentioned in subsection 7.1.2 on page 70, the
female individual Pat2 was represented by male anatomy of Pat2M. Despite the gross
gender-specific differences between Pat2 and Pat2M, the difference in the organ absorbed
dose coefficients from cross-fire were still below 25.0 % for most organs. The gender-specific
organs cannot be compared in this case, though.
As expected, for both overweight and slim individuals only minor differences in the
absorbed dose coefficients for urinary bladder wall computed for different phantoms were
observed. The energy deposited in the urinary bladder wall is almost entirely due to the
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activity accumulated in the bladder contents. For the bladder contents – bladder wall
source–target pair the same sets of SAFs derived by Andersson et al. [33] were employed
for all phantoms. Other source regions, where phantom-specific SAFs were used, did not
substantially contribute to the bladder wall absorbed dose coefficients. The computed
bladder wall absorbed dose coefficients remained unaffected by them.
Self-absorption is the main contribution to the organ absorbed dose coefficients for most
source organs, especially kidneys, pancreas, salivary glands, liver and thyroid. Figure 8.4
shows that the differences in the self-absorption were small. These were the results of the
applied mass-correction to the masses of Pat1 or Pat2, as described in subsection 7.4.1
on page 76. Higher differences in the self-absorption dose coefficients between the target
patients Pat1 and Pat2 and the models approximating them were observed for heart wall
(16 – 18 %) and stomach wall (4 – 8 %). The applied mass-scaling of the SAFs might have
limitations for walled organs. Additionally, Pat1 and Pat2 do not have the heart wall
segmented separately, but only the whole heart instead. This could be another reason for
the observed differences for the heart wall, since the self-absorption in the whole heart is
expected to be higher than in the heart wall only. For some source organs, e.g. stomach wall
and spleen, the absolute contributions to the absorbed dose coefficients from the cross-fire
were also substantial due to high activities of some neighboring source organs.
High contribution to the absorbed dose coefficients by the cross-fire from blood was
observed for some organs, e.g. lungs, oesophagus, extrathoracic airways, thymus, eyes and
eye lenses. The differences in the cross-fire from blood cannot be reduced by the phantom
adjustment though. This depends on how blood is attributed to different body organs and
tissues in the Monte Carlo calculations. Since individual blood volumes and individual mass
fractions of blood in different organs and tissues are usually not available, the cross-fire
from blood is a source of uncertainty of the absorbed dose estimation and requires further
careful considerations that go beyond the scope of this work.
8.4. Synopsis of performed anatomical modeling
The feasibility of reducing the difference between the individual-specific cross-fire and the
cross-fire estimated for non-personalized models was shown for most organs. All PET
radiopharmaceuticals have the same energy of photon component (annihilation photons
of 511 keV each). This is the main contribution to the cross-fire, since β-particles, due to
their short range in tissue, influence most the self-absorption. Nonetheless, depending on
branching ratio and energies of the emitted β-particles the results might differ for other
radiopharmaceuticals, which are based on other radionuclides than 18F and have other
source regions than 18F-FSPG. Final conclusions are radionuclide-specific and could be
drawn if the SAFs evaluated for all source-target pairs of the phantoms were compared.
However, such a comparison is practically very difficult because there are too many possible
source-target pairs. Additionally, it is not generally obvious how the differences in the SAFs
are propagated to the differences in the resulting organ absorbed dose coefficients, since
this also depends on the absolute values of SAFs and the absolute values of time-integrated
activity coefficients. A considerable methodological limitation of this work is the usage
of only two target patients. Pat1 and Pat2 were selected as, respectively, the biggest and
the smallest models in the HMGU library. They represent individuals with a pronounced
difference in the BMI (31.8 kg/m2 and 19.2 kg/m2 for Pat1 and Pat2, respectively). Pat1
and Pat2 also have unique and unrelated organ topology. With the applied relatively simple
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adjustments without matching the locations and masses of individual organs to those of
Pat1 and Pat2, < 25.0 % agreement in the cross-fire dose coefficients for the two employed
target patients was achieved (the corresponding value for most organs of the reference
phantoms relative to Pat1 and Pat2 was < 50.0 %). This might not hold true for other
individuals, though. To capture the whole range of inter-individual anatomic variability
more patients (i.e. individual phantoms) would be required. The results of this test study
showed the feasibility of improving the differences in the cross-fire absorbed dose coefficients
for both employed models.
The set of adjusted dimensions was selected in a way that they can relatively easily be
obtained for the patients. The individual organ masses and positions in Pat1M and Pat2M
were not adjusted to match the corresponding values of Pat1 and Pat2. The employed
mass-correction of the SAFs described in subsection 7.4.1 is phantom-independent and
requires only the masses of the target=source regions. The clinical quantification of the
absolute activities in the source regions – which in any case needs to be determined to
yield accurate personalized self-absorption doses – implicitly includes the estimation of the
source region masses as part of its procedure. The absolute activities are calculated via the
multiplication of the activity concentrations, determined from the PET images, and the
source region volumes, obtained from registered CT images.
The attempt of this thesis to capture inter-individual anatomic differences for dosimetric
calculations showed the potential to improve the dosimetry in nuclear medicine by adjusting
P-RCP-AM to the dimensions of an individual. The time required for the scaling of reference
polygon-surface phantom, the subsequent voxelization and contouring source organs to
obtain their masses is comparable to that needed for an experienced radiologist to contour all
regions of interest. Nonetheless, there are several advantages of the proposed method. Since
source organs accumulate activity, they are easily detected, and contouring is comparably
simple. Accurate segmentation of all regions of interest is, on the contrary, difficult due
to poor soft tissues contrast in CT image. The proposed approach can also be useful in
those scenarios where tomographic images of sufficient body coverage and resolution are
not available. The implementation of the proposed approach could potentially be optimized
by developing automatic tools for scaling the reference polygon-surface phantom. This
goes beyond the scope of this work, which aimed at evaluating the feasibility to capture
inter-individual anatomic differences by phantom scaling. An alternative option could be
to increase the diversity of human computational phantoms available for medical dose
evaluation, using the set of dimensions adjusted in this thesis, and subsequently select the
phantom from a collection of diversified models which best matches the external dimensions
of the patient. This would facilitate a fast clinical implementation of the approach proposed
and tested in this thesis. The level of personalization of an employed anatomical model
should depend on its application. The results of this work suggest that the proposed
approach could be sufficiently reliable for most situations involving low to moderate doses
(i.e. outside the therapy realm).
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Part IV.
Uncertainty and sensitivity analysis
93

In this part of the thesis global variance-based sensitivity analysis, accompanied by an
uncertainty analysis as part of its procedure, was applied to the internal dosimetry in
nuclear medicine according to the MIRD system. The fundamentals of uncertainty and
sensitivity analysis, main practical outcomes and general formalism of these procedures are
recapitulated in chapter 9. Chapter 10 describes each step of the variance-based sensitivity
analysis implemented in this thesis. The results of the uncertainty and sensitivity analysis are
presented in chapter 11. Chapter 11, thus, describes the effect of input factors on computed
uncertainties of organ dose coefficients, i.e. how these uncertainties are apportioned to the
variability of the input factors.
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9. Fundamentals of uncertainty and
sensitivity analysis
In this chapter objectives and commonly used methods of uncertainty and sensitivity
analysis are introduced. The purposes of these procedures are described in section 9.1.
Section 9.2 presents commonly used basic approaches of uncertainty and sensitivity analysis
and an advanced method of sensitivity analysis along with the advantages and drawbacks
of these methods.
9.1. Objectives of uncertainty and sensitivity analysis
The objective of the uncertainty analysis is to compute and quantify the uncertainty in
the model output, caused by the uncertainties of individual input factors of the model.
Thus it is a forward process, which propagates the variability in the inputs to the resulting
variability of the model.
Sensitivity analysis, denoted as SA from now on, is another key procedure used to assess
the quality of a model-based study [20]. It is an evaluation of the relative importance of
different input factors on the model output. In other words, SA breaks down the total
uncertainty in the model output into the parts caused by different input factors. Thus SA
is a backward process, in contrast to uncertainty analysis, because it projects the variability
in the model output back to the variability of the input factors.
Knowing the importance of the input factors, two settings are possible: investing efforts
in determining more precisely those input factors, which have a high influence on the
variability of the model output, and fixing those input factors, which do not affect the model
output anywhere in their range of variation. Saltelli et al. [97] denote the above mentioned
settings as “factor prioritization” and “factor fixing”, respectively. The important practical
outcomes of SA thus include a possibility to reduce the model complexity by applying
the “factor fixing” setting and to decrease the variability of the model output in the most
effective way by using the “factor prioritization” setting. For the sake of simplicity this
thesis will refer to the calculation of organ absorbed dose coefficients as to the model and
denote the computed doses as the model output in the following text.
9.2. Methods of uncertainty and sensitivity analysis
9.2.1. Uncertainty propagation
This commonly used method of error propagation relies on the assumption that a linear
approximation of a function Y (X) can be used around the mean value X of the input
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factor X. Then the change of the function around X can be written as:
Y− Y
(
X
)
= Y− Y ≈ ∂Y
∂X
∣∣∣∣
X=X
(
X −X
)
(9.1)
Then, denoting X −X = δX, the true value of the output Y lies in the interval Y± δY,
where δY is:
δY =
∣∣ ∂Y
∂X
∣∣∣∣∣∣
X=X
δX (9.2)
In case of a two-dimensional model Y (X1, X2) for the sake of convenience the mean value
of the input is denoted as X =
(
X1, X2
)
. Assuming again that a linear approximation can
be used around the mean value Y = Y
(
X
)
it follows:
Y− Y ≈ ∂Y
∂X1
∣∣∣∣
X
(
X1 −X1
)
+
∂Y
∂X2
∣∣∣∣
X
(
X2 −X2
)
(9.3)
analogously to equation 9.2 it follows for two input parameters:
δY ≈
∣∣ ∂Y
∂X1
∣∣∣∣∣∣
X
δX1 +
∣∣ ∂Y
∂X2
∣∣∣∣∣∣
X
δX2 (9.4)
From equation 9.4 follows that:
(δY)2 ≈
(
∂Y
∂X1
∣∣∣∣
X
δX1
)2
+
(
∂Y
∂X2
∣∣∣∣
X
δX2
)2
+ 2
∂Y
∂X1
∂Y
∂X2
∣∣∣∣
X
δX1δX2 (9.5)
Equation 9.5 is the error propagation formula for a two-dimensional model Y (X1, X2).
A special case of uncertainty propagation is the Gaussian error propagation. In this
case the input parameters X1 and X2 of the model Y (X1, X2) are assumed to be normally
distributed. From the definition of the variance σ2 for the case of n observations, the
variance σ2Y of Y is:
σ2Y =
1
n− 1
n∑
j=1
(δYj)2 (9.6)
From equations 9.5 and 9.6 it follows:
σ2Y ≈
1
n− 1
n∑
j=1
((
∂Y
∂X1
∣∣∣∣
X
δX1j
)2
+
(
∂Y
∂X2
∣∣∣∣
X
δX2j
)2
+ 2
∂Y
∂X1
∂Y
∂X2
∣∣∣∣
X
δX1jδX2j
)
(9.7)
Taking into account that the variances σ2X1 and σ
2
X2
of X1 and X2, respectively, are defined
as σ2X1 =
1
n− 1
n∑
j=1
(
δX1j
)2
and σ2X2 =
1
n− 1
n∑
j=1
(
δX2j
)2
, equation 9.7 becomes:
σ2Y ≈
(
∂Y
∂X1
∣∣∣∣
X
)2
σ2X1 +
(
∂Y
∂X2
∣∣∣∣
X
)2
σ2X2 + 2
∂Y
∂X1
∂Y
∂X2
∣∣∣∣
X
σX1,X2 (9.8)
where σX1,X2 =
1
n− 1
n∑
j=1
δX1jδX2j is a covariance of X1 and X2. If the input parameters
X1 and X2 are independent, σX1,X2 can be neglected. Therefore for independent X1 and
X2:
σ2Y ≈
(
∂Y
∂X1
∣∣∣∣
X
)2
σ2X1 +
(
∂Y
∂X2
∣∣∣∣
X
)2
σ2X2 (9.9)
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Equation 9.9 can be generalized for a model Y with arbitrary number of independent input
parameters Y (X1, X2, ..., Xk):
σ2Y ≈
k∑
i=1
(
∂Y
∂Xi
∣∣∣∣
X
)2
σ2i (9.10)
These error propagation approaches can be applied only to analytical functions. Another
substantial drawback of this method is the assumption of a linear approximation to the
model Y(X) around X, which does not always hold. These considerably reduce the area
of applicability of the error propagation method.
9.2.2. Local approach to sensitivity analysis
The local SA is the first historical approach to SA. It evaluates the effect on the model
output of small perturbations of the input factors. The values of the inputs are changed
around a specific point in the input space, often the mean value. According to this approach
the partial derivatives of the model output Y at e.g. the mean value of input factors X
are estimated. For instance, a value
(
∂Y
∂Xi
∣∣∣∣
X
σi
)2
can be considered as a sensitivity index
Si of the input Xi. The higher is the term Si =
(
∂Y
∂Xi
∣∣∣∣
X
σi
)2
, the higher is the influence
of input factor Xi on the variability of the output Y. A substantial disadvantage of this
method is the evaluation of sensitivity in one point of the input space only. Additionally,
only small perturbations of the inputs are studied in this case. Thus the local approaches
do not facilitate the full exploration of the input space. Usually these approaches do not
examine the cross-terms (interactions) between different input factors. In SA the input
factors “interact”, if the simultaneous change of these factors results in a higher variation
of the model output compared to that caused by the separate change of each input factor.
9.2.3. “One-factor-at-a-time” sensitivity analysis
One of the simplest SA methods is often called “one-factor-at-a-time”. It is the most
frequently used SA approach. Ferretti et al. [98] show in their review of the published
academic papers related to the SA that the majority of the papers use “one-factor-at-a-
time” SA. It evaluates the effect on the model output of change of one uncertain input
at a time around a selected point (often the mean value) while keeping the other inputs
constant. After moving one input factor, it is returned to its nominal value. Thereafter
the procedure is repeated for other variable input factors in the same fashion. Thus any
interactions between the input parameters are ignored in this case, since the simultaneous
variation of the inputs is not considered with this approach. Therefore, for reliable and
stable results, “one-factor-at-a-time” SA requires linearity and additivity of a model. In
an additive model interactions do not occur and the total variation of the model output
can be sub-divided into parts caused by different input factors separately. The input space
remains not fully explored with the “one-factor-at-a-time” SA. This effect becomes more
severe with increasing number of input parameters. Saltelli and Annoni [20] called this
effect a “curse of dimensionality” and provided a geometric proof of the inadequacy of
“one-factor-at-a-time” SA. Despite the simplicity of this method, it cannot be considered
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appropriate for any arbitrary model because of the substantial limitations and the required
assumptions mentioned above.
9.2.4. Global variance-based sensitivity analysis
In variance-based approaches probability distributions of the input factors are used to obtain
the distribution of the model output. The variance of the model output is decomposed into
the parts caused by the input factors. Thus the sensitivity measure for input factor Xi in
this case is a fraction of the total variance caused by Xi. In contrast to “one-factor-at-a-time”
SA approaches, global variance-based techniques [97,99–101] are effective and do not require
the assumptions of linearity and additivity of a model. They facilitate studying the influence
of several input factors on the model output. The basic concepts of the variance-based
methods are recapitulated in the following.
Sensitivity indices can be of a different order. The first-order sensitivity indices are also
called main effect indices and they indicate an effect of a particular parameter on the model
output. Higher-order effect sensitivity indices include interplay effects (combined effects) of
several inputs. Total effect indices include the first-order effect and all interactions of a
respective input factor [102,103]. It is usually considered that a model can be sufficiently
described by two sets of sensitivity indices – the first-order effect and the total effect indices
[97,99].
Consider a model Y = f (X1, X2, ..., Xi, ..., Xn) with n independent uncertain input
factors. Denote Y|Xi = x∗i the value of the model Y if the input Xi is fixed to a certain
value x∗i . X∼i is the set of all input factors but Xi. The mean value of the model Y for
fixed Xi = x
∗
i but all other inputs Xj 6=i varied is indicated as EX∼i (Y|Xi = x∗i ). Then the
first-order effect sensitivity index Si for the input factor Xi is defined as follows:
Si =
VXi (EX∼i (Y|Xi = x∗i ))
V (Y)
(9.11)
where the numerator is variance of EX∼i (Y|Xi = x∗i ) when varying all possible points x∗i .
V (Y) denotes the total unconditional variance of the output. V (Y) is computed according
to its definition:
V (Y) = E
[
(Y− E (Y))2
]
= E
[
Y2 − 2YE (Y) + E2 (Y)
]
= E
[
Y2
]
− 2E [Y]E [Y] + E2 [Y] = E
[
Y2
]
− E2 [Y] (9.12)
A high value of Si indicates an important input. A low Si does not necessarily mean a
non-influential input though, since higher-order effects can occur. To detect them the total
effect sensitivity index STi is computed. STi includes Si and all interactions of Xi. Thus
the fraction of output variance which is caused by X∼i alone needs to be excluded. This
fraction is described by the first-order effect sensitivity index for X∼i:
STi = 1−
VX∼i (EXi (Y|X∼i = x∗∼i))
V (Y)
(9.13)
Analogously to equation 9.11, EXi (Y|X∼i = x∗∼i) is the mean of the model Y when X∼i = x∗∼i
is fixed, i.e. all input factors except Xi are kept fixed. VX∼i (...) is variance of the
argument when varying all possible points x∗∼i. Considering the law of total variance
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V (Y) = V [E (Y|X)] + E [V (Y|X)] divided by V (Y), equation 9.13 for the total effect
sensitivity index STi of input factor Xi can be written as follows:
STi =
EX∼i (VXi (Y|X∼i = x∗∼i))
V (Y)
(9.14)
where VXi (Y|X∼i = x∗∼i) is the variance over possible Xi = x∗i of the model Y, while keeping
all input factors except Xi fixed. EX∼i (...) is the mean of the argument taken over X∼i, i.e.
all input factors but Xi.
Both, Si and STi can have non-negative values in the range [0, 1], where the importance of
the corresponding input factor increases with increasing values of the sensitivity index. For
example, Si = 0 and STi = 0 mean, respectively, no main effect influence and no influence
of the corresponding input factor on the model output. Si = 1 means that the variability
in the output is solely caused by the variability of the input Xi. Per definition STi ≥ Si,
since the total effect index includes main effect and all interactions of Xi. According to
variance decomposition formula (see reference [97]) for any arbitrary model with independent
inputs, the sum of all sensitivity indices of all orders, with each cross-term being considered
only once, is always equal to one:
∑
i
Si +
∑
i
∑
j>i
Sij +
∑
i
∑
j>i
∑
l>j
Sijl + ...+ S123...k = 1. For
perfectly additive models, i.e. for models in which no interactions between inputs occur,∑
i
Si =
∑
i
STi = 1. For non-additive models,
∑
i
Si < 1, since at least one of the higher-
order terms Sij, Sijl, ..., S123...k is nonzero. The sum of all total effect sensitivity indices
in a non-additive model is higher than one:
∑
i
STi > 1. It follows from the fact that e.g.
nonzero cross-term Sjl would be included in
∑
i
STi twice – once as part of STj and once as
part of STl .
Equations 9.11 and 9.14 present the general formalism of the variance-based SA. To
compute the sensitivity measures Si and STi according to this formalism, in practice Monte
Carlo estimators are used. The latter facilitate the calculation of Si and STi from two sets:
(1) input factors sampled multiple times from their distributions and (2) corresponding
model outputs calculated with each sample of the input factors. This procedure and the
Monte Carlo estimators employed in this thesis are discussed later in section 10.3.
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10.1. Uncertainties in internal dosimetry
The rationale of reliable internal dosimetry was already discussed in the introduction of
this thesis on page 4. As it is shown throughout this thesis, internal dosimetry relies on
computational methods, e.g. the MIRD framework [4] considered here, and on modeling
procedures – pharmacokinetic modeling, anatomical modeling and Monte Carlo radiation
transport simulations. Each type of the involved modeling is associated with various sources
of uncertainty [17, 19]. Therefore the total uncertainty of the computed organ doses can
amount to a high value [19]. It follows that the resulting dose estimates are to be provided
with the corresponding uncertainties. This is especially important in radionuclide therapy,
since the uncertainty in the computed organ doses may influence the decision-making. For
instance, the dose in the target that needs to be treated and the dose in the organs at risk
are usually two main factors defining an acceptance or a rejection of a treatment plan. The
former should be high enough to achieve the therapeutic effect, the latter cannot exceed the
highest tolerated dose for the particular organ or tissue. Thus the uncertainties associated
with these doses can affect the goodness of the plan and need to be taken into account.
Epidemiological studies in nuclear medicine also need to be accompanied by the uncertainty
analysis, since the outcome of the study can be affected by uncertainties of the documented
doses [18].
Pharmacokinetic modeling involves the uncertainties associated with the model struc-
ture, image acquisition and quantification, measurements of activity in collected blood
samples etc. Nonetheless, the main source of uncertainty in pharmacokinetic modeling,
indicated by Stabin [19], is the goodness of the model predictions for individual patients,
i.e. inter-individual differences in the distribution and excretion of an administered sub-
stance. The statistical uncertainties of Monte Carlo simulations of radiation transport in a
human computational phantom are usually small. Thus the major source of variations in
anatomical modeling is the difference between individuals and phantoms used to represent
the individuals, as also indicated in reference [19].
The details of uncertainty and sensitivity analysis implemented in this thesis and the
considered sources of variability are presented in the following.
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10.2. Evaluated model and considered sources of
uncertainty
Uncertainty and variance-based sensitivity analysis are applied in this thesis to the MIRD
model of internal organ dose computation [4]. This model is described in details in chapter 2
on page 23. It is an analytical model defined by equations 2.2, 2.4 and 2.8 on pages 23–24.
Moreover, a fixed urinary bladder model for the reference bladder content volume of 200 ml
was used to compute the absorbed dose coefficients to urinary bladder wall. For convenience,
the main equations of the considered model are repeated below:
d (rT ) =
∑
rS 6=rRoB
TIAC (rS)S (rT ← rS)
+ TIAC (rRoB)
MrTBS (rT ← rTB)−
∑
rS 6=rRoB
MrSS (rT ← rS)
MrRoB
 (10.1)
where
S (rT ← rS) =

∑
iEi Yi SAF (rT ← rS, Ei) , for photons
E0∫
0
P (E) E SAF (rT ← rS, E) dE, for β-spectrum of electrons
(10.2)
The dose-integration period TD has been eliminated in equation 10.1 in the arguments of the
absorbed dose coefficient d (rT ) and of the time-integrated activity coefficients TIAC(rS),
because it was fixed to TD = 1000 min (see section 5.1 on page 47). Note that for the sake
of simplicity the symbols ã (rS) and Φ (rT ← rS, E) used in equations 2.2, 2.4 and 2.8, are
replaced by TIAC(rS) and SAF(rT ← rS, E), respectively, in equations 10.1 and 10.2 and
in the following.
As it can be seen from equations 10.1 and 10.2, the input factors for the model include
time-integrated activity coefficients for the source regions rS and for the rest of body
rRoB (TIAC(rS) and TIAC(rRoB), respectively), S (rT ← rS) for all source-target pairs
and all considered radiation types, S (rT ← rTB), Ei, Yi and the masses of total body and
source regions. The latter were taken from the corresponding masses of the employed
human computational phantom. The values of Ei, Yi and the β-spectrum of the considered
radiation types were assumed to be constant. Thus the variable input parameters of the
model comprise the time-integrated activity coefficients and the specific absorbed fractions.
For the sake of convenience they are denoted as TIAC input factors and SAF input factors.
Thus for the output Y (the number of outputs is equal to the number of considered target
regions rT ) it can be written:
Y = f (TIAC1, TIAC2, ..., TIAC i, ..., TIACk, SAF 1, SAF 2, ..., SAF i, ..., SAF k) (10.3)
with the model f defined by equations 10.1–10.2 and the number of independent input
factors being equal to 2k, where k is the number of source regions. The model f was
implemented in the scope of this thesis in an in-house MATLAB-based program, which
utilizes discrete photon energies and detailed β-spectra from ICRP Publication 107 [55].
The developed program includes the option of mass-correction of the SAFs, as described in
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subsection 7.4.1 on page 76. Values denoted as “weighted dose coefficients” in the following
were also computed in this thesis. They were calculated as a weighted sum of individual
organ absorbed dose coefficients with the tissue weighting factors given in ICRP [34]. The
difference between the weighted dose coefficients computed here and the effective dose
coefficients defined by ICRP [34] is that the weighted dose coefficients are not sex- and
age-averaged and the following organs and tissues were excluded from their calculation:
endosteum, lymphatic nodes, oral mucosa, muscle tissue, uterus and prostate. These regions
were excluded because they were not present in at least one of the considered phantoms.
The employed tissue weighting factors were assumed to be constant.
10.3. Monte Carlo approach for variance-based sensitivity
analysis
Monte Carlo estimators were used in this thesis to compute the sensitivity indices Si and STi
given by equations 9.11 and 9.14, respectively. The Monte Carlo estimators were developed
by Saltelli et al. [99] for the first-order effect indices Si and by Jansen [104] and Saltelli
et al. [99] for the total effect indices STi based on the work of Sobol’ [100]. These Monte
Carlo techniques intrinsically include the uncertainty analysis and, hence, provide both,
uncertainty and sensitivity of the model output at once.
According to the implemented Monte Carlo technique, all uncertain input factors are
simultaneously sampled from their assigned distributions, providing a vector of inputs
(X1, X2, ..., Xi, ..., X2k)1. The model output is calculated with the vector of input factors
(X1, X2, ..., Xi, ..., X2k)1 and denoted as f (X1, X2, ..., Xi, ..., X2k)1. This procedure is re-
peated N times, giving a matrix A of input factors with a size N × 2k, where j-th row
represent j-th sample of the input factors (X1, X2, ..., Xi, ..., X2k)j. The model is executed
for each sample of the inputs, providing a vector of outputs Y = f (A) of the length N . In
this thesis the SA was implemented in a way that Si and STi are computed simultaneously
for the output dose coefficients for all target regions rT . Thus Y = f (A) is not a vector, but
a matrix of the size N× number of considered rT . Each column of this matrix corresponds
to a particular rT and is a vector. Therefore, for simplicity, the output Y is considered
to be a vector of length N in the following. The variability of the output Y can be thus
evaluated:
σY =
√
V (Y) (10.4)
Knowing the mean value E (Y) of model Y, the relative uncertainty is computed as follows:
RU =
σY
E (Y)
(10.5)
The generated samples of inputs and the corresponding model outputs are used for the
SA. Saltelli et al. [99] proposed the following approach to compute the first-order effect
index Si:
Si =
1
N
N∑
j=1
f (B)j
(
f
(
A
(i)
B
)
j
− f (A)j
)
V (Y)
(10.6)
with N being a number of model evaluations; A and B are independent sampled matrices
of input factors with a size of N × 2k and are both generated as described above for matrix
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A as an example (independence of A and B is ensured by an independent sampling of the
vectors of input factors 2N times in total); A
(i)
B is equal to the matrix A, except for the
column i, which is taken from the matrix B, i.e. Xi = const (see equation 9.11 on page 100);
(A)j and (B)j are the j-th rows of A and B, respectively. V (Y) is computed according to
equation 9.12 on page 100 using the outputs Y evaluated for both input matrices A and B.
The total effect index STi can be computed simultaneously with Si according to the
method proposed by Jansen [104] and Saltelli et al. [99]:
STi =
1
2N
N∑
j=1
(
f (A)j − f
(
A
(i)
B
)
j
)2
V (Y)
(10.7)
An in-house program was developed in the scope of this thesis to compute Si and STi
according to equations 10.6 and 10.7, respectively. The program was written in MATLAB
environment. Various values of the number of model executions N were used to evaluate
and ensure the convergence of the computed SA indices.
10.4. Input factors used in sensitivity analysis
As it is described in section 10.2, for each target region rT the set of uncertain in-
put factors considered in this work comprised the time-integrated activity coefficients
TIAC(rS) for source regions rS (and rest of body rRoB) and the specific absorbed fractions
SAF(rT ← rS, E).
TIAC input factors
Activity data for radiopharmaceutical 18F-FSPG derived in part II of this thesis were
employed in the sensitivity analysis. The case of blood being a distinct source region was
selected, as being more physiologically meaningful. These five sets of activity data are given
in table 5.4 on page 49. The 11 source regions for 18F-FSPG included kidneys, bladder
content, heart, thyroid, salivary glands, pancreas, stomach wall, liver, spleen, rest of body
and blood. Thus 11 TIAC input factors were considered, i.e. equal to the number of the
source regions (k=11 in equation 10.3 on page 104).
Employed anatomical models and SAF input factors
Six human computational phantoms were considered in the sensitivity analysis of this thesis.
These included two reference models – voxel ICRP adult male computational phantom [53]
(RCP-AM), polygon-surface ICRP adult male computational phantom [67] (P-RCP-AM);
two slim individuals – Irene [65, 72] (= Pat2) and the polygon-surface phantom Pat2M
obtained via adjustments of P-RCP-AM to fit selected characteristics of Irene (see chapter 8);
and two overweight individuals – Visible Human [65] (= Pat1) and the polygon-surface
phantom Pat1M obtained via adjustments of P-RCP-AM to fit selected characteristics
of Visible Human (see chapter 8). The description of the reference models is given in
section 6.2. The phantoms Visible Human (= Pat1) and Irene (= Pat2) are presented in
subsection 7.1.1. The anatomical models Pat1M and Pat2M developed in the scope of this
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Figure 10.1. Anatomical models of reference (RCP-AM and P-RCP-AM), slim (Irene
(= Pat2) and Pat2M) and overweight (VisHuman (= Pat1) and Pat1M)
individuals along with their BMI employed in sensitivity analysis.
thesis are described in section 8.1. Figure 10.1 shows the anatomical models employed in
the SA along with their body mass index (BMI).
The performed Monte Carlo calculations of the SAF of monoenergetic photon and electron
sources are described in sections 7.2 and 8.2. In the computational phantoms Irene and
Visible Human heart wall is not segmented, only the whole heart instead. Thus heart wall
was surrogated by heart for these two phantoms. Breast of RCP-AM was employed for
breast in Visible Human, since the latter is not present. For the urinary bladder dosimetry
the SAFs for photon and discrete electron energies computed by Andersson et al. [33] for the
bladder content as source and bladder wall as target were employed here for all phantoms.
Thus no variability of SAF(UBwall ← UBcont) among the anatomical models was considered
(UBwall and UBcont stand for urinary bladder wall and urinary bladder content, respectively).
The detailed β-spectrum of 18F from ICRP [55] was considered in this thesis for dose
computation. This includes SAFs for various energies of the emitted β component, ranging
from zero to the end-point energy Emax of the β-spectrum (for
18F Emax = 633.5 keV). The
SAFs corresponding to the discrete electron energies were not considered as input factors in
the sensitivity analysis though. The S values integrated over all energies of the β-spectrum
according to equation 10.2 on page 104 were used instead. Despite this, for the sake of
convenience these input factors are denoted SAF input factors, analogously to the photon
component. For each radiation type the number of considered sets of the SAFs is equal to
the number of source regions for the employed radiopharmaceutical. Thus in the presented
study 11 sets of SAFs for photon component and 11 sets of SAFs for electron component
were considered.
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10.5. Sampling of input factors
A truncated normal distribution (without the negative tail) was assigned to the input factors.
The negative tails of the distributions were cut, because negative values of TIACs and SAFs
are not meaningful. The parameters µ and σ (mean and standard deviation, respectively)
of the probability density functions were computed from the five volunteer-specific sets of
the TIACs for the TIAC input factors and from the phantom-specific sets of the SAFs for
the SAF input factors. The parameters µ and σ for the TIAC input factors are shown in
table 10.1. The mean µ and the standard deviation σ calculated for the distributions of the
SAF input factors for photons and electrons are given in tables 10.2 and 10.3, respectively.
Kidneys Liver Pancreas Spleen St-
wall
Thyroid S-
glands
UB-
cont
Ht-
wall
RoB Blood
µ 583.6 245.5 134.3 18.5 35.1 4.4 6.1 1175.4 44.3 1885.5 721.7
σ 79.2 88.2 33.6 9.7 15.2 1.1 1.2 123.2 25.2 392.8 118.5
Table 10.1. Mean µ [s] and standard deviation σ [s] of TIAC input factors distributions.
St-wall stands for stomach wall, S-glands – for salivary glands, UB-cont – for
urinary bladder content, Ht-wall – for heart wall, RoB – for rest of body.
10.6. Sobol’ low discrepancy sequence
The low-discrepancy (also called quasi-random) sequence developed by Sobol’ [105] was
used to generate the samples of the independent variable input factors. Such deterministic
sequences attempt to minimize the discrepancy, i.e. make the quasi-random points as well
spaced as possible in a unit hypercube. Averaged over all projections in a multidimensional
unit hypercube, the points in the Sobol’ sequence [105] are distributed with a greater
uniformity than random (or pseudo-random) numbers and, therefore, provide an accelerated
convergence of the computed SA indices. Figure 10.2 shows an example of 128 uniformly
distributed points generated with the pseudo-random generator of a personal computer
and 128 uniformly distributed points, generated with Sobol’ low-discrepancy sequence. To
generate Sobol’ quasi-random points, the program [106] distributed by the Joint Research
Centre of the European Commission (https://ec.europa.eu/jrc/en) was employed.
Figure 10.2 shows a two-dimensional case. In panel (a) of figure 10.2 clustering of the
points and empty areas can be observed, whereas the points in panel (b) are distributed
with much greater uniformity. Note that for a multi-dimensional model it becomes even
more difficult to achieve a low discrepancy in the sampled input factors with increasing
dimensionality. The Sobol’ sequence [105], and low-discrepancy sequences in general,
are particularly advantageous for problems with few dimensions and higher sample size.
Nonetheless, averaged over all projections, the Sobol’ sequence [105] generates points that
are considerably better spaced than random numbers. Consequently, it is likely to achieve
a faster convergence of the values computed with Monte Carlo methods. However, the
convergence is also dependent on the model, and some models will see much more marked
improvements from the usage of low-discrepancy sequences than others. Conventional
wisdom is to use the Sobol’ sequence [105], because it should at least be as good as random
sequence, and often is more accurate.
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(b) Sobol’ quasi-random points
Figure 10.2. (a) 128 points, generated with pseudo-random numbers generator of a personal
computer and (b) 128 uniformly distributed quasi-random points, generated
with Sobol’ low-discrepancy sequence.
As described in section 10.4, the considered model originally included 33 variable input
factors: 11 TIACs and 22 SAFs: 11 for photon- and 11 for β-components. For the same
source-target pair photon and electron SAFs cannot be considered uncorrelated inputs
because they are both dependent on the positions of the source and the target relative to
each other. For this reason the same quasi-random numbers were used for sampling the
photon and the electron SAFs for the same combination of source and target regions. This
decreased the dimensionality of the model from 33 to 22 dimensions.
A MATLAB-based program [106] was employed to generate Sobol’ points [105] in a
22-dimensional unit hypercube. These uniformly distributed points were converted to the
points from the desired truncated normal distributions with the pre-calculated parameters
µ and σ, summarized in tables 10.1 – 10.3, using the inverse cumulative density function.
10.7. Number of model executions and convergence
An important step, which should be considered in Monte Carlo approaches, is the selection
of the sample size. For the purpose of sensitivity analysis the sample size should be high
enough to adequately cover the input space and to facilitate the calculation of robust and
stable SA indices. At the same time, the number of the sampled input factors defines the
number of model executions. Thus, high sample sizes can result in a very computationally
intensive SA execution.
In this thesis the number of model runs was set to N = 4096. Thus N = 4096 Sobol’
quasi-random points [105] were generated in a 22-dimensional unit hypercube for each of
the independent matrices A and B as described in section 10.3. It was verified whether
with this sample size the convergence of the computed sensitivity indices Si and STi was
achieved, i.e. whether Si and STi were numerically stable and their values did not change
with further increasing the number of model runs. Note that the size of a sample generated
with deterministic quasi-random sequences in general and with the Sobol’ sequence in
particular can be increased if the convergence is not achieved with the originally selected
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number of model executions. The first N quasi-random (Sobol’) numbers (and model
executions) in the increased sample remain the same and, thus, they do not require model
re-evaluation.
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11. Effect of input factor variabilities on
computed uncertainties of organ
dose coefficients
Variance-based global SA was applied in this thesis to internal dosimetry in nuclear medicine,
according to the commonly used MIRD system [4]. The effect of changes of all uncertain
input factors on the model output was evaluated. The computed uncertainties of the dose
coefficients are presented in section 11.1. The convergence of the derived sensitivity indices
was verified and the results are shown in section 11.2. Section 11.3 summarizes the results
of the SA, i.e. how the variance of the dose coefficients was apportioned to the uncertain
input factors.
11.1. Uncertainty of computed dose coefficients
The uncertainties in the absorbed dose coefficients for various target regions were computed
as part of the Monte Carlo-based SA approach implemented in this thesis. Two sources of
uncertainties were investigated: the inter-individual differences in the cumulated activities
and the differences between the anatomical models employed in the dosimetry.
The box plot distributions of the computed absorbed dose coefficients and the weighted
dose coefficient are presented in figure 11.1. Each sample in figure 11.1 includes 2N = 8192
dose coefficients, i.e. model outputs evaluated with two independent matrices A and B of
sampled input factors (see section 10.3). The boxes comprise 25 and 75 % percentile, the
red horizontal lines show the medians of the calculated 2N = 8192 dose coefficients. It
can be seen in figure 11.1 that no outliers were observed. The red crosses present those
0.7 % of the values that are at the tails of the calculated distributions of absorbed dose
coefficients and weighted dose coefficient. Often to describe a spread of values in a sample
standard deviation is used, which for normally distributed values includes approximately
68 % of them. The standard deviations of the distributions of the dose coefficients from
figure 11.1 are presented in figure 11.2. Figure 11.2 also shows mean values and relative
uncertainties of the computed absorbed dose coefficients and the weighted dose coefficient.
The relative uncertainty in weighted dose coefficient amounted to approximately 10 %. Since
this value effectively averages several absorbed dose coefficients and the variability in the
tissue weighting factors was not considered, the expected uncertainty in the weighted dose
coefficient is lower than that in the individual absorbed dose coefficients. The computed
relative uncertainties in the absorbed dose coefficients were between 10 % for urinary
bladder wall and 30 % for heart wall. These uncertainties were caused by inter-individual
differences in TIACs and inter-phantom differences in SAFs (as shown in tables 10.1–10.3
on pages 108–110).
The uncertainty in the absorbed dose coefficient for bladder wall was the lowest, since
the same values of SAF(UBwall ← UBcont) calculated by Andersson et al. [33] were used for
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Figure 11.1. Box plot of computed dose coefficients. Each sample includes the results of
2N = 8192 model executions. The tops and bottoms of the boxes correspond
to 25-th and 75-th percentiles of the samples, respectively. Red horizontal
lines are the medians. The ranges of the whiskers include 99.3 % of the points.
The points outside these ranges are shown as red crosses.
St-wall is stomach wall, S-glands – salivary glands, UB-wall and ET denotes
urinary bladder wall and extrathoracic airways, respectively.
all phantoms (see section 10.4). Thus, the variability of the output in this case was caused
predominantly by the variability of the cumulated activities in the bladder contents. The
utilization of SAF(UBwall ← UBcont) derived by Andersson et al. [33] was more appropriate
here rather than the usage of the corresponding phantom-specific values. For a certain type
of radiation and energy, the above mentioned SAFs are dependent on the volumes of the
bladder content and the thickness of the bladder wall. Thus, if the phantom-specific values
of SAF(UBwall ← UBcont) were used, the differences in the bladder volumes segmented in
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the phantoms and in the thickness of the bladder wall, which is often limited by the voxel
size, would introduce additional artificial variation in the SAF input factors. The highest
uncertainty was observed for heart wall absorbed dose coefficient. The reason for this was a
high inter-individual difference in the TIAC(Heart wall). Additionally, heart wall of two
phantoms was surrogated by whole heart. This is another possible reason for the large
observed uncertainty for the heart wall dose coefficient.
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Figure 11.2. Computed dose coefficients along with their uncertainties. Error bars on the
lower panel represent standard deviations of the respective dose coefficients.
Relative uncertainty on the upper panel is defined as one standard deviation
of the respective sample divided by the sample mean (see equation 10.5). The
SAFs are mass-scaled to the reference masses of RCP-AM.
St-wall denotes stomach wall, S-glands – salivary glands, UB-wall – urinary
bladder wall, ET – extrathoracic airways.
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The TIACs were computed via integration under the time-activity curves predicted by
personalized pharmacokinetic models developed in the scope of this thesis and described in
chapter 5. The pharmacokinetic models were assumed to be fixed. Thus, the uncertainties
associated with the model structure, image acquisition, activity quantification from PET
images and collected blood samples were not a part of the SA in this work. The variability of
the tissue weighting factors [34] employed in the computation of weighted dose coefficients
was not considered. Xie and Zaidi [107] investigated another source of uncertainty in
the computed organ doses associated with respiratory motion. Despite this effect being
negligible for most organs considered in the study of Xie and Zaidi [107], the authors showed
few cases where it can be perceptible. Including all aforementioned uncertainties into the
variance-based SA would be of high interest, however it goes beyond the scope of this thesis.
The applied uncertainty analysis is an intrinsic procedure of the SA implemented in
this thesis. It facilitates the computation of variances of the dose coefficients caused by
simultaneous changes of all input factors. As suggested by Saltelli et al. [97], Sobol’ sequence
was employed for the sampling of the input factors, since, as a low-discrepancy sequence, it
facilitates good coverage of the input space. Consequently, for the considered input factors
and their assigned variability, the possibly full ranges of output variations were computed
and shown in e.g. figure 11.1.
11.2. Convergence of sensitivity indices
The convergence of the first-order effect sensitivity indices and the total effect sensitivity
indices computed with N = 4096 model executions was verified. Figures 11.3 and 11.4 show
the calculated SA indices for the absorbed dose coefficient for spleen and brain, respectively,
depending on the number of model executions. As it can be seen from these figures, with a
small number of model runs the SA indices are not stable and large fluctuations occurred.
Nonetheless, both first-order Si and total effect STi indices converge relatively fast. For
the output absorbed dose coefficient for spleen about 800 model runs were sufficient to
achieve the convergence of Si and STi . For the output absorbed dose coefficient for brain
the convergence of Si and STi was achieved later than for spleen. Nonetheless, the used
number of model executions N = 4096 was sufficient to ensure the convergence of the SA
indices for brain and all other considered outputs.
Figure 11.3 demonstrates that for spleen, which is a source region for the considered radio-
pharmaceutical 18F-FSPG, TIAC(spleen) is the most influential parameter for the variability
of the absorbed dose coefficient with Si[TIAC(spleen)] = STi [TIAC(spleen)] = 0.67. The
influence of SAF(spleen← blood) is also shown in figure 11.3 (Si[SAF(spleen← blood)] =
0.17 and STi [SAF(spleen← blood)] = 0.18). This result is consistent with the fact of spleen
being a highly vascularized organ. It can be seen from figure 11.3 that no higher order effects
were observed in this case, since the computed total effect SA indices are approximately
equal to the respective first-order effect indices (see subsection 9.2.4 on page 101). Brain is
not a source region for 18F-FSPG. Thus the dose absorbed in the brain is due to the energy
released by other organs and tissues – source regions. Since brain is located distantly from
the local sources, the influential input factors for the variance of the absorbed dose coefficient
for brain (figure 11.4) were TIAC(RoB) and SAF(brain← RoB). Si[TIAC(RoB)] = 0.51,
STi [TIAC(RoB)] = 0.52, Si[SAF(brain← RoB)] = 0.40 and STi [SAF(brain← RoB)] =
0.41.
Fast convergence of the computed sensitivity indices was shown. The considered number
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Figure 11.3. Convergence plots for the first-order Si (top) and the total effect STi (bottom)
SA indices for absorbed dose coefficient for spleen as output. The upper and
the lower panels of the plot show the dependence of the computed values of
Si and STi , respectively, on the number of model runs. Each panel contains
22 convergence curves. Each convergence curve corresponds to one of the 22
considered input factors: 11 TIAC (solid lines) and 11 SAF (dashed lines)
input factors. The list of the 22 considered input factors is shown in the
rightmost box. Ht-wall stands for heart wall, UB-cont for urinary bladder
content, St-wall for stomach wall, S-glands for salivary glands and RoB for rest
of body. TIAC(spleen) (magenta solid line) has the highest contribution to
the variance of absorbed dose coefficient for spleen, SAF(spleen← blood) (red
dashed line) has a notable contribution, whereas the contributions of other
inputs are negligibly low. Note that SAF(spleen← spleen) of all phantoms
were corrected to correspond to the mass of spleen in RCP-AM.
of model evaluations N = 4096 assured the stability of the presented values Si and STi .
Due to the relative simplicity of the studied model and the used implementation the pure
execution time of the SA with N = 4096 runs on a 3.10 GHz computer was approximately
0.05 seconds.
117
11. Effect of input factor variabilities on computed uncertainties of organ dose coefficients
0 800 1600 2400 3200 4000
−1
−0.5
0
0.5
1
1.5
2
F
irs
t−
or
de
r 
ef
fe
ct
 S
A
 in
di
ce
s,
 S
i Brain
0 800 1600 2400 3200 4000
0
0.5
1
1.5
2
T
ot
al
 e
ffe
ct
 S
A
 in
di
ce
s,
 S
T
i
Number of runs, N
 
 
Brain
TIAC−Kidneys
TIAC−Ht−wall
TIAC−UB−cont
TIAC−Spleen
TIAC−Pancreas
TIAC−Liver
TIAC−St−wall
TIAC−Thyroid
TIAC−S−glands
TIAC−RoB
TIAC−Blood
SAF−Kidneys
SAF−Ht−wall
SAF−UB−cont
SAF−Spleen
SAF−Pancreas
SAF−Liver
SAF−St−wall
SAF−Thyroid
SAF−S−glands
SAF−RoB
SAF−Blood
Figure 11.4. Analogue to figure 11.3, convergence plots for the first-order Si (top) and the
total effect STi (bottom) SA indices for absorbed dose coefficient for brain as
output. The rightmost box shows the list of the 22 considered input factors.
TIAC(RoB) (turquoise solid line) and SAF(brain← RoB) (turquoise dashed
line) are the two influential input factors for the variance of absorbed dose
coefficient for brain. The contributions of other inputs are negligibly low.
11.3. Effect of input factors on variability of dose
coefficients
There are several possible ways to illustrate the sensitivity. One of them is a graphical rep-
resentation using scatter plots. Each point in a scatter plot represents an output calculated
with one sampled vector of input factors. As it is described in sections 10.4–10.6, in this the-
sis such input vector has the length of 22: (TIAC1, TIAC2, ..., TIAC11, SAF1, SAF2, ..., SAF11).
A subset of scatter plots and the computed respective sensitivity indices for the absorbed
dose coefficients for small intestine wall and lungs are presented in figures 11.5 and 11.6,
respectively. Each subplot of figure 11.5 and figure 11.6 contains N = 4096 points. If Si = 0,
it means that there is no main dependence between the respective input variability and the
variance of the output. In this case the scatter plot looks like a “cloud” and no correlation
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can be observed. The more prominent patterns in the scatter plots correspond to the more
influential input factors, making such plots a convenient graphical representation of the
sensitivity.
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Figure 11.5. Scatter plots, sensitivity indices and distribution of absorbed dose coefficient
for small intestine wall. Upper row corresponds to the TIAC inputs, lower
row to the SAF inputs. The values S and ST are the first-order and the total
effect sensitivity indices, respectively. The histogram displays the distribution
of the output dose coefficient. The mean value of the computed absorbed dose
coefficient for small intestine wall is marked with red dashed line.
Being target regions and not sources, small intestine wall and lungs receive radiation
doses from the cross-fire from other source regions. The example in figure 11.5 shows that
the variability of the output is mainly caused by the variability in the cross-fire SAFs from
the sources located in the close proximity, e.g. SAF(small intestine← UBcont) for absorbed
dose coefficient for the small intestine wall, where Si[SAF(small intestine← UBcont)] =
0.75 and the corresponding total effect SA index STi is 0.76. For lungs, as for a target
region with substantial mass fraction of blood, notable effect of SAF(rT ← blood) and
TIAC(blood) is shown and quantitatively expressed via computed Si and STi values in
figure 11.6: Si[SAF(rT ← blood)] = 0.71, STi [SAF(rT ← blood)] = 0.73, Si[TIAC(blood)] =
0.19 and STi [TIAC(blood)] = 0.21.
Figure 11.7 shows the scatter plots and the distribution of the absorbed dose coefficient
for kidneys. Kidneys are a source region for 18F-FSPG. SAF(kidneys← kidneys) were mass-
scaled (see subsection 7.4.1 on page 76) to the reference mass of kidneys. The variance of the
absorbed dose coefficient for kidneys was solely caused by the variability of TIAC(kidneys)
with Si[TIAC(kidneys)] = STi [TIAC(kidneys)] = 0.98 (see also the prominent pattern in
the corresponding scatter plot in figure11.7).
Figure 11.8 shows the first-order effect sensitivity indices for all considered target regions.
Each horizontal line in figure 11.8 contains Si in color-codes for all input factors and a
119
11. Effect of input factor variabilities on computed uncertainties of organ dose coefficients
0
0.5
1
1.5
2
2.5
x 10
−11
01000
A
bs
or
be
d 
do
se
 to
Lu
ng
s,
 G
y/
B
q
frequency
0
0.5
1
1.5
2
2.5
x 10
−11
Kidneys Ht−wall UB−cont Spleen Pancreas Liver
First order and total sensitivity analysis indices for TIAC inputs
St−wall Thyroid S−glands RoB Blood
0
0.5
1
1.5
2
2.5
x 10
−11
01000
A
bs
or
be
d 
do
se
 to
Lu
ng
s,
 G
y/
B
q
frequency
0
0.5
1
1.5
2
2.5
x 10
−11
Kidneys Ht−wall UB−cont Spleen Pancreas Liver
First order and total sensitivity analysis indices for SAF inputs
St−wall Thyroid S−glands RoB Blood
S=0.00
S
T
=0.00
S=0.00
S
T
=0.00
S=0.00
S
T
=0.00
S=0.00
S
T
=0.00
S=0.00
S
T
=0.00
S=0.01
S
T
=0.01
S=0.00
S
T
=0.00
S=0.00
S
T
=0.00
S=0.00
S
T
=0.00
S=0.03
S
T
=0.03
S=0.19
S
T
=0.21
S=0.00
S
T
=0.00
S=0.00
S
T
=0.00
S=0.00
S
T
=0.00
S=0.00
S
T
=0.00
S=0.00
S
T
=0.00
S=0.00
S
T
=0.00
S=0.00
S
T
=0.00
S=0.00
S
T
=0.00
S=0.00
S
T
=0.00
S=0.03
S
T
=0.03
S=0.71
S
T
=0.73
Figure 11.6. Analogue to figure 11.5, scatter plots, sensitivity indices and distribution of
absorbed dose coefficient for lungs. The mean value of the computed absorbed
dose coefficient for lungs is marked with red dashed line.
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Figure 11.7. Analogue to figure 11.5, scatter plots, sensitivity indices and distribution
of absorbed dose coefficient for kidneys. The mean value of the absorbed
dose coefficient for kidneys is marked with red dashed line. Note that
SAF(kidneys← kidneys) of all phantoms were corrected to correspond to
the mass of kidneys in RCP-AM.
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selected output. Figure 11.8 breaks down the uncertainty of each output dose coefficient
presented in figure 11.2 on page 115 into parts caused by the variability of each input factor.
In figure 11.8 these contributions are numerically expressed by the corresponding Si.
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Figure 11.8. First-order effect sensitivity indices for all considered outputs. Each horizontal
line in this figure contains Si in color-codes for all input factors and a selected
output. The input factors are plotted from left to right and the output target
regions from bottom to top. Si = 0 means no main effect of the corresponding
input factor. Si = 1 means that the variability of the output is solely caused
by the variability of the corresponding input factor.
The computed total effect sensitivity indices were similar to those of the first-order and,
thus, are not presented here but included in appendix B instead. The similarity of main
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and total effect sensitivity indices indicates that no substantial higher order effects were
observed in the model. Another indication of the absence of notable higher order effects in
the studied model is that
∑2k
i=1 Si ≈ 1.
Several trends can be seen from figure 11.8. The uncertainty of the computed doses for
the source regions is predominated or, in some cases, solely defined by the variability in the
activities accumulated in the respective source regions (see the diagonal line of high Si in
the lower left corner of figure 11.8). For some rT = rS, Si[TIAC(rT=rS)] ≥ 0.9. For the
considered relatively low energies (511 keV for annihilation photons and, respectively, mean
and maximum energies of the β-spectrum of 18F equal to 249.8 keV and 633.5 keV) the dose
absorbed in the source region is mainly due to the self-absorption in this region. The applied
mass-scaling of the self-absorption SAF eliminated the inter-phantom differences in these
values and thus the variability in the output dose coefficients for the source regions was
mainly caused by the variability in the respective TIACs. Thus the accurate determination
of the absolute activities in the source regions substantially improves the accuracy of the
computed absorbed dose coefficients for the source regions. It also implicitly includes the
estimation of the source region masses needed for mass-scaling of the self-absorption SAF.
The results show that for the target regions, which are not sources, the most influential
factors for the variability of the computed doses are the cross-fire SAFs from closely located
sources. Thus, e.g. the variability in SAF(adrenals← kidneys) had the greatest impact on
the uncertainty of the absorbed dose coefficient for adrenals (Si[SAF(adrenals← kidneys)] =
0.6) and the variability in SAF(rT ← UBcont) on the absorbed dose coefficients for small intes-
tine (Si[SAF(small intestine wall← UBcont)] = 0.75), gonads (Si[SAF(gonads← UBcont)]
= 0.59) and colon wall (Si[SAF(colon wall← UBcont)] = 0.27). To a lesser extent but
nonetheless substantial was the influence of the integrated activities accumulated in the
source regions located in close proximity, e.g. for adrenals and gonads, Si[TIAC(kidneys)] =
0.14 and Si[TIAC(UBcont)] = 0.32, respectively.
For the targets that do not have high blood contents and are located distantly from the
source regions, e.g. eyes, eye lenses, skeleton, skin, extrathoracic airways (ET) or brain, the
variability of TIAC(RoB) was an important factor, contributing to the uncertainty of the
absorbed dose coefficients (see figure 11.8).
For the organs with substantial mass fractions of blood or located very close to highly
vascular organs, e.g. lungs, oesophagus, thymus, spinal cord, extrathoracic airways, eye
lenses, eyes, colon etc., the sensitivity indices for the input factors SAF(rT ← blood)
and TIAC(blood) amount to high values (see figures 11.6 and 11.8). This illustrates the
importance of an accurate determination of SAF(rT ← blood) and the blood activities in
dosimetric studies in nuclear medicine. The values of SAF(rT ← blood) are independent
on the relative positions of organs in anatomical models though. They are defined by
the blood contents of the respective organs rT . This shows that the determination of the
individual blood contents of organs has the potential to notably decrease the uncertainty of
the computed absorbed doses for highly vascular organs and organs closely located to them.
Each output absorbed dose coefficient had its own set of influential input factors. The
sensitivity indices cannot be compared between different outputs though. They allow ranking
the input factors according to their effect only on a particular output dose coefficient. Since
the absolute values of the absorbed dose coefficients notably vary for different target regions,
it is convenient to operate with a value that includes absorbed dose coefficients of various
organs and takes into account the differences in the absolute computed dose coefficients.
This was the purpose of computing a specific value denoted as weighted dose coefficient
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in the text. The SA was also applied to this artificial value to identify the input factors
which have the highest effect on the value similar to a risk-weighted average body dose.
The computed weighted dose coefficient was an adequate estimate for the effective dose
coefficient. Only few target regions were excluded: endosteum, lymphatic nodes, oral
mucosa, muscle tissue, prostate and uterus. Since these organs and tissues are not source
regions for the considered radiopharmaceutical 18F-FSPG, the expected absolute absorbed
dose coefficients for them are not very high. The corresponding tissue weighting factors
are also relatively low (0.01 for endosteum, and the other regions are parts of the reminder
tissues). The input factor SAF(rT ← blood) had the highest effect on the variability of
the weighted dose coefficient with Si = STi = 0.31. Each of the uncertain input factors
TIAC(St-wall), TIAC(UBcont), TIAC(blood), TIAC(RoB) and SAF(rT ← UBcont) accounts
for approximately 10 % of the variability of the weighted dose coefficient.
Six anatomical models representing slim, reference and overweight individuals were
employed in this thesis to construct the distributions of the SAF input factors. The models
covered the range in the BMI from 19.2 kg/m2 to 31.9 kg/m2. Although it cannot be claimed
that all possible anatomic variations were covered, the considered inter-phantom differences
were not limited to the six employed models. The tails of the normal distributions assigned
to the input factors covered a broader range of SAFs than that of the six considered
phantoms. The Sobol’ sequence ensured the sampling of the input factors also from the
less probable areas of the input space. The same holds here for the variations of the TIAC
input factors, whose distributions were constructed based on the activity data from five
volunteers. Thus it is reasonable to assume that the considered differences in the input
factors are an adequate estimate for their variability.
It is important to use in the SA computational phantoms with all required regions
segmented and blood properly distributed in various body organs. Otherwise additional
artificial variations in the SAF input factors could be introduced and lead to different and
possibly inadequate results of the SA. For this reason no organ surrogates, besides a whole
heart for a heart wall, were used in part IV of this thesis and organs that are not present in
one or more phantoms were omitted.
The activity data of a radiopharmaceutical designated for PET diagnosis were employed
in this thesis. Since the diagnostic investigations are associated with low to moderate doses,
individualized dosimetry is less relevant for this case, compared to therapy. Nonetheless, the
applied SA method and the developed framework and computer programs do not depend on
the clinical purpose of the radiopharmaceutical and can be applied equally for therapeutic
agents.
In this thesis the effect of changes of all uncertain input factors on model output was
evaluated by means of variance-based global SA. This method effectively explores the input
space and allows studying the interplay effects of any possible simultaneous perturbations
of the inputs on the variance of the model output. Additionally, it does not require the
studied model to be analytical. Therefore the variance-based global SA is superior compared
to more frequently used “one-factor-at-a-time” SA or Gaussian error propagation. The
global SA implemented in this thesis is a model-independent method, accompanied by an
uncertainty analysis as part of its procedure. All these properties make the variance-based
global SA a convenient and powerful procedure used to assess the quality of a model-based
study.
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12. Summary
This chapter highlights the motivation and the objective of this thesis, the main developments
done in the scope of this thesis and the most important results.
 Personalized internal dosimetry potentially increases the success of radionuclide
therapy. In diagnostic nuclear medicine applications, it has a potential to reduce
late negative effects of the radiation. Individualized dosimetry is also required for
epidemiological studies in nuclear medicine. Theoretically, personalized internal
dosimetry is a straight-forward process, since there is a clear formalism of how it is to
be done. In practice, it is very difficult to implement, though. Advanced modeling
procedures needed for individual dose assessment in nuclear medicine are not viable
for each patient, due to high time and effort costs. Consequently, internal doses are
estimated for available reference models and these values are applied to individual
patients. The accuracy of these estimations is limited.
 A comprehensive analysis was carried out in the scope of this thesis to evaluate
the variability in organ doses between reference models and individual patients.
To facilitate this analysis, advanced modeling procedures such as pharmacokinetic
modeling and anatomical modeling were implemented and evaluated.
 Individual pharmacokinetic models were established for five healthy volunteers admin-
istered with a novel diagnostic PET tracer. Based on these models, the inter-individual
variability in pharmacokinetics was analyzed and quantified for time-integrated activity
coefficients – the first group of input factors required for internal dose calculation.
 One of the important findings of this thesis is that the way how blood is treated in
pharmacokinetic modeling and internal dosimetry notably influences the computed
organ doses for highly vascular organs, which are not source regions. Blood should be
considered as a distinct source region to facilitate more physiologically meaningful
modeling and subsequent dosimetry. Therefore, blood samples should be collected
and their activity should be measured in all pharmacokinetic and dosimetric studies
for radiopharmaceuticals.
 The individual patient anatomy also limits the accuracy of internal dose estimates.
To capture the differences in organ doses caused by the inter-individual variations
in anatomy, the polygon-surface ICRP adult male model was scaled to fit selected
dimensions of patients. These dimensions comprised the distance between the iliac
crest and the clavicles, total height, front-to-back distance and width of the rib
cage. The implemented scaling requires less effort than is needed for the detailed
segmentation of a patient.
 Two computational phantoms were generated with the implemented anatomical
modeling: a slim and an overweight individual. These models along with two reference
127
12. Summary
computational phantoms and two other available models of slim and overweight
individuals from the HMGU library were used to evaluate and quantify the variability
in specific absorbed fractions – the second group of input factors required for internal
dosimetry. It was shown that the estimation of individual patient organ doses with
the developed scaling is possible within 25 % of error, whereas employing reference
phantoms without any scaling applied patient organ doses were estimated with about
50 % relative uncertainty.
 Variance-based sensitivity analysis was implemented in this thesis and applied to
dosimetry in nuclear medicine applications for the first time. This approach facilitated
an assessment of the variance of dose coefficients caused by inter-individual variations
in pharmacokinetics and differences in anatomy. Variance-based sensitivity analysis
allowed to break-down the variances of the dose coefficients into fractions caused by
different input uncertainties.
 By means of variance-based sensitivity analysis the input factors which have the
greatest impact on the variance of dose coefficients were identified in the scope of
this thesis. It follows that accurate determination of the time-integrated activity
coefficients in the source regions accompanied by the estimation of individual source
region masses and the usage of an appropriate blood distribution in a patient’s body
have the potential to substantially decrease the variance of computed dose coefficients
in nuclear medicine. For some organs located in close proximity to the source regions
the cross-fire specific absorbed fractions have an impact as well.
The presented work proposes a method of physiologically meaningful modeling of blood
activity in pharmacokinetic studies. It shows feasibility of reducing the difference in
estimated doses in nuclear medicine caused by anatomical differences between the patient
and a reference phantom. The approach proposed for this aim could be a good trade-off
between effort and accuracy and has the potential to be directly applicable in medical
practice. This thesis provides powerful tools, which facilitate the uncertainty analysis of
internal dosimetry and allow ranking the inputs according to their impact on the variance
of dose coefficients. The developed methods offer the possibility to reduce the uncertainty
of estimated doses in nuclear medicine and, consequently, to provide more reliable dose
estimates. Overall these findings give a potential to move from current reference internal
dosimetry towards personalized dosimetry in nuclear medicine applications.
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Several advanced modeling procedures were implemented in this thesis to facilitate a
comprehensive study on how to decrease the difference between reference internal doses and
individual-specific doses in nuclear medicine by practically viable methods. Ways to enhance
the reliability of internal dose estimates were studied and led to several recommendations.
Due to the demonstrated high impact of blood activity on organ doses, the measurement
protocols for pharmacokinetic and dosimetric studies should include the collection of blood
samples and the assessment of their activity. Subsequently blood should be considered
as a distinct source region. This increases the accuracy of internal dose estimates. Inter-
individual differences in anatomy also limit the accuracy of internal dosimetry. These
differences can be eliminated by personalized computational phantoms. The segmentation
of these data is too time and effort consuming though. The feasibility to capture inter-
individual anatomic differences by a less effort-expensive method was shown in the scope
of this thesis. The proposed and developed formalism is that a reference polygon-surface
phantom is adjusted to fit selected individual external dimensions. The introduced method
was tested and evaluated for one slim and for one overweight individual. For both individuals
overall reliable dose estimates were achieved (with relative uncertainty ≤ 25 %, compared
to that ≤ 50 % for most organs without any scaling applied). Thus, it is possible to improve
the estimation of person-specific internal doses with the developed approach. To capture
the full range of inter-individual anatomic variability more patients would be required.
To facilitate the fast implementation of this approach in clinical practice, the diversity of
human computational phantoms available for medical dose evaluation can be increased
using the set of dimensions adjusted in this thesis. Subsequently, these dimensions should
be considered in selecting the phantom that best matches the individual patient.
The powerful and model-independent variance-based sensitivity analysis was implemented
in this thesis and applied to the MIRD system of internal dosimetry for the first time. As an
intrinsic part of the sensitivity analysis, the uncertainties of organ dose estimates originating
from inter-individual variations in pharmacokinetics and anatomy were computed. The
variance-based sensitivity analysis facilitated ranking the input factors according to their
impact on the variance of organ doses. Reducing the uncertainty of the highly influential
input factors leads to effective gaining accuracy in internal dose estimations.
The accuracy level of internal dosimetry in nuclear medicine depends on the application
and on the available resources. When it is not viable to perform patient-specific dose
calculations, several steps can be taken to go from reference values to more patient-specific
dosimetry. Based on the sensitivity analysis of this thesis, for effective dose coefficients
four such steps can be identified. First, the SAFs for the source region total blood need
to be determined more accurately, since these SAFs have the highest contribution to the
uncertainty of effective dose coefficients. Patient-specific blood contents of organs and
tissues are required to increase the accuracy of blood SAFs. Methods to determine patient-
specific blood contents need to be evaluated in future studies. Second, self-absorption SAFs
are to be scaled to the patient-specific organ masses, since this eliminates the impact of
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these SAFs on the uncertainties of dose coefficients for source regions. Mass-scaling of the
SAFs described in this thesis requires the knowledge of individual organ masses, which are
relatively easy to determine from tomographic CT or MR images that usually accompany
PET or SPECT scans. The next step is the accurate estimation of TIACs. It has been
demonstrated in this thesis that the variability in TIACs almost solely defines the variance
of absorbed dose coefficients of respective source regions. The uncertainty of effective
dose coefficients is influenced by some of the TIACs, e.g. those for stomach wall, bladder
content and rest of body for the radiopharmaceutical 18F-FSPG. Detailed time-resolved
activity curves needed for calculations of patient-specific TIACs are usually not obtained
in routine clinical practice though. The scaling of reference time-activity curves based on
patient-specific activities measured at one or few time points is a possible solution, which
could be investigated in future studies. The last step to be taken to improve the accuracy of
internal dosimetry is to collect patient blood samples and to measure their activity. This is
needed for considering blood as a source region. Additionally, even when blood is a distinct
source, approximately 10 % of the variance in effective dose coefficients from 18F-FSPG is
apportioned to the uncertainty of blood TIACs.
To confirm the findings of this thesis regarding the list of influential input factors for
doses from radiopharmaceuticals other than 18F-FSPG, similar studies are to be done for
the radiopharmaceuticals of interest. Programs and methods developed in this thesis do
not depend on the radiopharmaceutical. Thus they can be applied equally for various
radiopharmaceuticals to enhance the accuracy and reliability of internal dosimetry for
individual patients in nuclear medicine applications. They provide the potential to move
from reference internal dosimetry towards personalized organ dose estimation in medical
practice. The viable level of accuracy of internal dosimetry is to be selected according to
the resources available in a particular institution.
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A. Comparison of organ dose
coefficients for employed
anatomical models
Here organ absorbed dose coefficients computed with four sets of activity data for vol-
unteers 1102/94–1105/94 (see table 5.4 on page 49) are compared between two selected
individuals, reference phantoms and the developed matched models. Note that the cor-
responding comparison for activity dataset 1101/94 is presented in section 8.3. The
comparison is done separately for the self-absorption and the cross-fire components of organ
absorbed dose coefficients in sections A.1 and A.2, respectively. Figures A.1–A.4 presented
in section A.1 are analogues to figure 8.4 on page 85. Figures A.5–A.8 and figures A.9–A.12
in section A.2 are analogues to figures 8.5 (page 86) and 8.6 (page 87) for overweight and
slim individuals, respectively.
A.1. Self-absorption component of absorbed dose
coefficients
The calculated absorbed dose coefficients due to the self-absorption along with the deviation
in % from the respective values calculated for Pat1 and Pat2 and the absolute contributions
of the self-absorption to the total organ absorbed dose coefficients are shown in figures A.1–
A.4. Note that for each phantom, i.e. RCP-AM, P-RCP-AM and Pat1M (Pat2M) the
relative differences (in %) between the computed self-absorption dose coefficients and the
corresponding values for Pat1 (Pat2) are independent of the employed activity. This can be
illustrated in the following example for e.g. the relative difference in the self-absorption
dose coefficients for kidneys between e.g. RCP-AM and Pat1. In this case the difference is
computed as:
Diff, % =
ã (kidneys)
∑
i
EiYiΦRCP-AM (kidneys← kidneys, Ei)− ã (kidneys)
∑
i
EiYiΦPat1 (kidneys← kidneys, Ei)
ã (kidneys)
∑
i
EiYiΦPat1 (kidneys← kidneys, Ei)
· 100 %
It follows that the time-integrated activity coefficient for kidneys ã (kidneys) cancels. Hence,
the middle panels of figures A.1a–A.4a are identical. The same is applied to the middle
panels of figures A.1b–A.4b.
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Figure A.1. Calculated self-absorption components of absorbed dose coefficients, differences
in % relative to the corresponding values for Pat1 (a) and Pat2 (b) and absolute
contributions of the self-absorption to the total absorbed dose coefficients. The
total height of the bars on the upper row corresponds to the total organ
absorbed dose coefficients, the filled areas to the self-absorption components.
The SAFs estimated with RCP-AM, P-RCP-AM and Pat1M (Pat2M) for
organs where source is equal to target were adjusted according to the masses
of the patient Pat1 (Pat2), as described in subsection 7.4.1. Absorbed dose
coefficients were computed with activity dataset 1102/94.
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Figure A.2. Analogue to figure A.1, calculated self-absorption components of absorbed dose
coefficients, differences in % relative to the corresponding values for Pat1 (a)
and Pat2 (b) and absolute contributions of the self-absorption to the total
absorbed dose coefficients. Absorbed dose coefficients were computed with
activity dataset 1103/94.
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Figure A.3. Analogue to figure A.1, calculated self-absorption components of absorbed dose
coefficients, differences in % relative to the corresponding values for Pat1 (a)
and Pat2 (b) and absolute contributions of the self-absorption to the total
absorbed dose coefficients. Absorbed dose coefficients were computed with
activity dataset 1104/94.
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Figure A.4. Analogue to figure A.1, calculated self-absorption components of absorbed dose
coefficients, differences in % relative to the corresponding values for Pat1 (a)
and Pat2 (b) and absolute contributions of the self-absorption to the total
absorbed dose coefficients. Absorbed dose coefficients were computed with
activity dataset 1105/94.
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A. Comparison of organ dose coefficients for employed anatomical models
A.2. Cross-fire component of absorbed dose coefficients
The subset of the calculated absorbed dose coefficients from cross-fire along with the
deviations in % from those calculated for Pat1 and Pat2 employing four activity datasets
(1102/94–1105/94) are presented in figures A.5–A.8 for the overweight individual and in
figures A.9–A.12 for the slim individual.
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Figure A.5. Calculated with activity dataset 1102/94 cross-fire components of absorbed
dose coefficients for Pat1 and models approximating it. The dose differences in
the upper panel are given relative to Pat1.
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Figure A.6. Analogue to figure A.5, calculated with activity dataset 1103/94 cross-fire
components of absorbed dose coefficients.
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Figure A.7. Analogue to figure A.5, calculated with activity dataset 1104/94 cross-fire
components of absorbed dose coefficients.
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Figure A.8. Analogue to figure A.5, calculated with activity dataset 1105/94 cross-fire
components of absorbed dose coefficients.
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A.2. Cross-fire component of absorbed dose coefficients
10
−12
10
−11
10
−10
10
−9
U
rin
ar
y 
bl
ad
de
r w
al
l
Ad
re
na
ls
G
al
l b
la
dd
er
 w
al
l
Pa
nc
re
as
Sm
al
l i
nt
es
tin
e 
w
al
l
Sp
le
en
St
om
ac
h 
w
al
l
C
ol
on
 w
al
l
Li
ve
r
Lu
ng
s
Ki
dn
ey
s
Sp
in
al
 c
or
d
O
es
op
ha
gu
s
Th
ym
us
Bo
ne
 m
ar
ro
w
H
ea
rt 
w
al
l
M
us
cl
e 
tis
su
e
Sk
el
et
on
, t
ot
al
Br
ea
st
, t
ot
al
Ex
tra
th
or
ac
ic
 a
irw
ay
s 
(E
T)
Ey
es
Ey
e 
le
ns
es
Sk
in
, t
ot
al
Br
ai
n
Th
yr
oi
d
Sa
liv
ar
y 
gl
an
ds
A
bs
or
be
d−
do
se
 c
oe
ffi
ci
en
t
fr
om
 c
ro
ss
−
fir
e,
 G
y/
B
q
 
 
Pat2
RCP−AM
P−RCP−AM
Pat2M
−60
−40
−20
0
20
40
D
iff
er
en
ce
, %
 
 
RCP−AM
P−RCP−AM
Pat2M
Figure A.9. Calculated with activity dataset 1102/94 cross-fire components of absorbed
dose coefficients for Pat2 and models approximating it. The dose differences in
the upper panel are given relative to Pat2.
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Figure A.10. Analogue to figure A.9, calculated with activity dataset 1103/94 cross-fire
components of absorbed dose coefficients.
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Figure A.11. Analogue to figure A.9, calculated with activity dataset 1104/94 cross-fire
components of absorbed dose coefficients.
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Figure A.12. Analogue to figure A.9, calculated with activity dataset 1105/94 cross-fire
components of absorbed dose coefficients.
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B. Total effect sensitivity indices for all
considered outputs
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Figure B.1. Total effect sensitivity indices for all considered outputs. Each horizontal line
in this figure contains STi in color-codes for all input factors and a selected
output. The input factors are plotted from left to right and the output target
regions from bottom to top. STi = 0 means no effect of the corresponding input
factor. The corresponding figure for Si (figure 11.8) is shown on page 121.
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Vries, Moritz Ludwig and others, I am sincerely thankful to you.
I thank my family in Russia and my family in Germany, especially my mother Marina
Zvereva, my sister Polina Zvereva, Ursula Fourier-Kamp and Winfred Kamp for the endless
support I received. Finally, I would like to thank Dr. Florian Kamp. Florian, thank you
for encouraging me, for supporting me whenever you can, thank you for inspiring and
energizing me, thank you for your patience and for being in my life.
This work was supported by the German Bundesministerium für Bildung und Forschung,
grant 02NUK026.
163
